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Glossary 
 
Active Reporting 
Reports which have been proactively sought.  Registers and 
data linkage techniques can be used to identify adverse 
events.  
Adverse event An event which follows the administration of a drug or a 
vaccine but is not necessarily caused by that event 
Passive reporting Reports where no active measures have been taken to 
encourage the reporting of safety concerns 
Pharmacovigilance Activities relating to the detection, assessment, understanding 
and prevention of adverse effects 
Primary care 
Part of the healthcare system which is accessed through a 
patient’s general practice surgery which can be the first point 
of contact for patients. The GP coordinates day to day and 
ongoing care that a patient may need. 
Routinely collected data 
Electronic data that is collected for purposes other than for 
scientific research.  An example of this is the hospital 
administration database which schedules appointments. 
Secondary care 
Services that are based at hospital and patient access the 
services either by Accident and Emergency departments or by 
referral from General Practice or other specialities. 
Signal 
The suggestion of a relationship between a drug/vaccine and a 
condition which has not been documented previously.  The 
information should be from multiple sources and judged to be 
sufficient for further investigation 
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1. Abstract 
Robust and responsive epidemiological post-licensure vaccine safety studies are the backbone 
to having confidence in a vaccination programme. Consideration must be given to the unique 
methodological challenges inherent when assessing a potential causal association between a 
vaccine and the condition of interest; these can be present from setting up the study through 
to communicating the results.  Public Health England (PHE) has addressed a number of 
vaccine safety concerns since the 1990’s using routinely collected healthcare data and 
methods specific to the disease and vaccine under scrutiny. 
This thesis comprises of seven published post-licensure vaccine safety studies which were 
carried out in response to a number of different pertinent safety concerns relevant to the UK’s 
immunisation schedule. As a background to these studies the history of routinely collected 
data is examined in the context of how we use the data today along with a description of the 
pre and post-licensure vaccine safety activities which often precede the epidemiological 
studies. By bringing together the methodological issues of these seven studies and 
demonstrating the different ways in which these issues have been handled it has created a 
blueprint for addressing vaccine safety concerns in the future.  The seven studies are i) 
Intussusception and Rotavirus vaccination ii) Narcolepsy in adults and Pandemic Influenza 
vaccine iii) Convulsions and Pandemic and Seasonal Influenza vaccine iv) Bacterial and 
Viral Infections and Measles Mumps and Rubella vaccine v) Guillain-Barré syndrome and 
Seasonal Influenza vaccine vi) Idiopathic Thrombocytopenic Purpura and the second dose of 
Measles Mumps and Rubella vaccine vii) Bell’s Palsy and Seasonal Influenza vaccine.  
In conclusion the methodological approaches employed in these studies can be used in the 
future to assess potential adverse events and the access to routinely collected health data is an 
essential element of this. 
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3. Introduction 
The safety of vaccines attracts great interest from both public and scientific communities 
through media stories and scientific debate.  Established methods are in place to assess the 
safety of vaccines from the development stage through to the pharmacovigilance activities 
after licensure. These post-licensure activities range from the passive reporting of adverse 
events to full epidemiological studies to quantify a risk.  Key to the post-licensure 
epidemiological safety study is the ability to identify and use the appropriate data and 
methods.  This thesis will present seven epidemiological studies that were carried out by 
Public Health England from 2006 to 2016 and use a number of different data sources and 
methods which all address pertinent vaccine safety concerns.  
Chapter 3 briefly describes the history of vaccine safety and its relevance today, the data 
sources and statistical methods used in the studies and their development and also discuss the 
ethical and legal frame work which is so critical in the ability to carry out this work.  Chapter 
4 summarises the seven published studies which this thesis is based on and presents a 
systematic review of the published evidence on each adverse event under study at the time 
the research was carried out. Chapter 5 discusses the methodical challenges from setting up a 
study to communicating the results. This includes a discussion on the many sources of 
potential bias that are possible when studying such complex conditions in challenging 
settings and the statistical methods developed to address specific issues in  vaccine safety.  
3.1 Vaccine safety concerns past and present 
There is no doubt that vaccination is one of the most significant health interventions ever 
developed, successfully controlling many serious diseases and saving countless lives 
globally. However, as with any medical treatment or drug, vaccination can never be risk-free 
in terms of unwanted side-effects.  Another important factor unique to vaccination is that 
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unlike therapeutic drugs, vaccines are given prophylactically to healthy individuals, often 
young children.  From the patient’s or parent’s perspective this changes the benefit to harm 
balance as the possibility and consequences of a certain serious adverse event occurring 
outweighs the benefits of being protected by the vaccine from a disease which they know 
little about.  For example, a patient would accept a high incidence of drug-related morbidity 
in the treatment of cancer but would not tolerate anywhere near this level of distress from a 
vaccination for a disease which they think will never affect them. The assessment of the risk 
from an event occurring shortly after vaccination may be incorrect as there may be events 
that occur in time shortly after vaccination, which would have happened by chance without 
vaccination.  It can be hard to disentangle these temporal associations when there is a strong 
parental perception that a temporal association is necessarily evidence of a causal association 
and the timing of the onset of the condition relies on parental recall  (Andrews et al., 2002). 
Ever since the 18th century when farmer Benjamin Jesty (c. 1736 – 16 April 1816) was one of 
the first people to deliberately inoculate his wife and two children with cowpox to protect 
against smallpox, there has been suspicion and mistrust in vaccination (Plotkin & Plokin, 
2013).  Although Jesty seriously considered the consequences of his actions, and only carried 
out the procedure when the smallpox outbreak was imminent, he was ridiculed and scorned 
by his neighbours for injecting his family with an animal disease and never publicised his 
experiments.  Although Jesty was one of the first to deliberately administer the less virulent 
cowpox to induce immunity to smallpox, it was the work of Edward Jenner, a doctor, twenty 
years later that was credited with developing the world’s first vaccine.   
Unfortunately future public health officials did not seem to have Jesty’s cautious and 
thoughtful approach to vaccination when making harm to benefit assessments in the 
implementation of the new vaccine programmes.  In the early 20th century it was a 
combination of mandatory vaccination programmes and a mild form of smallpox that led to 
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some people questioning the benefits of vaccination.  This together with high profile reports 
of vaccine related tetanus deaths the anti-vaccine movement began to gain strength.  Still 
today it is these three factors that have damaged vaccination programmes in the developed 
world.  It is this combination of an illness which is perceived not to be a threat, the health 
official’s communication being perceived as dogmatic, combined with notorious historic 
vaccine safety scares prevalent in the public consciousness. As it did then, more than a 
hundred years ago,  these factors have reduced vaccine uptake and decimated campaigns 
resulting in the resurgence of the disease (Offit et al., 2013).  
Due to the success of vaccination many vaccine preventable diseases are now seen as 
illnesses confined to history and not a threat to a person’s everyday health. Individuals may 
know others who are unvaccinated but have not been affected by the vaccine preventable 
disease so feel the optimum strategy is not to be vaccinated and avoid any potential adverse 
events following the vaccination.  These individuals are depending on the indirect protection 
afforded to them by herd immunity, which relies on the protection afforded to them by others 
being vaccinated around them.  This protection is of course crucial to those who cannot be 
vaccinated due to an underlying medical condition, but if the vaccine coverage falls below a 
threshold in the population, this protection can no longer be relied upon.  Similarities with the 
early 20th century anti-vaccine movement can be found with some people disillusioned with 
the one size fits all approach to medicine turning to alternative practitioners where knowledge 
is based on personal experience not scientific rigor (Allen, 2007).  Often people live and 
associate with like-minded individuals, so whole communities can be left vulnerable to 
disease if vaccination is rejected and the benefits afforded from herd protection are drastically 
reduced as so few in the community are vaccinated. 
A key part of ensuring that public confidence in vaccination remains high is to have timely, 
robust and transparent procedures in place to monitor and investigate vaccine safety 
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concerns.  Although most side-effects from vaccination are minor and self-limiting, such as a 
fever or a rash at the injection site, on occasion more serious unexpected adverse events can 
occur (Miller et al., 2007; Stowe et al., 2016a; Stowe et al., 2016b). These can be unexpected 
adverse events due to the rarity of the adverse event and the limited population available in 
the pre-licensing clinical trials, or it could occur in a sub-group of the population not 
significantly represented.  Passive reporting systems of adverse events after medicines should 
identify these rare adverse events if they occur shortly after vaccination, but often a more 
active surveillance is required.  The use of routinely collected healthcare data can be used to 
investigate and strengthen signals from various sources and to carry out hypothesis-testing 
epidemiological studies to quantify a risk. 
 
3.2 Routinely Collected Healthcare Data 
Healthcare data within the NHS fulfils many purposes, from direct patient care in 
administration, treatment and diagnosis to being the foundation of the NHS funding system.  
The data’s epidemiological and public health value are seen as secondary purposes.  Given 
epidemiology is not healthcare data’s primary role, care must be taken when using such 
datasets to assess its suitability to address the question being asked and the usefulness in the 
answer that is produced.  
The first statistical study of disease using routinely collected data was carried out by John 
Graunt in 1662 using 50 years’ worth of the weekly Bills of Mortality. He estimated the 
proportion of live-born children who died before reaching the age of six by producing 
mortality tables, but as age of death was unavailable he used childhood illness and disease as 
a proxy for age (Morabia, 2013). Although this early work produced a fairly accurate 
estimate, the measure of usefulness of any clinical data for epidemiological study is the 
ability to accurately identify the relevant individual, condition and treatment under study.     
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Much of the healthcare data within the NHS in England is currently held in physically or 
logically distinct silos of data. Although secondary care data which includes inpatient, 
outpatient and emergency episodes are available for all hospitals in England within the NHS, 
primary care and community health data are held in separate databases with often limited 
electronic communication between them. Attempts have been made to address this situation 
with the NHS National Programme for IT (Department of Health, 2011) which endeavoured 
to have a single, centrally-mandated electronic healthcare record for all patients which would 
connect primary care and secondary care. This now abandoned but ambitious programme 
commenced in April 2005 and came under wide criticism in the attempt to deliver this vision 
due to the spiralling costs, failure to deliver key elements and insufficient attention given to 
the privacy and security of patient data.  
Another difficulty in utilising these data is the manner in which the clinical and diagnostic 
information are stored. In all these systems’ codes are applied to the activities within the 
health care data or Electronic Healthcare Record (EHR).  This enables clinicians, healthcare 
professionals and financial teams to assess and administer activity.  The coding schemes used 
within each system are unrelated and involve extensive interpretation and understanding to 
adapt them for epidemiological purposes.    
Primary care data 
Primary care data is mainly derived from general practitioners in England which are often the 
first point of contact for many people when they are ill and has the potential to hold a 
complete medical picture of the patient from birth. Details about the patient’s management, 
treatment, diagnosis, health interventions such as vaccinations, and referrals to secondary 
care should all be recorded in the GP record.  
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GP’s are paid to carry out specific duties under a national contract, so like the hospital data, 
information within these systems are also utilised for financial and administrative purposes. 
A number of systems are used within the NHS and unlike in secondary care there is no 
national database available for all primary care episodes. This issue was to be addressed by 
the care.data programme which would collect a minimum dataset for purposes beyond direct 
care and for the benefit of patient care (NHS England, 2016)  in a similar way to HES.  In 
2014 just months before its implementation the project was irretrievably delayed due to 
public and clinical concern around privacy and confidentiality.  
Primary care data for research can be purchased from a number of providers which have 
some geographic overlap and usually up to 9% of the population and identifiers such as NHS 
number and date of birth are unavailable reducing the usefulness of these data in some 
situations. The main benefit of using these data is the robustness of the immunisation records, 
for those vaccines given in General Practice, but this is often outweighed by the small 
population coverage unless the adverse event under scrutiny is fairly common.  
 
Secondary Care Data 
The importance of high quality healthcare data has been recognised for many years.  Much of 
this focus has been in secondary care within the NHS which comprises the hospital trusts in 
England. To fully understand the Hospital Episodes Statistic (Health and Social Care 
Information Centre, 2016a) data that is used today an explanation is required as to how this 
data came into existence. A national review of NHS data chaired by Edith Korner produced 
the first NHS data model which was implemented in April 1987 (NHS/DHSS, 1982). Before 
this time only 10% of admitted patient records were collected nationally.   The focus of the 
1982 Korner report was the use of information in the management of care of patients and not 
for clinical care or epidemiological purposes.  It was recognised in the 1982 Kings Fund 
paper that the manpower and financial data required by Korner was already available and 
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could be retrieved from personnel and finance departments.  The Korner report ambitiously 
set out to identify a minimum dataset to be collected and included financial, facilities and 
clinical information all the way through a patient’s episode of care. As the dataset was to be 
focused on the management of patients, it was held in financial years and this has continued 
today.  In order to categorise illness and treatment, individual identification of patients was 
required.  The minimum dataset required the following data to positively identify an 
individual; sex, geographic code of current address, date of birth, marital status.  It was 
recognised that there were two main concerns; patient confidentiality with holding names on 
centralised computers and identifying individuals, as twins living at the same address would 
not be unique. In an article in the BMJ in 1982 commenting on the Korner Report, Black 
(1982) stated that it is “a matter of fine judgement whether one makes an information system 
so open that no one will contribute to it, or so confidential that no one can get anything out of 
it”  and noted that excluding names had lessened the clinical and epidemiological value of the 
system. 
The key to the implementation of any healthcare data system is to identify each individual but 
also strike a balance between usefulness and openness. The NHS number was introduced in 
1969 and is a unique person identifier within the NHS system. Prior to 1995 when it was 
allocated to every birth in England coverage was low. Now it is allocated at the first point of 
contact with the NHS making it a valuable tool in linking data across the NHS.  
This Korner minimum dataset devised in the 1980’s now forms the basis of the Hospital 
Episode Statistics data used in post licensure vaccine safety studies and the NHS number 
allows linkage to immunisation datasets and the validation of the diagnostic and clinical 
codes. 
Immunisation history data 
The national immunisation programme (Public Health England, 2006) is mainly delivered 
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through primary care at GP surgery’s but some vaccines which target specific age groups are 
given elsewhere, for example, teenage girls are given the Human Papilloma Virus vaccine in 
schools and babies can be given Bacillus Calmette-Guérin (BCG) vaccine at birth in hospital 
so neither may have their vaccine recorded in the GP system although it is recommended that 
this should occur.   
The main repository for vaccine information for children under 5 years of age in England are 
the regional Child Health Information Systems (CHIS) (NHS England, 2015). CHIS are used 
for the scheduling, recording and monitoring of public health programmes in the NHS from 
pregnancy to children aged up to 5 years old. Child health areas use a variety of different 
databases from a range of providers and have inconsistent and limited electronic links with 
neighbouring CHIS and GP systems. All childhood vaccinations in school, at GP surgeries 
and in hospital should be recorded in their regional CHIS.  School immunisations will be 
recorded in the CHIS local to the school, not the address of the child. 
The immunisation data that each system holds does vary but generally the following relevant 
information is available; vaccine type in a coded format which is often unique to that regional 
computer system; dose number which may need further interpretation as it may be coded a 
first dose if it’s the first  given in that area but care must be taken to look at the age given as 
previous doses may well have been given elsewhere or missed; date of vaccination, which is 
held in a non-standard date field so 32nd of the month is often entered if the day of 
vaccination is not known; batch/lot number is available in some areas for some vaccines 
which is held in a free text field. Care must be taken when interpreting vaccine information 
from CHIS as finding no information on a specific vaccine for a registered child may not 
necessarily mean that they are unvaccinated due to inconsistent and limited links to other 
CHIS systems. 
Other systems are being developed to improve on the weaknesses of the CHIS and to provide 
a national immunisation dataset for Public Health use. 
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Clinical coding  
 
The need to have consistent, retrievable comparable classifications has been recognised by 
scientists for many centuries with Carl Linnaeus (1707-1778) formalising the modern system 
of naming groups of organisms.  It was the work of William Farr (1807-1883) which 
grappled with the census data to develop better classifications for diseases and enabled the 
data to have international uniformity of use (Dunn, 2002).  Farr developed a “statistical 
nosology” which described 27 fatal disease categories to be used by registrars when 
recording the cause of death in local death registers (Halliday, 2000). Importantly, Farr, in his 
role as the first Medical Statistician for the  General Register  Office of England and Wales, 
saw the need to extend the system of nomenclature from mortality to non-fatal diseases that 
caused disability (World Health Organization, 2010).  This is the basis of The International 
Statistical Classification of Disease (ICD) which we use today in secondary care data with the 
classification of diseases that caused morbidity included from 1938 onwards.    
 
In the EHR it is the accuracy of the clinical and diagnostic coding which gives the data its 
value. Coding within the hospital setting in carried out by trained administrative staff but as 
Black stated clinicians should accept the responsibility of making diagnostic coding as 
accurate as possible (Black, 1982).  This accuracy has been incentivised over recent years 
with the Payment by Results scheme (PbR), where certain activities within the hospital are 
linked to funding.  This activity is recorded through the diagnosis and procedure coded data 
and errors in this data can have a substantial financial impact on the hospital (Peeraully et al., 
2016). PbR made clinical coding even more essential although it is still carried out by trained 
administrative staff.  The completeness of coding is variable, with admitted patient care very 
well completed but not so in outpatient and emergency care data, but it is intended to be an 
important expansion of the PbR scheme in the future (Department of Health, 2013a). 
Similarly in primary care the Quality and Outcomes Framework (QOF) is an annual reward 
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incentivisation programme which changes annually, targeting key indicators such as blood 
pressure or ethnicity.  This is a voluntary process and as it changes annually interpretation of 
such data items must be done so cautiously.  
 
Types of coding  
Within the HES admitted patient care data diagnoses are coded using the ICD10 system.  
This classification system translates diagnosis of disease and other health problems into 
alphanumeric codes. Each episode of care can be given up to 20 diagnosis codes with the first 
diagnosis code being the primary reason for admission.  Within each of these episodes, 
Classification of Interventions and Procedures (OPCS-4) codes can also be applied for 
operation or procedure carried out within that episode.  
The data within General Practitioner databases currently are Read coded, which is also 
known as Clinical Terms Version 2/3 (CTV3).  Developed by Dr James Read, this coding 
system has been maintained by the HSCIC.  It is a much more complex coding system than 
ICD and contains thousands of terms covering all aspects of patient care including signs and 
symptoms, treatment, investigations, diagnosis and prescriptions.  
When data were held in small databases, interrogation of the information was simpler but in 
an EHR there needs to be the ability to grow in function and complexity but also for coding 
to be maintained and relevant (Cimino, 1998).  Due to parts of the Read code vocabulary 
being full, new codes have had to be allocated to unrelated areas in the dictionary.  The 
decision was made for READ terms to be retired from primary care and a new coding system 
called SNOWMED CT to be used from financial year 2017/18.  SNOWMED CT is a merger 
of CTV/READ and SNOWMED RT, an American system (Health and Social Care 
Information Centre, 2016b). SNOWMED CT enables changes to be made more easily and is 
currently used in 27 countries and in over half of European Union countries.  It is envisaged 
that by April 2020 all the NHS, including secondary and social care, will move to 
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SNOWMED CT to enable better digital sharing of coded data so a fully integrated personal 
healthcare record can be realised.  
Harmonisation of vaccine safety data 
The usefulness and interpretation of the conclusion of any study depends on the 
comparability and definition of the condition under study.  There are many circumstances 
where the ability to have comparable data in studies is advantageous especially in vaccine 
safety as often the adverse event is rare and requires a large dataset to power the study.  This 
issue could be addressed by pooling data between countries or in a meta-analysis (Andrews et 
al., 2012). Even if a study can be carried out successfully in a single country having the 
ability to compare to other studies can help validate the findings.   
 The use of standard case definitions can be helpful in this task and the Brighton 
Collaboration has developed case definitions for many potential adverse events following 
vaccination through international collaborative working groups (Bonhoeffer et al., 2002). The 
ability to have comparability between studies is valuable but often, due to the variability of 
the datasets used, the data items required to fulfil standard case definitions are not available 
from routinely collected datasets so definitions cannot be implemented.  To improve its 
utilisation conditions such as Guillain-Barré syndrome have levels of diagnostic certainty 
within their Brighton definition so data from electronic databases can be used to implement 
the definition. 
 
 
3.3. Pre –licensure 
Vaccines like other pharmaceutical products are assessed through phased clinical trials.  The 
purpose of these in terms of safety is to assess the type and frequency of the common adverse 
events that may occur, for example fever or swelling. This involves the close monitoring and 
active follow up of events after vaccination. Due to the intensity of this follow up and 
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monitoring, the size of the population studied has to be limited.  Even the largest clinical trial 
does not have the ability to detect rare adverse events and events that may occur in a sub 
group of the population. An example of this was intussusception cases following the 
administration of the rotavirus vaccine where large pre-licensure trials (Vesikari et al., 2006; 
Ruiz-Palacios et al., 2006) did not identify an increased risk but these trials lacked the power 
to detect this rare adverse event.  
If suspected adverse events are detected but not confirmed in pre-licensure trials an enhanced 
post-licensure passive surveillance for the conditions of interest is specified as part of a 
pharmacovigilance risk management plan. In Europe these conditions are reported using 
standard case definition to the European Medicines Agency (EMA) passive reporting system, 
EudraVigilance, along with any fatal or life threatening adverse reactions (European 
Medicines Agency).    
3.4 Post-licensure  
There are two main areas in post-licensure safety assessment; firstly the detection of an 
adverse event and secondly the use of epidemiological studies to investigate a possible 
association and quantify a risk.  Both elements are essential to identify and quantify a 
potential adverse event and must be timely, robust and transparent in order to give the 
population confidence in the safety of the vaccination programme. 
3.4 .1 Signal detection 
Many countries have a specific pharmacovigilance system that passively monitor adverse 
events following vaccination and can detect rare adverse events. In the UK the Medicines & 
Healthcare products Regulatory Agency (MHRA) administer a passive reporting system for 
patients and healthcare professionals to report adverse events after utilisation of all healthcare 
products including vaccines (Medicine and Healthcare Regulatory Agency, 2016).  This 
system called the Yellow Card System monitors these reports to assess whether the 
background rate of that condition has been exceeded in form of an observed over expected 
analysis.  
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As vaccines are often administered in a number of countries and as post-licensure adverse 
events are rare it is advantageous to pool data in order to detect a signal.  EudraVigilance 
administered by the (European Medicines Agency, 2016) (EMA), is a database intended to be 
a single repository for all reports of suspected serious adverse events concerning medicines 
within the European Union.  In the United States, the Food and Drug Administration (FDA) 
run a vaccine specific passive reporting system, The Vaccine Adverse Event Reporting 
System (VAERS) (Chen et al., 1994). When the pandemic influenza vaccine was introduced 
in Europe, the core risk management plan stated that individual countries should report 
certain “Adverse Events of Special Interest” but it was left to the discretion of the countries to 
monitor other conditions and report to the EMA when necessary. The plan also specified that 
each country should carry out an observed over expected analysis to assess whether the 
reports constituted a signal. Any signals raised by the passive reporting system in individual 
countries or via EudraVigilance were to be discussed by a pandemic pharmacovigilance 
expert group which was established on a weekly basis discussing any safety concerns.  
With an aim to establish a truly global vaccine safety support structure the WHO has 
established The Global Vaccine Safety Blueprint (World Health Organization, 2012). In low 
to middle income countries, often pharmacovigilance systems do not exist and this blueprint 
sets out the minimal capacity needed for a successful pharmacovigilance system.  It includes 
basic principles such as the need for stable funding, designated staff, specific reporting forms 
and encouraging health professional to report safety issues.  These systems will become 
increasingly important as new vaccines are introduced in such settings.  
Another important passive surveillance system which was established in 1978 is the WHO 
Programme for International Drug Monitoring at the Uppsala Monitoring centre. Its database 
VigiBase contains spontaneous individual safety case reports and is used by regulatory 
bodies, the pharmaceutical industry and academia through data requests. It has a 
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pharmacovigilance network of more than 120 countries but it is dominated by the United 
States of America which contributed 63% of the reports between 2000 to 2005 (Lindquist, 
2008).  
Although passive systems can rapidly identify rare adverse events it does rely on the adverse 
event being seen to be related to the vaccine.  Events which occur many weeks after the 
vaccine, such as narcolepsy, may not be reported to passive systems. This can lead to under 
ascertainment and reporting bias. Specific statistical methods have been developed to analyse 
and interpret these passive reports. The proportional reporting ratio compares the proportion 
of a specific adverse event reports after a vaccine to the reports to another vaccine given to 
the same age group. Another method is the observed over expected, where an expected 
incidence of the condition is calculated based on the background incidence and compared to 
the observed incidence. This method has the advantage of allowing for different levels of 
under reporting. 
A method which tries to address some of these issues with the passive reporting system uses 
large routinely collected data to identify new adverse events in real time. At regular intervals, 
the system uses a large dataset to investigate pre-specified adverse events of interest, meaning 
that issues with selected or underreporting through passive systems are avoided (Leite et al., 
2016).   
3.4.2 Signal strengthening- active surveillance 
Once a signal has been detected often a more detailed investigation is needed before a full 
epidemiological study is performed.  This phase can be called signal strengthening. 
Ecological studies using large routinely collected datasets are often carried out if the 
coverage of the vaccination is high in a certain population. It can look at disease rates over 
time and if a vaccine is newly implemented, before and after the vaccine was introduced.  
The vaccination status of the individual is not required as it is only the rate of the condition of 
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interest that is compared. These studies can be used to help identify the need for further 
hypothesis-testing studies.  
3.4 .3 Individual Causality assessment 
Epidemiological studies cannot be used assess causation on an individual level but this 
individual detailed assessment is needed in some instances, for example when a product 
specific or vaccine delivery issue is suspected.  The World Health Organisation has published 
a methodology to be used to guide health professionals and public health officials to try and 
assess a causal relationship with the vaccine in a systematic manner (World Health 
Organization, 2013).  It uses information on clinical history and timing to come to a 
conclusion but this is reliant on timely high quality information. The criteria used to assess 
the Adverse Events Following Immunisation (AEFI) includes; a temporal relationship; 
population evidence for causality; biological plausibility; consideration of alternative 
explanations and evidence of the vaccine causing the same event in the individual previously. 
3.4 .4 Hypothesis Testing-epidemiological studies 
In order to establish whether the signal seen is associated with the vaccine and to quantify the 
risk a formal epidemiological study is needed.  This requires a pre-specified protocol 
detailing the population under study, the period after vaccination which an elevated risk is 
suspected and the methods for case identification and statistical analysis. Most importantly 
the ascertainment of the condition of interest must be unbiased with respect to vaccination 
history (Miller & Stowe, 2012). 
Few countries have the capacity to carry such studies in the timely manner needed to address 
imminent vaccine safety concerns as pre-established systems are needed with timely data in 
the population of interest.  In the US, the Vaccine Safety Datalink (VSD) established in 1990 
uses electronic health data from nine health care organisations which includes the date of 
vaccination, emergency and hospital admissions (Centers for Disease Control and Prevention, 
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2016). In response to the H1N1 influenza pandemic in the US the Food and Drug 
Administration (FDA) established a post-licensure rapid immunization safety monitoring 
program (PRISM) which actively monitors the safety of medical products using electronic 
health information (Baker et al., 2013).  It uses health insurance claims databases and links 
these with immunisation registries for 50 million individuals making this dataset unique in its 
size and geographic diversity and its ability to detect rare adverse events following 
vaccination. 
In Demark a national cohort is available with a person identifier linking vaccine history, 
hospital admissions, and disease registers (Hviid, 2006).  Similarly in Finland, where since 
2004 up to 90% of primary care centres, where vaccines are given, have computerised 
medical records making data linkage to hospital records to adverse event monitoring possible 
(Postila & Kilpi, 2004). Since the early 1990’s Public Health England has used national 
hospital admission data linked on the person identifier to regional vaccine history databases 
to assess vaccine associated adverse events (Nash et al., 1995). It also uses primary care data 
for conditions seen in General Practice. For rare conditions, PHE also has the ability to 
contact an individual’s general practitioner to obtain vaccine history data as it has legal 
permission to use and process such data for the good of public health (The Stationary Office, 
2012). 
3.4 .5 Epidemiological Statistical methods  
Ecological  
The ecological design is often used at the signal strengthening stage of post-licensure vaccine 
safety assessments.  An ecological study compares the rate of an adverse event in the relevant 
population with different vaccine exposures without obtaining information on the individual. 
This can be most effective when a vaccine has been introduced into a national schedule for a 
certain age group and high coverage has been achieved. In this situation a pre and post 
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vaccine assessment can be made in relation to the adverse event under scrutiny. This method 
has also taken advantage of short catch-up campaigns such as the 2-week mass MMR 
campaign when all children aged 1-11 in August 1997 were  targeted for vaccination because 
that is when the peak of cases of aseptic meningitis was seen (Dourado et al., 2000).   
This design cannot establish causation or quantify a risk but is seen as an exploratory analysis 
with the view to inform the epidemiological hypothesis-testing stage of the assessment. 
Ideally this epidemiological hypothesis-testing stage should be carried out in a separate 
dataset from which the hypothesis was generated or strengthened. If sufficiently large enough 
the database could be split in half with one half used to conduct an exploratory analysis and 
the other half to test any hypotheses generated. It must be remembered that any bias in 
relation to the way the data were collected would be inherent in both studies. 
Cohort 
Cohort studies need to be very large to detect rare vaccine adverse events and this often 
makes them impractical for a prospective study.  Retrospective cohort designs can use 
routinely collected data and cases identified by clinical coding but this study design may be 
disadvantaged by the need to collect a great number of confounding variables.  The 
advantage is that an entire population is studied and relative and absolute incidence estimates 
can be reported. In a cohort study the risk of developing the condition is compared in the 
vaccinated and unvaccinated. When studying a vaccine which is given as part of a national 
schedule and high coverage is achieved, the small unvaccinated group may be very different 
in terms of underlining illness and demographics from the vaccinated group.  Also, care must 
be taken to insure unvaccinated cases are indeed unvaccinated and the data are not missing.  
This can occur when regional vaccine datasets are used and transfer and sharing of data are 
not comprehensive.  
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Case-Control 
A case-control study requires smaller numbers than a cohort study but the same confounding 
and bias can occur but it also has the added difficulty of selecting the correct controls for 
comparison. For vaccinations given in the short age range in the first and second year of life 
the close matching of the controls on date of birth is required. To obtain enough power to 
assess the required risk, multiple controls per case are often needed. Selecting a relevant 
control condition can be problematic and a novel approach to address this issue called the 
test-negative design has been used in measuring influenza vaccine effectiveness (Jackson & 
Nelson, 2013) and could potentially be used for vaccine safety studies. It uses all patients 
tested for a certain condition and calculates the ratio of the odds of vaccination in those 
testing positive for the condition to the odds of vaccination in those testing negative. This 
design can have two benefits as it can be less prone to misclassification of the condition as it 
is using a diagnostic test to identify the case but additionally it controls for differences in 
healthcare-seeking behaviour. 
Case Only Methods 
The self-controlled case-series method was specially designed for rapid unbiased assessment 
in vaccine safety studies (Farrington, 2004). The cases act as their own controls as the 
incidence in pre-defined risk-periods following vaccination are compared to the incidence 
outside the risk period. As individuals are matched to themselves, individual level 
confounders are controlled for.  Adjustment for time varying confounders such as age is also 
possible. It has been demonstrated that the power of the SCCS method is nearly as good as a 
cohort study when uptake is high and risk intervals are short, and it is superior to that of a 
case control study (Andrews, 2001). A consideration when using the SCCS method is when 
individuals with the condition of interest postpone vaccination this gives a pre-vaccination 
low period (Stowe et al., 2009b; Stowe et al., 2009a; Stowe et al., 2011).  When this is 
evident (Figure 1) this pre-vaccination low period should be removed as it is included in the 
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background rate for the SCCS calculation and if included would bias away from the null 
hypothesis.   
 
Figure 1: An example of the pre-vaccination low period in episodes of convulsions in the two weeks prior 
to vaccination with pandemic influenza vaccine 
 
The case crossover design is similar to the self-controlled case-series method and can be used 
for rare acute conditions when the exposure period is short and has been used in vaccine 
safety assessments.  The proportion exposed is compared in the equally sized risk and control 
periods and analysed using conditional logistic regression (Andrews, 2001; Maclure, 1991) 
The case-coverage design is another approach recently used in vaccine safety studies. It is 
similar to the screening method but until now has been primarily used for vaccine 
effectiveness assessment (Farrington, 1993) although it is more limited in terms of 
adjustment for possible confounders than the SCCS method. Each case is matched to a 
population coverage estimate and this is then used to see if the number of cases vaccinated is 
greater than expected. The method uses logistic regression on the odds of vaccination with an 
offset for the log-odds of the matched population coverage so it is similar to a case control 
study with 1000’s of controls per individual.  
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3.5 Ethical and Legal Framework  
Routinely collected healthcare data is an indispensable tool for epidemiological research but 
in vaccine safety surveillance these databases can never be used without the consideration of 
a great number of factors specific to the disease and vaccine under scrutiny. Also underlining 
every vaccine safety study is the ethical and legal framework within which this work is 
carried out.  The need to carry out vaccine safety studies must be balanced with the rights of 
the individual to privacy and confidentiality of their medical records against the biases that 
might arise as a result of selected participation. 
Data deemed as identifiable does not necessarily include the identifiers such as name, address 
or even NHS number, but a combination of different data items such as name of hospital, date 
of admission and diagnosis that could disclose a person’s identity. Due to this deductive 
disclosure there is often a requirement for small cell numbers to be supressed in Tables when 
the data are published. 
Research studies carried out in the NHS are approved by the Health Research Authority’s 
National Research Ethics Service (Health Research Authority, 2016).  The post-licensure 
vaccine safety surveillance carried out by PHE is not classed as research but public health so 
ethics committee approval is not required. There are key principles and legalisations which 
govern how data can be used in vaccine safety studies and these are outlined here. 
 
Data Protection act 
The main piece of law in the UK that protects an individual’s data is The Data Protection Act 
and provides a way of individuals to control the information held about themselves (Great 
Britain, 1998).  It covers all types of data on living people both administrative and health.  
The act defines “personal data” as any data that can be used to identify an individual.  It also 
describes eight protection principles. Under the act individual consent is required to collect 
and use the data 
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Health Service (Control of Patient Information) Regulations 2002 
Although the Data Protection Act 1998 specifies that individual consent is required for use of 
data, in England and Wales there is a legal basis for using patient identification information 
without individual patient consent.  Public Health England is able to process identifiable data 
under Regulation 3 of The Health Service (Control of Patient Information) (Secretary of State 
for Health, 2002).  This is for purposes related to communicable diseases and other risks to 
public health and includes the delivery, efficacy and safety of immunisation programmes and 
adverse reactions to vaccines and medicines. 
 
Caldicott review 
A review was commissioned by the Chief Medical Officer in England in 1997 to investigate 
concerns around the use of patient information in the NHS and to ensure confidentiality was 
maintained.  These concerns stemmed from the growing use of electronic data and its ability 
to quickly distribute sensitive personal data.  The review was chaired by Dame Elizabeth 
Caldicott and six key principles were established.  These principles, known as the Caldicott 
Principles, set out who, what and how patient information should be used (Department of 
Health, 2013b).  
A recommendation to come out of the review was the appointment of a Caldicott Guardian in 
every NHS organisation. This person should be a senior health professional who has the 
responsibility to keep patient data secure and ensure the Caldicott Principles are upheld in the 
management and use of data in their organisation.   
Assumed consent 
When a person is absent from a dataset it can be difficult to assess the reason for this.  It 
could be for a number of reasons such as they have not had the opportunity to opt in or were 
not aware of the need for this or actively did not want to participate. The reasons behind this 
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are also multi-factored but it is crucial if the reason for non-participation is related to 
vaccination. The advantage of many routinely collected databases is that assumed consent is 
applied allowing investigators to have a representative population.  This assumption has been 
challenged recently when an NHS initiative was launched to make all GP records centrally 
available for purposes beyond direct care (NHS England, 2016).  In an attempt to address the 
issue of deemed consent a leaflet was delivered to every household in England stating that 
anyone wanting to opt out "should speak to" their GP. Unfortunately many did not receive 
this leaflet and those that did were left not knowing who was to have access to their data and 
a public debate in the media ensued around the transfer and use of patient and health data.   
Paradoxically this NHS initiative which aimed to maximise the potential of patient data has 
had the opposite effect and has now been abandoned but with serious consequences for 
epidemiology. The misinformation surrounding data sharing and its importance has led to 
many patients applying to a new Government scheme to allow patents to opt out and not to 
have anything that could identify themselves shared beyond their GP practice. A bias towards 
the null hypothesis could occur if the vaccinated patients who have also had the adverse event 
under study opt out of sharing their data. This would be more likely to happen if the 
hypothesis is in the public consciousness for example with in the erroneous association with 
MMR and Autism.    
Opt-out requests are not carried out in certain situations including when the data are used to 
support the management of communicable disease under Regulation 3 of The Health Service 
(Control of Patient Information) Regulations 2002 under which the vaccine safety work at PHE 
is carried out.  Statistics on the opt-out rate from July 2016 show that 2.2% of patients have 
opted out but this ranges from 0.2 to 13.3% in some areas (Health and Social Care 
Information Centre, 2016c).  It is important that the public are confident in the systems in 
place to protect their data and that it is being used in a responsible manner.  This confidence 
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is gained if systems are transparent and their effectiveness and usefulness demonstrated in a 
robust manner. 
3.6 Summary 
Many of these issues are discussed in the seven studies presented here in this thesis. The 
studies optimise routinely collected coded data from various data sources for vaccine safety 
assessments carried out over a ten year period in which the legal framework has evolved. 
Going forward the demonstration of the value of patient data from such studies will be 
needed in any conversation with the public on data sharing.  There is a responsibility to use 
the data in the appropriate manner and so in this thesis the epidemiological methods used are 
critically appraised and the challenges highlighted in order to inform future studies.   
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4. Critical account of published works 
Seven studies have been selected which have focused on a number of different safety 
concerns and demonstrate the epidemiological methods needed to quantify a risk, if any, of 
an adverse event after vaccination. The studies described here were the first studies in 
England and in many cases the first in Europe to test the specific hypothesis.  The results 
from these studies have been used to support the national immunisation programme by 
advising health professionals and policy makers.  
This thesis is comprised of seven publications which are presented in Chapter 7.  A full list of 
the publications in the area of vaccine safety is given in Appendix II. The seven studies are 
summarised in Table 1 detailing the study question, data sources, design and results.   
In this chapter each study in the thesis is critically reviewed and a systematic review carried 
out using PubMed, a search engine accessing the MEDLINE database which holds abstracts 
and references in the fields of life and biomedical sciences (United States National Library of 
Medicine, January 1996).  
4.1 Study 1: The risk of intussusception following rotavirus vaccination  
Aim: Using hospital admission data this study investigated the risk of intussusception 
following either the first or second dose of the Rotavirus vaccine (RV1) in infants in England.  
Systematic review: A systematic review was carried out using the following search terms: 
rotavirus"[MeSH Terms] OR "rotavirus"[All Fields]) AND ("vaccination"[MeSH Terms] OR 
"vaccination"[All Fields]) AND ("intussusception"[MeSH Terms] OR "intussusception"[All 
Fields]). 
This search retrieved 209 articles (Appendix 1).  There were 199 published prior to our study 
with the first from the US VAERS passive reporting system reporting an increase  of 
intussusception after the now withdrawn rotavirus vaccine- Rotashield™ (Centers for Disease 
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& Prevention, 1999). Eleven of the studies investigated the risk after this now withdrawn 
vaccine, Rotashield™. In 2004 a new rotavirus vaccine was introduced into Mexico (Perez-
Vargas et al., 2006) with the US following in 2006 (Centers for Disease et al., 2008). The 
epidemiological studies carried out before the introduction of the new generation of Rotavirus 
vaccines assessed the characteristics of intussusception cases and looked at the background 
rates in various populations in preparation for the introduction of the vaccine, so that passive 
reports could be interpreted accurately (Kramarz et al., 2001; Chang et al., 2001; Saez-
Llorens & Guevara, 2004).  
There were 10 epidemiological hypothesis-testing studies that investigated the risk after the 
monovalent Rotavirus vaccine (RV1), the vaccine that is used in the UK childhood schedule. 
All but 2 studies (Perez-Vilar et al., 2015; Buttery et al., 2011) reported a small increased risk 
after the first dose of this new rotavirus vaccine. The risk after the second dose remained 
uncertain (Patel et al., 2011; Carlin et al., 2013; Yih et al., 2014; Yung et al., 2015; 
Velazquez et al., 2012; Weintraub et al., 2014; Haber et al., 2015; Bauchau et al., 2015).  
Summary:  Intussusception was first identified as an adverse event following rotavirus 
vaccination in the 1990’s. Intussusception is a telescoping of the intestine and the most 
common cause of bowel blockage in infants. The first rotavirus vaccine, Rotashield® was 
withdrawn from the market after it was shown in the United States to have a 20 to 30 times 
increased risk of intussusception (Murphy et al., 2001). Now two new rotavirus vaccines have 
been developed the monovalent Rotarix (RV1) and pentavalent Rotateq (RV5). The work 
which this study concentrated on concerns the monovalent Rotarix which was introduced in 
the UK in July 2013. It was shown to be effective. The uptake of the rotavirus vaccine was 
immediately high and a reduction in rotavirus cases was seen in both laboratory confirmed 
cases and hospital cases of gastroenteritis (Atchison et al., 2016).  
To determine whether there was a risk of intussusception after Rotarix vaccination in 
England,  Hospital Episode Statistics (HES) data was used to identify infants aged 42 to 183 
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days from the start of the national Rotavirus immunisation programme until October 2014, 
with an ICD10 code for intussusception from any of the 1-20 diagnosis fields in their record 
(Stowe et al., 2016a). Using a questionnaire, rotavirus vaccine histories were independently 
ascertained from individual’s General Practioners (GPs) as this is where the vaccine had been 
given. In order to identify the date on which the symptoms of intussusception started, data 
was initially collected from GPs as primary care is often the first point of contact following 
adverse vaccination events. In addition, a copy of the hospital discharge summary from the 
GP was requested so that the hospital coding could be validated and the Brighton diagnostic 
certainty levels assigned without knowledge of the vaccination status (Bonhoeffer et al., 
2002). To assist with the Brighton classification any relevant surgical or procedure codes 
specific to the intussusception admission and treatment was also extracted from HES. 
Using the self- controlled case- series method, three risk periods after vaccination were 
assessed, 1-7, 8-21 and 1-21 days overall. In addition a meta-analysis was performed 
combining these results with studies from Australia, Mexico, Brazil and Singapore, where the 
same vaccine was used.  
New knowledge gained from this study: This study was able to estimate that the rotavirus 
vaccine programme had caused around 21 intussusception admissions annually in England. 
As a previous study had shown that the vaccination programme had prevented 25,000 gastro-
intestinal infection admissions (Atchison et al., 2016)  this study was able to conclude that the 
overall benefit/risk profile remains strongly positive. This study was the first in the European 
region to demonstrate an association and the first using a schedule in which the second dose 
is given at 3 months of age (a lower age than most schedules) which is of importance as the 
risk of intussusception increases with age.   
There have been eight studies published since this study.  The eight papers include three 
investigating the impact of the vaccine on the disease but no further epidemiological 
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hypothesis-testing studies quantifying the risk of intussusception from the Rotavirus vaccine 
have been published.   
 
4.2 Study 2:  Narcolepsy in adults following the administration of the 
Pandemic Influenza Vaccine  
Aim: To assess the association, if any, between narcolepsy and pandemic influenza vaccine 
in adults using data from sleep centres in England and vaccine histories independently 
obtained from GP practices.   
Systematic review: A systematic review was carried out using the following search terms: 
("narcolepsy"[MeSH Terms] OR "narcolepsy"[All Fields]) AND ("influenza, human"[MeSH 
Terms] OR ("influenza"[All Fields] AND "human"[All Fields]) OR "human influenza"[All 
Fields] OR "influenza"[All Fields]) AND ("vaccines"[MeSH Terms] OR "vaccines"[All 
Fields] OR "vaccine"[All Fields]) AND ("adult"[MeSH Terms] OR "adult"[All Fields] OR 
"adults"[All Fields])  
This search retrieved 38 articles (Appendix 1) with 36 published prior to our study.  From 
these 36 studies nine studies were epidemiological hypothesis-testing studies but only two 
included adults in their study (Persson et al., 2014; Dauvilliers et al., 2013).  
Both of these studies had significant methodological challenges; in the French case-control 
study (Dauvilliers et al., 2013) 28% of potential cases declined to take part and the onset of 
the narcolepsy symptoms were based on patient recall which could lead to an overestimation 
of an association.  The Swedish study saw no overall increase in adult cases but the diagnosis 
date was used as the index date which could potentially lead to an underestimation of the 
association (Persson et al., 2014). The remaining articles were narcolepsy incidence studies, 
commentary articles or laboratory studies looking at the possible biological mechanism. 
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Summary: In this study the risk of narcolepsy in adults following pandemic influenza 
vaccine was assessed. An increased risk of this serious sleep disorder following the 2009 
pandemic influenza vaccine, Pandemrix, had been established in children in a number of 
countries including England where Miller et al. (2013) confirmed a 14-fold increase risk in 4 
to 18 year olds but studies in adults remained inconclusive.  Stowe et al. (2016b) looked at 
the risk in adults using a similar methodology to the Miller et al. (2013) study. Unlike other 
conditions it was found that Narcolepsy was not reliably coded in HES. It was possible to use 
HES to assess which centres diagnosed narcolepsy but extensive manual searches of 
databases were required and were then supplemented with the HES cases. A possible 1446 
cases were identified but most were excluded as their symptoms started before 2009 or were 
not narcolepsy when the notes were reviewed.  To independently assign the case definition to 
the remaining possible cases, an independent panel of narcolepsy experts was convened to 
assign the diagnostic criteria without knowledge of their vaccine history.  
As the vaccine was given by GPs, a questionnaire was designed which requested a first 
symptom date, their vaccine history and in addition whether the patient had a condition that 
put them in a risk group to make them eligible for the pandemic vaccine.  
Using the 40 confirmed cases, the case-coverage analysis method was applied and gave a 
significantly increased risk, with an odds ratio of 4.24 (95% confidence interval 1.45-12.38) 
and an attributable risk of 0.59 cases per 100,000 doses, but this was lower than the risk seen 
in the childhood study with an attributable risk of 1.74 per 100,000 (Miller et al., 2013).  
 
New knowledge gained from this study: This study showed the causal association between 
narcolepsy and pandemic influenza vaccine was not confined to children as had been 
previously thought. This study will have implications for those who are seeking 
compensation for vaccine injury as previously only epidemiological evidence for children 
had been available.   
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Subsequent to this study only one study has been published.  This is a statistical methods 
paper analysing the effect of multiple bias in the epidemiological hypothesis-testing studies. 
 
4.3 Study 3: Convulsions following Pandemic and Seasonal Influenza 
Vaccines 
Aim: To use the General Practice Research Database to investigate whether there was an 
increased risk of convulsions following monovalent H1N1 influenza vaccine in the 2009/10 
season and also following administration of the seasonal influenza vaccine. 
Systematic review:  A systematic review was carried out using the following search terms: 
("safety"[MeSH Terms] OR "safety"[All Fields]) AND ("influenza, human"[MeSH Terms] 
OR ("influenza"[All Fields] AND "human"[All Fields]) OR "human influenza"[All Fields] 
OR "influenza"[All Fields]) AND ("vaccination"[MeSH Terms] OR "vaccination"[All 
Fields]) AND ("seizures"[MeSH Terms] OR "seizures"[All Fields] OR "convulsions"[All 
Fields])  
This search retrieved 41 articles (Appendix 1) with 10 published prior to our study. There 
were three papers from passive reporting systems reporting fever and seizure as the two most 
common serious adverse events after influenza vaccine. A rise in febrile convulsions after a 
specific brand of influenza vaccine was also reported in New Zealand (Petousis-Harris et al., 
2011). In a study looking at passive reports after the pandemic MF59-adjuvanted H1N1 
vaccine, no increase in reporting was seen when compared to the seasonal vaccine (Banzhoff 
et al., 2011).  
Summary: In this third study the risk of convulsions was assessed after the pandemic and 
seasonal influenza vaccine was administered. Febrile convulsions can occur in young 
children and are due to a sudden rise in body temperature which can be caused by an 
infection or a vaccine. The pandemic influenza vaccine was known to be reactogenic 
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especially for fever in children and there had been limited studies assessing the risk of this 
following vaccination with the seasonal influenza vaccine.  
 Stowe et al. (2011) used primary care data to look at the question of an increase in 
convulsions after vaccination with the pandemic and seasonal vaccine.  The convulsion 
coding had previously been validated in a study (Andrews et al., 2010) by reviewing the free 
text comment entered by the GP around the time of the consultation and it had been found it 
to be robust.  A code list was developed for the exposures, the pandemic and seasonal 
influenza vaccine and the outcome of interest, the convulsions.   It was found that a specific 
code for “febrile” convulsions was not available within the coded data. HES data admissions 
for convulsions in children under 10 years of age were also extracted so that the age 
distribution could be compared to the General Practice Research Database (GPRD) and this 
was found to be similar. 
Using the self-controlled case-series method it was demonstrated that there was no increased 
risk of convulsions in the week after receiving either of the vaccines but it was determined 
that there was a signal of an elevated risk in the first few days after the second dose of the 
pandemic vaccine 3.48 (95% confidence interval 0.86-14.07).  
New knowledge gained from this study: Although the pandemic influenza vaccine had been 
reported to be reactogenic especially for fever in children this study saw no increased risk of 
convulsions following either the pandemic or seasonal influenza vaccine. As influenza itself 
can cause fever, convulsions and serious neurological disorders (Moore et al., 2006; Chiu et 
al., 2001; Kwong et al., 2006), this study provides evidence for extending the current UK 
influenza programme in healthy children.  
Following this study the risk of febrile seizures after inoculation of the influenza vaccine has 
been closely monitored through passive reporting and active surveillance systems and it has 
been reported that the risk differs according to the brand of influenza vaccine administered 
(Petousis-Harris et al., 2012; Brady et al., 2014).  
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4.4  Study 4: The risk of Bacterial and Viral Infections following Measles 
Mumps and Rubella Vaccine (MMR) Vaccine 
Aim: Using data linkage techniques and data from hospital admissions and regional 
immunisation databases, the hypothesis was tested that infections should increase after 
vaccination due to the vaccine inducing an “immune overload” allowing for opportunistic 
bacterial and viral infections.   
Systematic review: A systematic review was carried out using the following search terms: 
Immune[All Fields] AND overload;[All Fields] AND ("Mil Med Res"[Journal] OR 
"mmr"[All Fields]) AND ("measles"[MeSH Terms] OR "measles"[All Fields]) AND 
("mumps"[MeSH Terms] OR "mumps"[All Fields]) AND ("rubella"[MeSH Terms] OR 
"rubella"[All Fields]) 
This search retrieved 5 articles (Appendix 1) with 3 published prior to our study. These 
included a study published in 2005 reporting that physicians decline or delay their own 
children’s combined vaccinations, such as MMR (Posfay-Barbe et al., 2005). Another study 
reported  British  parents’ concern with regards to their child’s immune system being able to 
cope with combined vaccines (Hilton et al., 2006).   
Summary: The hypothesis that multi-antigen vaccines, such as the MMR, might overload the 
immune system and make an individual susceptible to other infections was being debated 
around the time when many parents were still concerned about these vaccines due to the 
erroneous link between MMR and Autism.  Stowe et al. (2009b) used established record 
linkage methods (Nash et al., 1995) to link child health immunisation data from the Child 
Health Information System (CHIS) to hospital admission records from the North Thames 
region. After a code list was designed to identify a number of bacterial and viral infections, 
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children aged 12-23 months with a relevant ICD9 or 10 codes were linked by NHS number or 
by sex, date of birth and postcode to the immunisation history data.  
Using the self-controlled case-series method, no evidence of an increase in bacterial and viral 
infections following vaccination using the MMR vaccine was seen, except for an increase in 
herpes infections in the 31-60 days post vaccination (Relative Incidence 1.69 95% confidence 
interval 1.06-2.70). Analysis was also carried out on data from individuals those given the 
Meningococcal serogroup C (MCC) vaccine concomitantly, in which no increased risk was 
seen. Thus, this work concluded that the study did not support the hypothesis of an induced 
immune deficiency due to overload of the immune system from multi-antigen vaccines.  
New knowledge gained from this study: At the time of publication uptake of the MMR 
vaccine remained sub-optimal so this study gave reassurance to parents concerned about 
giving multi-antigen vaccines such as MMR. This work continues to be of relevance and 
provides reassurance as new vaccines are developed and added to the childhood 
immunisation schedule in the UK. 
Since this work was published there has been one study published in relation to this topic 
which discusses parents’ decision-making ten years following the MMR controversy  (Brown 
et al., 2012).  This study also has relevance to the non-specific effects hypothesis which 
suggests that a live vaccine, such as MMR, not only protects against the pathogens to which 
the vaccine being administrated is specific but it also has other broader effects (Sorup et al., 
2014). 
 
4.5  Study 5: Investigation of the risk of Guillain-Barré syndrome (GBS) 
following Seasonal Influenza vaccine 
Aim: The General Practice Research Database (GPRD) was used to test the hypothesis that 
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there was an increased risk of Guillain-Barre syndrome post vaccination with parenterally 
administered inactivated influenza vaccine and also after influenza-like-illness.  
Systematic review: A systematic review was carried out using the following search terms: 
("guillain-barre syndrome"[MeSH Terms] OR ("guillain-barre"[All Fields] AND 
"syndrome"[All Fields]) OR "guillain-barre syndrome"[All Fields] OR ("guillain"[All Fields] 
AND "barre"[All Fields] AND "syndrome"[All Fields]) OR "guillain barre syndrome"[All 
Fields]) AND ("influenza, human"[MeSH Terms] OR ("influenza"[All Fields] AND 
"human"[All Fields]) OR "human influenza"[All Fields] OR "influenza"[All Fields]) AND 
("vaccination"[MeSH Terms] OR "vaccination"[All Fields]) 
This search retrieved 215 articles (Appendix 1) with 64 published prior to our study. This 
included the first reports of GBS following the swine influenza vaccine in military personnel 
in 1976 and an epidemiological study which reported a risk of one case per 100,000 
vaccinations.  Further epidemiological studies followed in the subsequent influenza seasons 
with no increased risk reported (Schonberger et al., 1979; Kaplan et al., 1982; Roscelli et al., 
1991; Lasky et al., 1998). More recently some studies have reported a small risk (Juurlink et 
al., 2006). In passive reporting systems such as VAERS in the United States (US) GBS 
remains the most reported neurological condition following vaccination with seasonal 
influenza vaccine (Haber et al., 2004). 
 
Summary: This study was carried out before the influenza pandemic in 2009 as part of the 
pre-pandemic preparedness work.  Stowe et al. (2009c) carried out a study looking at the risk 
of Guillain-Barré syndrome (GBS) after seasonal influenza vaccination because the 1976 
national program for swine influenza vaccination in the United  States was suspended after an 
increased risk of GBS was seen following vaccination and also because further studies had 
found conflicting results.  
GPRD data was used because most symptoms of GBS are initially reported to primary care 
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providers and then referred to hospital for tests and formal diagnosis. The cases were selected 
using the relevant READ codes and a two stage validation was carried out for those who had 
received at least one dose of vaccine. Firstly the patient profile was reviewed, which was a 
summary of the whole patient record, in order to identify confirmatory symptoms such as 
limb weakness at the time of diagnosis and to identify the onset date of any earlier symptoms. 
The anonymised free-text comments recorded by the GP for one week before the coded GBS 
consultation and 23 weeks after that date were also used.  To validate the recording of GBS in 
the primary care setting, HES admission records for GBS over the same period were 
compared and found to follow a similar seasonal pattern with a peak incidence of admissions 
in January.  Along with the influenza vaccine records, influenza-like illness records were also 
identified to assess the risk. The self-controlled case-series method was used and found no 
evidence of an increased risk in the 90 day period following vaccination but in contrast an 
increased risk was seen following influenza-like illness which was consistent with anecdotal 
reports of GBS following respiratory illness.  
New knowledge gained from this study: This study identified a risk of GBS following 
influenza-like illness but not following the influenza vaccine and it was used in the 2009 
influenza pandemic as it had important implications for the risk/benefit assessment of using 
pandemic vaccines in England. 
 Following publication of this study and the subsequent 2009 influenza pandemic the risk of 
GBS following influenza vaccine remains unclear.  Although our study saw no increased risk 
more recent studies have found a small increased risk (Prestel et al., 2014; Kwong et al., 
2013; Dodd et al., 2013). 
 
4.6  Study 6: Investigation of the risk of Idiopathic Thrombocytopenic 
Purpura (ITP) following the second dose of MMR 
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Aim: Following the establishment of an association between ITP after MMR vaccination, 
Hospital Episode Statistics data and computerised vaccination records were linked to 
investigate the hypothesis that there was an increased risk of ITP following the second dose 
of the MMR vaccine.  
Systematic review: A systematic review was carried out using the following search terms: 
("purpura, thrombocytopenic, idiopathic"[MeSH Terms] OR ("purpura"[All Fields] AND 
"thrombocytopenic"[All Fields] AND "idiopathic"[All Fields]) OR "idiopathic 
thrombocytopenic purpura"[All Fields] OR ("idiopathic"[All Fields] AND 
"thrombocytopenia"[All Fields] AND "purpura"[All Fields]) OR "idiopathic 
thrombocytopenia purpura"[All Fields]) AND ("measles"[MeSH Terms] OR "measles"[All 
Fields]) AND ("mumps"[MeSH Terms] OR "mumps"[All Fields]) AND ("rubella"[MeSH 
Terms] OR "rubella"[All Fields]) AND ("vaccines"[MeSH Terms] OR "vaccines"[All Fields] 
OR "vaccine"[All Fields]). 
This search retrieved 24 articles (Appendix 1) with 13 published prior to our study. This 
included three case reports on ITP, three incidence studies using passive reports of ITP after 
vaccination, a statistical methods paper using ITP vaccine safety data and five hypothesis-
testing studies assessing the risk after MMR (Black et al., 2003; Andrews et al., 2007; 
Rajantie et al., 2007; Miller et al., 2001b; Farrington et al., 1995). None of these five studies 
assessed the risk specifically after the 2nd dose of MMR vaccine. When a search was carried 
out using PubMed using the search terms “idiopathic thrombocytopenia purpura, measles 
mumps and rubella vaccine, second dose” no articles were found that were published prior to 
our study.  
 
Summary: An estimated risk of 1 in 22,000 in the 6 weeks following the first dose of MMR 
vaccine had previously been reported by Miller et al. (2001a) but the risk after the second 
dose had not been assessed. Stowe et al. (2008) extracted HES admission records for ITP in 
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children aged 3 to < 6 years and linked these to CHIS immunisation records for the second 
dose of MMR vaccine.  Validation of the hospital discharge diagnosis coding had previously 
been performed to confirm the validity of the coding and was therefore not repeated for this 
study. 
Analysis was carried out using the self-controlled case-series method and a relative incidence 
during the 6 weeks after vaccination was estimated to be 1.04 (95% confidence interval 0.37-
2.92) and the study concluded that there was no evidence of an increased risk during the 6 
weeks following the second dose of MMR. 
New knowledge gained from this study: This study provided reassurance that the 
established small risk after the first dose of MMR does not extend to the second dose.  
The risk of ITP following MMR continues to be observed (Bertuola et al., 2010; Svanstrom 
et al., 2010; Owatanapanich et al., 2014) but this risk has not been seen following other 
childhood vaccines (O'Leary et al., 2012).  
 
4.7  Study 7: Investigation of the risk of Bell’s Palsy following Seasonal 
Influenza Vaccine 
Aim: The  General Practice Research Database (GPRD) was used  to investigate the signal 
indicated by the passive reporting systems and to test the hypothesis that there is an increased 
risk of Bell’s palsy post parenteral inactivated influenza vaccine  
Systematic review: A systematic review was carried out using the following search terms: 
("bell palsy"[MeSH Terms] OR ("bell"[All Fields] AND "palsy"[All Fields]) OR "bell 
palsy"[All Fields] OR ("bell's"[All Fields] AND "palsy"[All Fields]) OR "bell's palsy"[All 
Fields]) AND ("influenza vaccines"[MeSH Terms] OR ("influenza"[All Fields] AND 
"vaccines"[All Fields]) OR "influenza vaccines"[All Fields] OR ("influenza"[All Fields] 
AND "vaccine"[All Fields]) OR "influenza vaccine"[All Fields]) 
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This search retrieved 20 articles (Appendix 1) with 8 published prior to our study. This 
included two studies that used from passive reporting systems, a case-control study reporting 
an increased risk, three letters commenting on these studies and two studies not related to 
vaccine safety, one study on the benefits of the vaccine in inducing a local mucosal response 
and a study on Bell’s palsy as a condition. 
Our study was the first epidemiological hypothesis-testing study to be carried out following 
publication of the case control study from Switzerland reporting a risk of Bell’s palsy 
following the intranasal vaccine (Mutsch et al., 2004). Prior to this the VAERS passive 
reporting systems in the US saw a possible signal between influenza vaccines and Bell’s 
palsy (Zhou et al., 2004). Since the introduction of the new live attenuated influenza vaccine 
nasal spray  for children in the US, the VAERS passive reporting system has shown no 
unexpected serious risks with this specific influenza vaccine in its  first two seasons (Izurieta 
et al., 2005).   
Summary: The question of a possible risk of Bell’s palsy following vaccination with the 
influenza vaccine was raised after a Swiss study by Mutsch et al. (2004) found an increased 
risk following the nasal inactivated formulation of the vaccine. Cases of Bell’s palsy usually 
present in primary care, therefore Stowe et al. (2006) selected the GPRD to carry out this 
study.  After selection of the cases a validation of the data was carried out using the patient 
profile of a randomly selected sample of cases and a diagnosis was confirmed if a relevant 
prescription was found within a month of diagnosis and no other reason for this prescription 
was identified.  The GP’s free text comments were also assessed for the episodes where the 
diagnosis could not be confirmed using the patient profile and for events on the day of 
vaccination. When the analysis was carried out using the self-controlled case-series method 
there was no increased risk seen in the three months following vaccination. However, when 
the cases on the day of vaccination were compared, a significantly increase in risk of Bell’s 
Palsy was seen (RR 4.38 (95% confidence interval 2.47-7.79)). These cases of Bell’s palsy on 
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the day of vaccination were reviewed by reading the free text held within the electronic 
record and it was found that the Bell’s palsy cases were historical and were opportunistically 
recorded when the patient came for their influenza vaccination. 
New knowledge gained from this study: This study provided reassurance to the UK 
influenza vaccine programme because no increased risk was seen of Bell’s palsy in the three 
months following the paternal influenza vaccine and it indicated that the risk seen with the 
intranasal vaccine may be specific to that vaccine.  
Following our study it has been confirmed that the adjuvant in the nasal vaccine was a causal 
factor in the increase of Bell’s palsy (Lewis et al., 2009). Although we found no association 
with the parenteral vaccine case reports have been published (Chou et al., 2007) and an 
increased risk has been reported after administration with the pandemic influenza vaccine 
(Bardage et al., 2011; Lee et al., 2011). 
 
  
Table 1: Details of data sources and study questions 
Study number 1 2 3 4 5 6  7 
Details Intussusception/ 
rotavirus 
vaccination  
Narcolepsy in 
adults/Pandemic 
Influenza Vaccine  
Convulsions/ 
Pandemic and 
Seasonal 
Influenza Vaccine 
Bacterial and 
Viral 
Infections/MMR 
Vaccine 
Guillain-Barré 
syndrome/Seasonal 
Influenza vaccine 
Idiopathic 
Thrombocytopenic 
Purpura/second dose 
of MMR 
Bell’s 
Palsy/Seasonal 
Influenza Vaccine 
Source of the question Previous vaccine 
shown to have 
increased risk/ 
passive 
surveillance 
Follow up from 
childhood study 
Vaccine was 
known to be 
reactogenic 
especially for 
fever  
In response to the 
immune overload 
hypothesis 
Pre pandemic 
preparedness  
Follow up study 
after risk found after 
1st dose of MMR 
Risk seen in nasal 
formulation of 
vaccine 
Year of question 2013/14 2014 2011 2008 2008/9 2007 2006 
Adverse event Intussusception Narcolepsy Convulsion Bacterial and viral 
infections 
Guillain-Barré 
syndrome 
Idiopathic 
Thrombocytopenic 
Purpura 
Bell’s Palsy 
Data source of cases HES Sleep centres/HES GRPD/HES HES GPRD HES GPRD 
Coding ICD10/OPCS ICD10/ OPCS READ/ICD10 ICD9/10 READ ICD10 READ 
Age of cases 48-183 days old >18 years under 10 years 12-23 month All ages 3 to <6 years  All ages 
Validation Medical notes 
from GP- 
Brighton Criteria 
Multiple data 
sources cross 
referenced.  
Expert panel for 
diagnosis 
previously 
validated by case 
note review 
 previously 
validated 
Patient profile/ Free 
text/HES cases 
previously validated 
by case note review  
patient 
profile/prescription 
data/free text 
Vaccine data source GP GP in GPRD dataset Child health  in GPRD dataset Child health  in GPRD dataset 
Statistical analysis SCCS Case-Coverage  SCCS  SCCS  SCCS SCCS SCCS 
Result RI 4.53 (CI 2.34-
8.58) after 1st 
dose and 2.60 
(1.43-4.81) after 
2nd dose in 1-
21days post 
vaccine 
OR 9.06 (1.90–
43.17) attributable 
risk of 0.59 
cases per 100,000 
doses 
H1N1 vaccine -
IRR 0.99 (CI 
0.61–1.60)   TIV 
1st dose IRR 0.89 
(CI 0.53–1.52) in 
week after vaccine 
Bacterial RI = 
0.68,(CI 0.54–
0.86)   Viral 
RI=0.68 (CI 0.49–
0.93) 0-30 days 
after vaccine 
RI 0.76 (CI 0.41- 
1.40) 90 days after 
vaccination    
RI 1.04 (95% 
confidence interval 
0.37-2.92) in 6 
weeks after 
vaccination 
RI 0.92 (95% 
confidence interval 
0.78–1.08) 
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5. Methodological Challenges in Post-Licensure Vaccine 
Safety Studies. 
The methodological challenge in post-licensure vaccine safety studies is the ability to select 
appropriate epidemiological methods and data so timely robust studies can answer vaccine 
safety concerns before confidence in the vaccination programme is lost or to confirm a risk to 
enable appropriate risk-benefit assessments. This challenge has many facets from the study 
design and case identification through to analysis and publication. For each study question 
methods should be adapted and potential biases considered in the context of the population 
under study, the dataset being utilised and the hypothesis being tested.   
5.1 Setting up the study 
Once the need for an epidemiological hypothesis-testing study is identified there are many 
scientific and practical issues to address in setting up the study in a timely manner.  A clear 
hypothesis is needed and an unbiased data source with a sufficient number of cases needs to 
be identified.  This hypothesis may come out of any signal strengthening activities carried 
out, such as an ecological analysis. Once this is decided a detailed study protocol should be 
written and should include an introduction, study aim, design and assessment of feasibility, 
the definition of the population of interest, the case definition and timing of outcome, details 
on the exposure of interest and interval of exposure, key confounding variables, method of 
analysis, descriptive analysis, sensitivity analysis, data management with data security 
considerations. Once the protocol is complete it can be advantageous for the document to be 
reviewed by an independent expert.  
The first practical consideration is capacity, as personnel and funding need to be in place; 
with the appropriate expertise it is possible to carry out a study with very few staff.  At PHE 
46 
 
in England the studies over the past 17 years were carried out with three key personnel and 
experts brought in for specific disease areas.  In the adult narcolepsy study (Stowe et al., 
2016b) the sleep experts at the study centres were co-authors which enabled the PHE team to 
build good relationships.  Key to the study was to understand the process of the narcolepsy 
diagnosis in each hospital so cases could be ascertained in an appropriate manner. Having 
staff dedicated to the area of vaccine safety allows for rapid response, sustained data flows 
and retention of expertise. However this requires dedicated resources to be identified. 
Often the ethical permissions to access the information needed can be a barrier.  Specific 
datasets will have ethics committees, such as the Independent Scientific Advisory Committee 
(ISAC) for the GPRD. These committees will consider the medical, epidemiological and 
methodological aspects of the proposed study.  If ethics approvals are needed this will have a 
considerable impact on the timeliness and responsiveness of the study.  PHE has previously 
been able to obtain generic permissions to gain access to immunisation data in order to 
respond to future safety concerns. A key aspect especially when dealing which rare outcomes 
is whether the database has sufficient cases to give a statistically useful answer. In England 
large datasets are available such as the Hospital Episode Statistics but linkage to vaccination 
histories is incomplete as no national immunisation register is available.  PHE is able to 
supplement this system by contacting GPs for the immunisation histories using the high level 
approval under Regulation 3 of The Health Service (Control of Patient Information) without the 
permission of the patient. 
 
5.2 Study Design and Dealing with Confounding 
Due to the problems in carrying out large cohort studies and the difficulties with selecting the 
correct controls in case-control studies as previously described, case only methods have been 
extensively used and have now become the gold standard for vaccine safety analysis (Stowe 
et al., 2011; Stowe et al., 2016a; Stowe et al., 2009b; Stowe et al., 2006; Stowe et al., 2009a).   
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The Self-Controlled Case-Series method also has its own difficulties when certain 
assumptions which are central to the method are not followed. The standard method will not 
work if the event itself alters the exposure under study; for example when the condition under 
study is a contraindication for the vaccine of interest.  This occurred in the rotavirus vaccine 
and intussusception study (Stowe et al., 2016a) as the vaccine is contraindicated in patients 
with a history of intussusception due to the previous rotavirus vaccine being associated with 
intussusception. To enable the method to be used in such situations an adaptation has been 
developed (Farrington et al., 2009).  The SCCS method also requires a risk period to be pre-
specified which is then compared to the baseline in the analysis. The definition of the risk 
period can usually be calculated from other studies or the biological mechanism of the 
suspected association. In the study of narcolepsy and pandemic influenza vaccine in children 
in England, a SCCS analysis was performed with a pre-specified risk period of six months 
following vaccination as defined by the initial cases from Scandinavia. The actual risk period 
was much longer than initially thought and four of the 11vaccine associated cases had their 
onset of symptoms after six months from vaccination and as a consequence were allocated in 
to the background reducing the relative incidence (Miller et al., 2013). It is often useful to 
present the data visually with a frequency graph with the count of episodes by interval from 
vaccination to episode (Figure 1) but this should only be carried out after the post vaccination 
risk periods have been documented in the analysis plan.   
Another approach recently used for investigating narcolepsy after pandemic influenza 
vaccine  is the case-coverage design (Farrington, 1993). This method was used in both the 
childhood and adult narcolepsy and H1N1 influenza vaccine studies carried out in England 
(Miller et al., 2013; Stowe et al., 2016b).  The case-coverage method relies on the 
representativeness of the vaccine coverage data used in the analysis so if a comparison can be 
sought this can be advantageous as demonstrated when the RCGP and GPRD coverage data 
were compared and found to be similar (Stowe et al., 2016b).  
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5.3 Case Identification 
A great advantage of using an administrative dataset setup for purposes other than the 
question you are investigating is that it has the potential to be a non-biased set of cases. HES 
for example should be independent of the vaccine history which is more difficult to ascertain 
if relying on clinicians’ reports. As previously described, the use of codes is an efficient way 
of identifying the required case in most routinely collected data.  A combination of diagnosis, 
prescription or treatment codes can be used to assist in the identification of the case. An 
example of this is in the study assessing the risk of intussusception after rotavirus vaccine in 
England (Stowe et al., 2016a) when not only the ICD code for the diagnosis for 
intussusception was used but addition procedure codes such as “Open reduction of 
intussusception of ileum” was used in conjunction to validate the diagnosis. Often a number 
of different codes are used to describe a condition especially in primary care data where a 
greater variety of codes are available for each condition. Care must be taken if a procedure or 
diagnosis is incentivised through government targets such as the QOF or Payment by Results 
which can result in an increase of cases in particular years or populations. 
The issue of retrospective recording of conditions often needs to be addressed at this stage 
and this can occur in primary care data on the day of vaccination. An example of this was in 
the study of Bell’s Palsy and influenza vaccine (Stowe et al., 2006) and it can also be seen in 
hospital admission data if secondary diagnosis codes are used when studying chronic 
conditions such as GBS.  
In some instances no routine data are available, for example, in identifying cases of 
narcolepsy, so case lists need to be built from a number of different data sources (Stowe et 
al., 2016b).  When a case list is being developed all potential cases need to be included even 
if when reviewed they are excluded, so this stage should have a high sensitivity.  In the adult 
narcolepsy study 1,446 possible cases were initially identified through multiple sources 
which were then reduced to 40 cases after thorough case note review and validation.  Cases 
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should be identified independent of vaccine history and care must be taken when ad hoc 
cases are identified in study centres when the study hypothesis is known. This may lead to a 
biased set of cases in relation to vaccination history due to preferential reporting of 
vaccinated cases. 
To minimise this bias, PHE linked computerised hospital cases on NHS number to 
computerised immunisation histories for many of its studies.  Due to the lack of a national 
immunisation register in England this is only feasible when the study outcome is common, 
for example in the study investigating bacterial and viral infections following MMR vaccine 
where 2077 admissions were successfully linked to an MMR record (Stowe et al., 2009b). 
This linkage was also possible when studying ITP and the second dose of MMR where 
adequate numbers of hospital episodes were identified for the area for which there was 
vaccine information (Stowe et al., 2008).   When the condition is rare and linkage to a 
vaccination register is not feasible writing to the GP to request details of the immunisation 
history has been successfully carried out at PHE.  Care must be taken when designing the 
questionnaire which ideally should not exceed one page so as not to discourage the 
completion and ensure the highest possible return rate.  In many studies the diagnosis coding 
and date of the onset of the symptoms have been successfully verified when requesting the 
vaccine history.  Care must also be taken in the wording of questions to ensure the correct 
hospital admission is being discussed in terms of first symptom date, as this can be important 
when studying chronic conditions with multiple admissions (Stowe et al., 2016b; Andrews et 
al., 2011).   
 
5.4 Defining index dates  
Accurately identifying when a symptom of the condition under study commenced and when 
the vaccine was given is a key requirement in vaccine safety studies in order to correctly 
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assess whether a case falls within the pre-defined risk period after vaccination.  In some 
studies, for example, rotavirus vaccine and intussusception (Stowe et al., 2016a), the risk 
period was within a few weeks following vaccination but for other conditions, such as 
narcolepsy and pandemic influenza vaccine, the risk period was more prolonged (Stowe et 
al., 2016b). If the first symptoms date is not available, the diagnosis date is often used as the 
index date, but this can lead to inaccuracies in assessing the risk if there was a long period of 
time between the first symptom and diagnosis. This was demonstrated in the PHE childhood 
narcolepsy study when data analysed using the first symptom date and the diagnosis date 
showed a bias towards the null when analysed by diagnosis date (Miller et al., 2013). 
The assignment of the vaccine status in each of the cases under study needs careful 
consideration.  Recall of vaccination date from patient interviews should not be relied upon 
and independent recording of vaccination status should always be sought.  Vaccination status 
may be inaccurate if based on the status at the time of an event which is after the date of 
symptom onset in the cases.  Evidence of vaccination must be recorded prior to the symptoms 
onset and not retrospectively documented after the event, however if the vaccination is given 
at outreach clinics it may take time to be recorded on the computer system.  An example of 
this was during the pandemic influenza vaccination campaign when clinics were held in local 
communities and also for the HPV vaccine where it delivered in schools.  It is essential 
however that the vaccination event is recorded before the specific adverse event hypothesis is 
established. This can often be determined from a field in the electronic database which 
documents the data entry date.  
5.5 Cleaning data  
Once the data has been extracted the process of cleaning the dataset and identifying the 
pertinent information begins.  As previously described these databases are primarily a tool for 
patient administration so the data needs to be explored and understood in order to correctly 
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interpret the data and correctly answer the study question.   It is often difficult to define 
incident cases of a condition in large electronic databases as no one database 
comprehensively holds a patient’s medical history from birth to death. There are often 
multiple recordings of a patient’s diagnosis throughout their stay in hospital so it becomes 
necessary to de-duplicate the records.  Depending on the condition under study it must be 
decided now many days between repeat episodes constitutes the same episode.  For example, 
in the study looking at convulsion and influenza vaccine an episode with ten days of a 
previous constituted a new episode (Stowe et al., 2011) but when looking at GBS a six month 
period was allocated (Stowe et al., 2009a).   
Basic internal validation to assess the accuracy of the data needs to be carried out for example 
no events recorded before the date of birth or no age more than 115 years.  Often databases 
have “acceptable status” or “up to standard dates” which are a flag in the data to aid such data 
cleaning. Other recording errors in the database need to be uncovered; for example in the 
study on Bell’s palsy after influenza vaccination some patients were found with more than 
one dose of influenza vaccine in a season so these cases were excluded due to likely 
recording errors as only one dose is recommended, except in children who have not had an 
influenza vaccine previously where two doses are recommended (Stowe et al., 2006).  
An issue especially in primary care data is the retrospective recording of a person’s medical 
history when a patient joins a new practice, resulting in previous long standing or significant 
clinical conditions being recorded on the day of registration.  This issue was addressed in the 
study assessing the risk of convulsions after influenza vaccine when the data in the three 
month  period after the patients first registration date was excluded (Stowe et al., 2011). This 
can also occur in hospital inpatient data when there is up to 20 diagnosis fields so often long 
standing conditions or illnesses, not the primary reason for the current admission, can be 
recorded in diagnosis fields 2-20.  It is recommended that a review of the cases is carried out 
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to establish the timings of the symptoms and diagnosis or only cases with the relevant ICD 
code in the primary diagnosis field are used (Stowe et al., 2016a) (Figure 2). 
 
Figure 2: Algorithm for identifying adult narcolepsy cases
 
5.6 Media attention 
The awareness of the hypothesised association which may lead to increased reporting of 
cases has two aspects; public awareness and professional awareness. Firstly, this heightened 
awareness may lead to vaccinated individuals presenting to health care and diagnosed earlier 
than unvaccinated cases leading to ascertainment bias.  If a condition has an insidious onset 
making the recall of the first symptom difficult to determine media attention may lead to a 
differential recall of the symptom onset date in the vaccinated cases. 
Using source documents which were created prior to any media attention in the country of 
study has been used as a method to address this potential recall bias.  Professional awareness 
is likely to occur even if media attention is low as health professionals in the field of interest 
will be aware of current topics of interest through professional bodies and literature. 
53 
 
Differential misclassification bias will occur if cases known to have been vaccinated are more 
likely to be assigned a diagnosis of narcolepsy than unvaccinated cases.  In the narcolepsy 
studies we were able to assess public awareness of the association by analysing Google 
searches for “narcolepsy” in the period of interest and found there was little activity in the 
UK compared to Sweden (Miller et al., 2013) (Figure 3). 
 
. Figure 3: Googles searches for “narcolepsy” or narkolepsi” from UK and Sweden 
*relative scaling is based on the ratio of searches in each month to the long term average
 
 
5.7 Validation  
It is important to use cases with a diagnosis validated by objective criteria, such as the Multi 
Sleep Latency Test (MSLT) in the narcolepsy studies (Stowe et al., 2016b) or procedures 
specific to the diagnosis such as an air enema in the treatment of intussusception (Stowe et 
al., 2016a).  It has demonstrated that prescription data can also be used to validate cases 
(Stowe et al., 2006).  For informed interpretation of medical records an expert panel may be 
required to assess each case according to internationally recognised criteria as demonstrated 
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by the use of the International Classification of Sleep Disorders criteria (ICSD-2) in 
narcolepsy studies in England (Stowe et al., 2016b; Miller et al., 2013).  It is important the 
relevant information is available to the panel in order to make the assessment against the 
appropriate criteria.  The use of an international criterion can greatly strengthen the 
comparability and generalisability of the study results but this needs to be weighed up against 
excluding cases due to information not being available.  If clinic letters which are to be given 
to a panel for review include details of the vaccination status of the patient this needs to be 
removed or the relevant information abstracted (Stowe et al., 2016b).  
In some primary care datasets free-text information is available but it can be costly as any 
personal identifiable information need to be manually removed.  Often it cannot be viable to 
validate all the cases but a random subset can be validated as was carried out in the studies 
assessing the risk of Bell’s palsy and GBS after influenza vaccine using the GPRD (Stowe et 
al., 2006; Stowe et al., 2009a).   
If potential index dates are available from multiple sources for the same individual, for 
example from hospital admission data, primary care data or from the medical records, the 
earliest recorded date can be used in the final analysis or a sensitivity analysis can carried out 
using the earliest and latest dates available for that individual (Stowe et al., 2016b; Stowe et 
al., 2016a).  The use of un-validated cases from electronic databases reduces specificity and 
can lead to random misclassification which biases the result towards the null.   
5.8 Publication  
The most common type of publication bias is when a positive result has a better chance of 
publication and is often published earlier (Dubben & Beck-Bornholdt, 2005). In the case of 
vaccine safety studies there may also be less expert scrutiny by journals of the scientific 
quality of the work and potential conflicts of interest by the authors if the study reports a 
novel association of high public interest. Such factors may have influenced the decision to 
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publish the high profile study which linked MMR and autism which was subsequently 
retracted by the journal (Wakefield et al., 1998).   
There may be other reasons which influence the likelihood of a manuscript being published 
for novel associations with no clear biological mechanism and this is evident in recent 
vaccine safety studies.  The first narcolepsy and Pandemrix studies were initially published 
without peer review on the internet and many of the studies were not published in a peer 
reviewed journal for many years after this initial publication. It is likely the reason for this 
was the need to get the information into the published domain swiftly along with the 
reluctance of a journal to publish the results.  
Publication by peer review is the backbone of the dissemination of scientific knowledge and 
in the field of vaccine safety especially this needs to be carried out in a timely manner. It is 
important that robust methods, data and results are disseminated so others can assess the risk 
and carry out complementary studies where necessary. 
5.9 Communication of a risk 
If a risk is found following a vaccine, the way this risk is communicated is important so the 
audience are able to put the risk into the context of the benefit it is providing in preventing a 
disease. As the events of interest are rare it is often useful to give an attributable risk per 
100,000 doses instead of a relative risk which can be misinterpreted.  In the studies looking at 
the risk of narcolepsy following pandemic influenza the childhood study in England found an 
odds ratio of  14.4,  but the attributable risk was 1.74 cases per 100,000 doses (Miller et al., 
2013).  Similarly in the adult study the odds ratio was 9.06 with an attributable risk of 0.59 
cases per 100,000 (Stowe et al., 2016b), this was because of the rarity of the event.  This 
allowed the audience to put the risk into perspective in terms of risk per dose. In the study 
assessing the risk of intussusception after the rotavirus vaccine (Stowe et al., 2016a) a 2-3 
fold elevated risk was found with an attributable risk of 1.91 per 100,000  after the first dose 
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and 1.49 per 100,000  after the second dose.  However the number of intussusception cases 
the rotavirus vaccine programme had caused, which was 21, was calculated and this was set 
against the 25,000 gastro-intestinal infection admission the programme prevented concluding 
that the benefit/risk profile of the vaccine remained strong. 
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6. Conclusions 
The studies described here have been carried out over a ten year period at Public Health 
England and have contributed to maintaining confidence in the national vaccination 
programme in England.  The methods employed have been tailored for each hypothesis and 
dataset, in order to minimise bias and give a robust measurement of the risk.  Knowing the 
strengths and weaknesses in the dataset being analysed is critical so checks and validation of 
the data can be performed. With increasing numbers of vaccines in the routine schedule it is 
essential that adverse events are reported to pharmacovigilance systems so assessments can 
be made in a timely manner before confidence in the vaccine is reduced.  The ability to have 
available individual level national healthcare databases is central but it has been demonstrated 
here that even when datasets are not suitable for the study question, a dataset can be 
constructed using information from various sources.  
Future vaccines safety concerns cannot be forecast but as new vaccines are introduced into 
the national schedule safety concerns from similar products should be monitored.  Examples 
of which include the intranasal influenza vaccine in children in relation to Bell’s Palsy and 
the newly introduced Meningitis B vaccine, which is known to be pyrogenic, and febrile 
convulsions.  
Vaccines are now being manufactured and introduced in a global market with many countries 
using similar schedules and timings. At the same time countries are seeing the benefits of 
developing large linked healthcare datasets so in the future there may be an increase of 
available data for post licensure vaccine safety epidemiological research. This will then give 
the opportunity for studies to be carried out and then validated on a global level.  Currently 
international epidemiological vaccine safety studies have been carried out using a common 
protocol (Dodd et al., 2013) or pooled data (Dieleman et al., 2011).   
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Such approaches maximise the potential of a country’s data which can be beneficial when the 
availability of data is limited as it can result in a much larger number of cases than any one 
country alone increasing the power of the study.  These approaches highlight the need for a 
transparent information governance and ethics framework on a global level. When designing 
an international study, consideration of the appropriate data and methods should be the main 
priority. If this is not done the results and conclusions from the study could be confusing.  
This was demonstrated in a multi European country study assessing the risk of narcolepsy 
after Pandemrix (VAESCO) when the study reported no risk outside the “signalling” 
countries including the UK when a risk was robustly demonstrated when appropriate methods 
were employed (Miller et al., 2013).   
With the devolution of NHS healthcare many regions in England carry out public health 
surveillance. Cities and regions are putting resources into linking healthcare datasets on a 
local level and seeing the benefits such data can provide (Greater Manchester Academic 
Health Science Network, 2016). Vaccine safety surveillance requires very large numbers in 
order to identify these rare adverse events so regional datasets are of little benefit. The future 
of individual level national healthcare databases is unclear.  The implementation of a new 
harmonised coding system should assist in the flow of data between primary and secondary 
care and the public’s concern around confidentially and the use of their personal data needs to 
be carefully addressed. To assist in this the methods used in vaccine safety studies need to be 
communicated in such a manner that public are informed and reassured so that they are 
content with their data being used for this purpose.  The basis of this discussion should be the 
acceptance that vaccination does carry a small risk but this risk needs to be put into 
perspective. It is essential that the rapid assessments of safety signals through robust 
epidemiological studies are carried out to ensure that public confidence is maintained in the 
national immunisation schedule.  
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Objective: To investigate  the  risk  of  intussusception  after  monovalent  rotavirus  vaccine (RV1) given to
infants aged  2 and  3 months  in England.
Methods:  Hospital  Episode Statistics  (HES)  were  used to identify  infants aged  48–183 days admitted
between 11/03/2013  and  31/10/2014  with  intussusception.  Diagnosis  was confirmed from  medical
records  and  HES  procedure  codes. Vaccination status  was obtained  from  general  practitioners.  The risk
of admission within  1–7  and 8–21 days  of  vaccination was analysed  using the  self-controlled  case-series
(SCCS)  method with age  effect adjustment  by including historical  data  before  RVI introduction  in  July
2013.
Results:  A total of 119 cases  were  identified during  the  study  period  and  intussusception  confirmed in 95
of whom  39 were  vaccinated  1–21  days before onset. An  increased  relative  incidence  (RI) in this  period
was found, 4.53 (95%  confidence  interval 2.34–8.58)  and 2.60 (1.43–4.81)  respectively after  the 1st and
2nd doses with  an attributable risk of 1.91 and  1.49  per  100,000 doses respectively. The peak  risk was
1–7  days after  the  first dose,  RI 13.81 (6.44–28.32),  with an  estimated 93%  of the  15 cases  being vaccine-
attributable.  Mean interval  between  onset and admission, and  clinical  features  were  similar between
vaccine-associated  and background  cases.  Despite intussusception  being  a  contraindication to  rotavirus
vaccination,  10 infants  received  a further  dose;  none  had a recurrence. The  RIs  in a meta-analysis  combing
our results with  Australia, Mexico,  Brazil  and  Singapore using RV1, a 2, 4 month schedule  and  SCCS gave
pooled  RI estimates  of 2.35  (1.45–3.8) and  1.77  (1.29–2.43) in the  21  day period after  the  1st  and  2nd
doses,  respectively.  The  earlier age at  the  2nd dose in  England  did not  affect the  risk.
Conclusion:  We estimate that  the  RVI  programme  causes  around  21  intussusception  admissions  annually
in England  but,  since  it prevents  around  25,000 gastro-intestinal  infection  admissions,  its benefit/risk
profile remains strongly  positive.
Crown Copyright  ©  2016 Published by  Elsevier  Ltd.  This is an  open access article  under  the  CC
BY-NC-ND  license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1.  Introduction
Rotavirus infects nearly every child by five years  of age and
is the leading cause of gastroenteritis worldwide [1]. In healthy
infants in developed countries the infection results in a mild self-
limiting illness with low mortality though it has a high healthcare
burden and causes parental anxiety [2].  It  is  estimated that in
England and Wales in  the absence of vaccination rotavirus infection
is responsible for around 45% of hospitalisations, 20% of accident
and emergency attendances and 25% of primary care consulta-
tions for acute gastroenteritis in children under five years  of age,
∗ Corresponding author. Tel.: +44 2083277485.
E-mail address: Julia.Stowe@phe.gov.uk (J. Stowe).
corresponding to annual incidences per 1000 of 4.5, 9.3 and 28–44
consultations respectively [3].
The first rotavirus vaccine, Rotashield®,  was shown to have an
attributable risk of intussusception of between 10.5 and 21.4 per
100,000 infants vaccinated [4] and was  withdrawn from  the mar-
ket. Subsequently two new rotavirus vaccines were licensed, one
containing a  monovalent attenuated human rotavirus strain (RV1)
and the other a pentavalent human-bovine reassortant vaccine.
Although a  risk  of this magnitude was not seen with these new
rotavirus vaccines in randomised controlled trials, they lacked the
power to  rule  out a small risk [5,6].  In post-licensure studies, an
increased risk of intussusception after the first dose of  these vac-
cines has been reported in  the 1–7 day post-vaccination period
with an attributable risk after the first dose of between 1.1 to  4.3
per 100,000 [7–12].  The risk following the second dose appears to
http://dx.doi.org/10.1016/j.vaccine.2016.04.050
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be smaller, with most studies not finding a  significantly increased
risk.
In the United Kingdom (UK) the rotavirus vaccine was first  added
to the routine vaccination programme in  July 2013 using the RV1
vaccine, Rotarix® (GlaxoSmithKline). It  is given as a  2 dose schedule
at 2  and 3 months with the  second dose to be given by  24 weeks of
age to avoid coinciding with the peak in the background incidence
of intussusception around this time [13]. Rotarix® is contraindi-
cated for infants who have had a prior intussusception episode
or an uncorrected congenital malformation of the gastrointestinal
tract that would predispose to intussusception. Since its introduc-
tion in the UK, the uptake of rotavirus vaccine has been high, with
a 77% decline in laboratory-confirmed rotavirus infections and a
26% decline in all-cause acute gastroenteritis-associated hospitali-
sations compared with the pre-vaccination era [14].
In this study, we investigate whether there is an increased risk
of intussusception following either the first or second dose of RV1
vaccine in infants in England. We  also examine the timeliness of
presentation to hospital which is essential in preventing complica-
tions from this rare event.
2. Methods
The Hospital Episode Statistics (HES) [15] database was  used
to identify cases of intussusception in  infants eligible to  receive at
least one dose of rotavirus vaccine from the start of the national
programme until 31/10/2014. The HES  database contains details
of all admissions to National Health Service hospitals in England.
Infants aged 42–183 days old at the start of their admission with
an ICD-10 code for intussusception in  the primary diagnosis field
and born from 11/03/2013 were selected as the vaccine was made
available to any babies born  up to 15 weeks prior  to vaccine intro-
duction on 1st July 2013. Office of Population Censuses and Surveys
(OPCS) Classification of Interventions and Procedures version 4
codes attached to each  admission were also extracted to investigate
any procedures or  operations during that admission. An  admission
for intussusception within 3 days of a previous one was  treated as
the same admission.
As rotavirus vaccine is  delivered in primary care, infants’ gen-
eral practitioners were contacted to ascertain whether the vaccine
was given and, if so, the date(s). Each case was categorised accord-
ing to the Brighton Criteria for intussusception which contain 3
levels of diagnostic certainty [16]; level 1 is the highest level of
certainty requiring confirmation by  surgical or radiological reduc-
tion of the intussusception; level 2 is  assigned by the evidence on
a number of diagnostic features including intestinal obstruction,
intestinal invagination and blood  per rectum. Level 3 cases, which
comprise those where the diagnostic evidence was less robust,
were excluded from the analysis, together with cases for whom
clinical information was lacking.
Diagnosis level was assigned without knowledge of vaccination
status based on three sources of information; OPCS codes that indi-
cated whether a surgical or  radiological procedure was  undertaken
to reduce the intussusception, any additional information from the
GP on treatment and symptoms, validated by  a  copy of the hospi-
tal discharge summary where available, and if no information was
available from the HES  database or GP, the paediatrician involved in
the patient’s care was contacted. Information from the GP and the
discharge summaries was used to ascertain the date of first  symp-
toms. For the  analysis a  single event date was determined which
was the date of onset identified by the GP or in  the hospital let-
ters, or where this information was lacking, the date of hospital
admission. Where the onset of symptoms was more than 3 days
prior to admission this was only taken as the episode onset if on
blinded review the events on this date were clearly part of  the
intussusception event.
The self-controlled case-series (SCCS) method was  used to  test
the hypothesis of an increased risk  of intussusception in  three risk
periods of 1–7,  8–21 and overall 1–21 days after  rotavirus vacci-
nation, where day 0  is  the day of vaccination. The SCCS method
[17] automatically controls for time-invariant confounding and
has been used in  previous studies investigating vaccine and intus-
susception [7,8,10,18].  We  used the adaptation of the method
developed by Farrington et al. [19] because the standard SCCS
approach could not be used as intussusception is a  contraindica-
tion to  vaccination, thus violating the assumption that vaccination
is  not dependent on the occurrence of the event.
Age adjustment was by  2 weekly intervals, but  age had a degree
of collinearity with vaccine risk periods due  to the  lack of control
person time around the time of vaccination because the doses were
only given a month apart and the risk  interval was  3 weeks. To
address this, a  pre-specified additional analysis was planned where
five years of historical HES  intussusception data from the period
prior to vaccine introduction was included to  enable better esti-
mates of age effects. For these cases, hospital admission date was
used as the index date.
Sample size calculations based on HES incidence data by age
indicated that the expected number of cases from a  year of follow-
up post-vaccine introduction in  the 7 day period after doses one
and two  was 1.6 and 4.0 respectively. This would enable detection
of risks (80% power, 5% significance) of about 5–6 fold after dose 1
and 3–4 fold after dose 2.
The attributable risk was calculated from the relative incidence
(RI) estimates. First the attributable fraction (AF) was calculated
as (RI-1)/RI for each period after each dose. This was then applied
to the cases observed to  get an attributable number of cases, and
finally this was divided by the estimated number of vaccine doses
given to the population from which the cases arose.
To compare cases that were likely to be vaccine-associated with
those that were not the features of the cases, including treatment,
duration of admission and length of time from symptoms to  admis-
sion in  the 1–7 day risk interval after the first dose were compared
to those outside the 1–21 day risk period after either dose. Logis-
tic regression was  used to  adjust for age when comparing these
groups.
A random effects meta-analysis was  performed, combining our
results with those from four other countries using RV1 and repor-
ting RI estimates by the SCCS method [7,8,10,11].  Estimates for
the 8–21 and 1–21 day post-vaccination risk periods were not
reported for every country; however, these could be  derived from
the reported estimates in  other risk periods. Pooled estimates were
then obtained for the 1–7, 8–21 and 1–21 day post-vaccination
periods using the point estimates and 95% confidence intervals (CIs)
from each country. Analysis was carried out using Stata version 13
(StataCorp, College Station, TX).
3. Results
A  total of 590 admissions in  the period 1/07/08 to 31/10/2014
were identified from HES, with age at admission from 42 to 183 days
and a K561 ICD-10 code for intussusception in  the primary diagno-
sis field. There were 471 episodes in  the 5 years prior to  vaccine
introduction with a date of birth before 11/03/2013 (age distribu-
tion shown in  Fig. 1), and 119 with a  date of birth after 10/03/2013
and, therefore, eligible for vaccination. Of the 119 episodes in  the
vaccine-eligible period, 90 were confirmed as Brighton level 1 after
review and five as Brighton level 2.  Of the remaining 29, one episode
was assigned level 3,  eight did not  fit the criteria for intussuscep-
tion and, for the remaining 15, the relevant information could not
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Table 1
Description of the 95  Brighton level 1 and 2  intussusception cases included in the  risk analysis, that are in the risk period 1–21 days after dose  1 or 2 of rotavirus vaccine.
Variable Level Count of cases in risk period Count of cases outside the risk period Total count (%)
Sex Male 29 37 66 (69%)
Female 10 19 29 (31%)
Radiological reduction No 17 26 43 (45%)
Yes  22 30 52 (55%)
Surgery No 23 34 57 (60%)
Yes  16 22 38 (40%)
Brighton 1  38 52 90 (95%)
2  1 4 5 (5%)
Vaccine doses 0 0 13 13 (14%)
1  12 7 19a (20%)
2  27 36 63b (66%)
Age 6w–9w/6d 10 4 14 (15%)
10w–13w/6d 11 8 19 (20%)
14w–17w/6d 15 12 27 (28%)
18w–21w/6d 2 16 18 (19%)
22w–26w/1d 1 16 17 (18%)
a 1 individual had onset before vaccination.
b 12 individuals had onset before vaccination (2 before first dose, 10 between doses).
Fig. 1. Age distribution of the  historic cases.
be traced. Copies of medical discharge summaries and letters were
available for  72 of the 95 level 1 and 2 cases (76%). Of the 95 cases,
66 (69%) were in males with an age range of 6–26 weeks (Table 1).
Overall there were 20 intussusception events 1–21 days after
dose one and 19 events in the same period after dose two  (Table 2
and Fig. 2).  After the first dose, 15 of the  20 cases occurred in the
1–7 day period, with the interval between vaccination and onset of
symptoms ranging from 4 to 6 days. After the second dose, there
were 5  cases in  the 1–7 day post-vaccination risk  period and 14 in
the 8–21 day risk period. A  significantly increased risk was  seen in
the overall 1–21 day period post-vaccination for both the first and
second dose of rotavirus vaccine (RI, 4.53; 95% CI, 2.34–8.58, and
RI, 2.60; 95% CI, 1.43–4.81, respectively) (Table 2). When this post-
vaccination risk period was spilt into 1–7 days and 8–21 days, the
RI in the period 1–7 days after the first dose and 8–21 days after
the second dose remained significantly elevated (Table 2). When
the cases born  before 11/03/2013 were included, the age effects
were better specified which improved precision of the vaccine risks.
The model incorporating the historic data also happened to give a
lower background incidence in the younger age groups than the
model without these data which led  to  higher relative incidence
estimates for  the vaccine risk periods (Table 2).
Using the model with the historical age data, the attributable
fractions for  days 1–7 and 8–21 after doses one and two  were
93%, 37%, 55% and 64%, respectively, and the estimated number of
vaccine-attributable cases  13.91, 1.86, 2.73 and 8.94 respectively.
Based on dose one and two national vaccine coverage of 93.3% and
88.3% [20] and an England population estimate for infants under
Fig. 2. Distribution of intussusception events 4  weeks before to 10 weeks after
monovalent rotavirus vaccine doses 1 and 2.
1 year of age of 664,517 [21] and 1 year 4 months follow-up, the
number of first and second doses given were around 826,659 and
782,358, respectively. The attributable risk  in  the 1–21 day period
after dose one was, therefore, 15.77/826,659 (1.91 per 100,000
doses) and 11.67/782,358 (1.49 per 100,000 doses) after dose two.
For the 1–7 day period after dose one only, the attributable risk is
1.68 per 100,000 doses.
Fifty-two (55%) of the 95  cases had their intussusception
reduced radiologically, 38 (40%) underwent surgery and 5 had no
intervention. In the 15 infants with intussusception in  the 1–7 days
after the first dose, 8 (53%) had radiological reduction and 7 (47%)
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Table  2
Relative incidence of intussusception in  risk periods after first  and second monovalent rotavirus vaccine doses.
Historical cases for age  effect Dose Risk period (days) Cases in risk  period RI  (95% CIa)
Yes 1 1–7 15 13.81 (6.44–28.32)
8–21 5  1.59 (0.34–3.75)
1–21 20 4.53 (2.34–8.58)
2  1–7 5 2.20 (0.50–5.02)
8–21 14 2.77 (1.36–5.32)
1–21 19 2.60 (1.43–4.81)
No  1 1–7 15 8.50 (3.27–28.75)
8–21 5  1.18 (0.28–3.99)
1–21 20 3.13 (1.34–7.57)
2  1–7 5 1.74 (0.37–5.16)
8–21 14 2.74 (1.22–5.89)
1–21 19 2.41 (1.15–5.59)
a Percentile bootstrap (n =  1000) 95% confidence intervals.
Table 3
Features of  the intussusception admissions in infants in  the 1–7 day post first dose risk period compared to those outside vaccine risk  periods.
Feature 1–7 days  post first dose n/N (%) Out of risk period-baselineb n/N (%) Odds ratio (95%CI)a
Treatment
Radiological 8/15 (53.3%) 30/56 (53.6%) 0.96 (0.24–3.91)
Surgical  7/15 (46.7%) 22/56 (39.3%) 1.58 (0.38–6.59)
Days  from onset to  admission
Same day 5/15 (33.3%) 29/56 (51.8%) 1.04 (0.24–4.60)
Mean  (range) in days 0.71 (0–4)  0.77 (0–4)
Duration of  admission
0–1 days 9/15 (60.0%) 32/56 (57.1%) 0.44 (0.11–1.85)
Mean  (range) in days 0.33 (0–8)  0.50 (0–12)
Gender
Male 10/15 (66.7%) 37/56 (66.1%) 0.54 (0.11–2.58)
a Odds ratio adjusted for in age in days.
b Not within 1–21 days of dose 1 or 2.
Table 4
Meta-analysis of  results from four countries using monovalent rotavirus vaccine: relative incidence and 95% confidence intervals.
Country Period post dose  1 Period post dose 2
1–7 days 8–21 days 1–21  days 1–7 days 8–21 days 1–21 days
Australia 6.76 (2.40–19.01) 3.45 (1.33–8.94) 4.55 (2.21–9.38)a 2.84 (1.10–7.34) 2.11 (0.97–4.62) 2.35 (1.28–4.33)a
Mexico 5.30 (3.00–9.30) 0.99 (0.52–1.91)b 2.43 (1.51–3.90)a 1.80 (0.90–3.80) 2.20 (1.40–3.45)b 2.07  (1.41–3.04)a
Singapore 8.36 (2.42–28.96) 0.10 (0.01–10.0)c 2.85 (1.13–7.19)a 3.09 (0.41–12.37) 1.54 (0.20–11.69) 2.06 (0.47–8.94)a
Brazil 1.10 (0.30–3.30) 0.51 (0.20–1.33)b 0.71 (0.33–1.50)a 2.60 (1.30–5.20) 1.12 (0.65–1.93)b 1.61 (1.05–2.48)a
Mexico (2) 6.49 (4.17–10.09)d 1.08 (0.90–1.30)d 1.75 (1.24–2.48)d 1.29 (0.80–2.11)d 1.00 (0.84–1.20)d 1.06  (0.75–1.48)d
England 13.81 (6.44–28.32) 1.59 (0.34–3.75) 4.53 (2.34–8.58) 2.20 (0.50–5.02) 2.77 (1.36–5.32) 2.60 (1.43–4.81)
Poolede 6.03 (3.61–10.07) 1.13 (0.71–1.79) 2.35 (1.45–3.80) 1.83 (1.35–2.50) 1.61 (1.04–2.47) 1.77 (1.29–2.43)
a Estimated from combining published 1–7 and 8–21 day period risks.
b Estimated from combining published 8–14 and 15–21 day period risks.
c Actually zero events in this period, RI  of 0.1  with wide 95% CI used.
d Estimates are for 0–6, 7–30 and 0–30 days with 7–30 estimated by subtraction of 0–6 from  0  to 30 estimates.
e Pooled using random effects method of DerSimonian and Laird (Metan command in  stata) due to  heterogeneity between countries for some periods.
needed surgical intervention, which was similar to  the manage-
ment of cases outside the vaccine risk periods (Table 3). In the
period the vaccine was given and in  the 5 years prior to  the vaccine’s
introduction there were no intussusception admissions in  which an
infant died.
The interval from onset of symptoms to  admission ranged from
0 to 4  days. Five of the 15 (33.3%) infants with onset in the 1–7
day risk window after the first  dose were admitted on the same
day as their symptoms started compared to 29 of the 56 (51.8%)
of those outside the vaccine risk  periods, although this difference
was not statistically significant (Table 3), and not different when
adjusting for age. The duration of the admission ranged from 0 to
12 days and was similar in  infants with onset shortly after the first
dose and those outside the vaccine risk periods (Table 3), and non-
significantly lower when adjusting for age.
Although rotavirus vaccine is  contraindicated for children with
a  previous intussusception, 3  infants had an admission for intussus-
ception in the 2  months before receiving their first dose of rotavirus
vaccine and 10 children went on to  have their second dose after con-
firmed intussusception following the first dose. No repeat episodes
of intussusception were recorded in  the HES data.
The pooled results for  the meta-analysis showed a  significantly
increased RI after dose one and dose two  21 days after vaccination
(Table 4). A significantly increased RI was also seen following dose
one and two in the 1–7 day post-vaccination period and also post
dose two in  the 8–21 day period.
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4. Discussion
This is the first study of the risk  of intussusception after rotavirus
vaccine to be  reported from the European region and the first using
a schedule in which the second  dose is  given at  3 months of age. Our
relative risk estimate of 13.81 (6.44–28.32) for  the 1–7 day period
after the first dose of RV1 is somewhat higher than those obtained
for RVI using the SCCS  method in Mexico, Australia and Singapore
(Table 4).  This may  reflect the use of symptom onset in  our anal-
ysis rather than the later admission date as used by  others; had
admission date been used instead of onset date for the 15 cases in
the 1–7 day period after the first  dose, 5 would have been assigned
to  the 8–21 day risk period, thus decreasing the RI in this earlier
interval. Our RI estimate for the 1–7 day period after dose two  was
within the range reported by the other three countries, indicating
that the earlier age at administration of the second dose in England,
which is closer to that in countries using the Expanded Programme
on Immunisation schedule recommended by the World Health
Organisation, is unlikely to influence the vaccine-associated risk of
intussusception. When pooling results across the six studies there
was an approximate three-fold increased risk 1–21 days after the
first dose and two-fold increased risk after  the second dose. The
characteristics of the cases in the 1–7 day period after the first
dose in our study (where we  estimated that 93% were vaccine-
attributable) were similar to  those outside the vaccine risk period,
confirming the findings from Singapore [10].
We also found a  significantly elevated risk in  the 8–21 day period
after the second dose but not after the first. The results of the other
three SCCS studies for this post-vaccination period were mixed,
although the pooled estimate was consistent with our findings. The
RI for this period will  be  affected by whether symptom onset or
hospital admission date is used in the analysis, as with the 1–7 day
period, though in  the opposite direction. Using the overall RI for the
1–21 period should capture all vaccine-attributable cases and, in
the meta-analysis, significantly elevated RI estimates for  the 1–21
day period were found after both the first  and second doses; in
our study in England this gave AR estimates of 1.91 and 1.49 per
100,000 doses respectively.
In the UK, the risk  of intussusception after  rotavirus vaccine
is  explicit in written guidance provided to healthcare profession-
als administering the vaccine and parents are told to be aware of
abdominal pain, vomiting and redcurrant jelly stools and to contact
a  doctor immediately to ensure rapid treatment [22]. In April 2015,
two deaths from intussusception temporally related to  rotavirus
vaccination were reported in  France in infants who did not receive
timely medical care [23]. This led the World Health Organisation
Global Advisory Committee on Vaccine Safety to  publish a state-
ment underlining the importance of close  monitoring of infants
after vaccination and the need for prompt medical care for infants
with suspected intussusception at any time  [24].  In  our study, the
interval between symptom onset and admission was short (mean
<1  day) and similar in cases with a close temporal association with
vaccination and those outside the post-vaccination risk period.
However, the causal association with vaccination may  not  be recog-
nised as  there was absence of any mention of the vaccination in the
medical records in all but one case. This case was  one of 10 infants
who received a second dose despite confirmed intussusception
episode after their first dose. Although none of these infants had
a repeat episode following their second dose, greater awareness of
the contraindications to vaccination and of the vaccine-associated
risk is needed.
This study uses routinely collected hospital data which has
the potential for inaccuracy in the diagnostic coding. While we
minimised misdiagnoses by  excluding cases with insufficient
information to confirm the diagnosis according to the Brighton
Collaboration criteria, this may  have resulted in exclusion of true
cases. Furthermore, a  recent study found that only 86% of  intussus-
ception cases reported to the British Paediatric Surveillance Unit
had a HES  admission with an intussusception code [25]. Both of
these factors would lead to  an underestimate of the attributable
risk though not  the RI estimates, assuming that missed cases were
randomly distributed in relation to the timing of vaccination.
The 2–3 fold elevated risk of intussusception after a first and
second dose of RV1 demonstrated by our study, would result
in an estimated 21 additional intussusception cases each year
in  England. This number needs to  be compared with the 25,000
annual admissions for an acute gastrointestinal infection that the
rotavirus vaccine programme has prevented [14].  The benefit/risk
profile of the programme is  therefore still strongly positive [26]. It
is however unclear whether the increased risk  of intussusception
in  the post-vaccination period translates into a  sustained increase
in the absolute risk of an intussusception episode in  the first year of
life or whether, as suggested by ecological studies, this overall risk
remains unchanged [27]. If so this would suggest that the vaccine
acts as a  trigger for an event that would anyway occur albeit
later. Surveillance of intussusception in infants eligible to  receive
rotavirus vaccine in England will be  continued in order to evaluate
the overall ecological impact of the vaccination programme on this
rare event.
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Study Objectives: An increased risk of narcolepsy has been observed in children following ASO3-adjuvanted pandemic A/H1N1 2009 (Pandemrix) vaccine. 
We investigated whether this risk extends to adults in England.
Methods: Six adult sleep centers in England were visited between November 2012 and February 2014 and vaccination/clinical histories obtained from 
general practitioners. Suspected narcolepsy cases aged older than 17 y were selected. The risk of narcolepsy following Pandemrix was calculated using 
cases diagnosed by the time of the center visits and those with a diagnosis by November 30, 2011 after which there was increased awareness of the risk in 
children. The odds of vaccination in cases and in matched population data were compared using a case-coverage design.
Results: Of 1,446 possible cases identified, most had onset before 2009 or were clearly not narcolepsy. Of the 60 remaining cases, 20 were excluded after 
expert review, leaving 40 cases with narcolepsy; 5 had received Pandemrix between 3 and 18 mo before onset. All the vaccinated cases had cataplexy, two 
received a diagnosis by November 2011 and two were aged 40 y or older. The odds ratio for vaccination in cases compared to the population was 4.24 (95% 
confidence interval 1.45–12.38) using all cases and 9.06 (1.90–43.17) using cases with a diagnosis by November 2011, giving an attributable risk of 0.59 
cases per 100,000 doses.
Conclusions: We found a significantly increased risk of narcolepsy in adults following Pandemrix vaccination in England. The risk was lower than that seen 
in children using a similar study design.
Keywords: adult, case-coverage, narcolepsy, Pandemrix, vaccination
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after AS03 adjuvanted pandemic A/H1N1 2009 influenza vaccine in adults: a case-coverage study in England. SLEEP 2016;39(5):1051–1057.
INTRODUCTION
Narcolepsy is a disabling and chronic sleep disorder character-
ized by excessive daytime sleepiness, hypnagogic hallucinations, 
sleep paralysis, and cataplexy. Narcolepsy is divided into narco-
lepsy with cataplexy (type 1) and narcolepsy without cataplexy 
(type 2).1 Cataplexy is a unique symptom in which there is tran-
sient loss of skeletal muscle tone, with preservation of conscious-
ness that is triggered by emotions such as laughter or anger.
The prevalence of narcolepsy with cataplexy is between 25 
and 50 per 100,000 people with an incidence of around 0.74 
per 100,000 person-years.2 Onset usually occurs between 15 
and 40 y of age and symptoms develop gradually, so time from 
onset to diagnosis can be many years. Both environmental and 
genetic factors play a role in its etiology. There is a strong as-
sociation with the HLA DQB1*06:02 genotype, but this alone 
is not sufficient for the disease to develop. Narcolepsy is as-
sociated with specific loss of cells producing the neuropeptide 
hypocretin, resulting in low levels of hypocretin in the cere-
brospinal fluid.
An H1N1 ASO3-adjuvanted pandemic vaccine (Pandemrix, 
GlaxoSmithKline Biologicals, Wavre, Belgium) was used in the 
pii: sp-00484-15 ht tp://dx.doi.org/10.5665/sleep.5752
Significance
Our study shows that the causal association between narcolepsy and the oil-in-water adjuvanted pandemic H1N1 influenza vaccine is not, as previously 
thought, confined to children and adolescents and will add further impetus to the research into the etiology of this condition. While possession of the 
DQB1*06:02 gene is clearly implicated, environmental or other triggers appear to be necessary to instigate the onset in susceptible individuals. Further 
surveillance of populations who have received pandemic strain vaccines is needed in order to document whether the association is seen with other 
products and to provide insights into the likely auto-immune pathway by which the oil-in-water adjuvant and/or the viral antigens in the HIN1 pandemic 
strain trigger the pathological process that results in loss of orexin-producing neurons.
United Kingdom (UK) from October 2009, initially for people 
comprising a seasonal influenza vaccine risk group3 or health or 
social care workers, followed by children younger than 5 y from 
November 2009 onward.4 Approximately 5.5 million people in 
the UK were vaccinated with Pandemrix.5 It was the predominant 
H1N1 vaccine used within the European Union.6 In August 2010 
concerns were raised in Finland and Sweden about a possible as-
sociation between narcolepsy and Pandemrix. A cohort study in 
Finland reported a 13-fold increased risk of narcolepsy following 
Pandemrix in children aged 4 to 19 y.7 This was confirmed by 
a study in sleep centers in England, which identified a 14-fold 
increased risk in those aged 4–18 y.8 Other studies subsequently 
published from Ireland and Norway also indicated an increased 
risk of narcolepsy in children who received Pandemrix.9,10
The initial signal in the Scandinavian countries was in chil-
dren but more recently adult cases have been reported. A small 
case-control study in 25 adults in France suggested an elevated 
risk11 as did a follow-up study in Finland published as an on-
line report.12 A record linkage cohort study in Sweden found 
no overall increased risk in adults, although there was a mar-
ginally elevated risk in those aged 21–30 y.13 Using the same 
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published methodology as the childhood study in England,8 we 
investigated whether there was an increased risk of narcolepsy 
in adults who received Pandemrix.
METHODS
Case Ascertainment and Validation
The sleep centers in England where the largest numbers of 
cases of narcolepsy are diagnosed were identified through the 
Hospital Episode Statistic (HES) database.14 HES episodes in 
those age 16 y and older with an ICD 10 code of G474 in any 
diagnosis field were extracted for the period January 2009 to 
December 2012. Six sleep centers were identified as being 
the major centers that together covered 33% of the narcolepsy 
coded episodes in HES during this period. We estimated that 
within these centers approximately 30 cases may be seen with 
onsets from 2010 which should give sufficient power to detect 
at least a fivefold increased risk (80% power, 5% significance 
level, 5% vaccine uptake).
The six centers were visited between November 2009 and 
February 2010 (Table S1, supplemental material) and all those 
aged 16 y and older at the time of diagnosis were ascertained 
with the aim to include those aged 18 y and olderon September 1, 
2009. These cases were found by searching local databases and 
electronic clinic letters for the keyword *narco* or searching 
for multiple sleep latency test (MSLT) reports for a diagnosis 
of narcolepsy. The cases from HES and those identified from 
the local searches were then merged and deduplicated using 
National Health Service (NHS) number or surname and date 
of birth. These potential cases were reviewed using medical re-
cords to establish symptom onset details, clinical history, and 
sleep study results. If any information was missing from the 
electronic records, the case notes were reviewed to identify the 
relevant information.
Details of the anonymized cases collated at center visits 
were evaluated by a review panel (authors GL, JShn, AH, SE) 
who were blinded to vaccination status. To expedite the review, 
cases with a clear history of excessive daytime sleepiness 
(EDS) and cataplexy or EDS with a positive MSLT or cere-
brospinal fluid positive for narcolepsy were not all sent to the 
panel for review; rather, a few examples of these cases were 
first shown to the panel for their agreement. The four sleep 
center consultants on the review panel categorized each case 
as definite narcolepsy with cataplexy; definite narcolepsy 
without cataplexy; probable narcolepsy and insufficient evi-
dence to confirm a diagnosis of narcolepsy. The panel based 
their diagnosis on the International Classification of Sleep Dis-
orders, Second Edition (ICSD-2) criteria.15 A diagnosis based 
on the consensus view of three of the four panel members was 
taken, with remaining cases discussed by teleconference.
Pandemrix vaccination histories for cases with definite or 
probable narcolepsy were obtained from the patient’s general 
practitioner (GP) who was asked for date and batch number of 
any pandemic vaccine given, the date of first symptoms and/or 
first consultation for narcolepsy symptoms, presenting symp-
toms, history of pandemic influenza illness, and whether the 
patient was in a clinical risk group for which pandemic strain 
H1N1 vaccine was recommended.
Index Dates: Definitions
The date of symptom onset was defined as the earliest date of 
EDS or cataplexy as given by the GP or recorded in the sleep 
center notes or referral letters. When the exact date was not 
available we used the midpoint of the month of the approxi-
mate date and also approximated an earliest and latest date of 
onset for sensitivity analysis. The date of first known health 
care contact was the earliest recorded consultation for a sleep 
related problem as reported by the GP or in the center notes. 
The date of diagnosis was the date when there was either a 
clinical history and sleep study confirming narcolepsy or suf-
ficient clinical information to diagnose probable narcolepsy.
Statistical Analysis
We assessed the association between vaccination and narco-
lepsy using the case coverage method16 in which the odds of 
vaccination in cases is compared to the odds of vaccination in 
matched population data. The analysis is by logistic regression 
with the outcome as vaccinated (yes/no) in the cases and with 
an offset for the log odds of the matched coverage. Popula-
tion vaccine coverage was calculated from the Clinical Prac-
tice Research Datalink (CPRD).17 We used patient-level data 
to derive cumulative coverage stratified by exact date (from 
September 2009 to March 2011), age on January 1, 2010 (cat-
egorized as 18, 19, 20–24, 25–29, …, ≥ 80 years) and, when 
matching by risk group, being in a vaccine target clinical risk 
group. This was then used to look up the appropriate matched 
coverage for each narcolepsy case based on their age, risk 
group status (if matching on risk group) and narcolepsy index 
date (e.g. date of onset). To determine vaccine coverage within 
6 mo of an index date, the coverage 6 mo earlier was subtracted 
from the matched coverage on the index date. Patients were 
categorized as being in a risk group if there was any clinical 
code denoting chronic heart disease, chronic kidney disease, 
chronic obstructive pulmonary disease, diabetes, chronic liver 
disease, immunological disorders, multiple sclerosis, or stroke/
transient ischemic attack in the 5 y prior to September 2009 
for the 2009–2010 vaccination season and September 2010 for 
the 2010–2011 season. We used similar criteria for allocating 
narcolepsy cases to a risk group based on the information 
provided by the GP on clinical conditions considered high 
risk for influenza.
The primary analysis was restricted to cases diagnosed by 
November 30, 2011 after which there was increased awareness 
of the risk seen in children with the potential for accelerated di-
agnosis in vaccinated cases. It also used first symptoms as the 
index date and the odds of vaccination at any time before onset. 
Additional analyses were performed using first health care con-
tact and diagnosis as the index date, all cases diagnosed by the 
center visit date, not matching coverage by risk group status 
and calculating the odds of vaccination within 6 mo of the index 
date. Stratification by age younger than 30 y and age 30 y and 
older on September 1, 2009 was also done. Sensitivity analyses 
in which population coverage was increased or decreased by a 
relative 20% (for example, 10% coverage decreasing to 8% or 
increasing to 12%) and using the earliest and latest estimated 
onset dates were also conducted. These analyses were docu-
mented in a statistical analysis plan prior to receipt of the data 
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by the statistician (NA) for analysis. Analysis was done using 
Stata version 13 (StataCorp, College Station, TX).
RESULTS
Vaccine Coverage
Coverage data were obtained from approximately 3.5 million 
patients aged 18–99 y registered in the CPRD practices on 
September 1, 2009. Vaccination coverage was low in healthy 
young adults and increased with age. As expected for those 
in a risk group, uptake was higher and also increased with 
age (Figure 1). Most vaccination was during 2009–2010 with 
only small increases in 2010–2011, which is in agreement with 
other data.8
Study Cases
A total of 2,554 potential patients were identified through 
the different search strategies and data sources. When cross 
Figure 1—Vaccine uptake by age, risk group, and period from the Clinical Practice Research Datalink (CPRD) by clinical risk group status.
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referenced and de-duplicated 1,446 patients remained and 
were taken forward for case note review (Table S1). The ma-
jority, 926, had symptom onset before 2009 and 441 clearly did 
not have narcolepsy when the notes were reviewed; these 1,367 
cases were excluded. The case notes of 10 could not be traced 
and one person was seen in two centres. Of the remaining 68 
patients 30 were considered definite cases after reviewing the 
available information and 38 were sent to the panel for review. 
The panel members were in initial agreement on 28, with 
agreement reached after teleconference for the remaining 10. 
Twenty cases were categorized as not narcolepsy/insufficient 
evidence and excluded with the remaining 18 cases added to 
the 30 definite cases. Of the 48 cases, 8 were not included in 
the final analysis because although age 18 y or older at diag-
nosis they were younger than 18 y on September 1, 2009. This 
left a total of 40 adults with narcolepsy of whom 28 were cat-
egorized as definite narcolepsy with cataplexy, 8 as definite 
narcolepsy without cataplexy, and 4 probable narcolepsy.
Four individuals were reported to have an influenza-like ill-
ness prior to first symptoms, although only one within 3 mo of 
symptoms; none of these four cases was vaccinated.
Vaccination History
We obtained vaccination history on all 40 cases and risk group 
status for 38 (Table 1). Five patients had received Pandemrix 
prior to first symptoms of whom three were in a clinical risk 
group recommended for vaccination; all five had cataplexy. 
One had onset within 3 mo, two within 3 to 6 mo, and two 
between 7 and 18 mo after vaccination; two had a confirmed 
human leukocyte antigen (HLA) DQB1*06:02 genotyping, 
with the other three not tested.
Figure 2 shows the timing of onset for the 40 adult narco-
lepsy cases by vaccination status and monthly vaccine uptake 
in the age-matched population. The first vaccinated case had 
onset in early 2010 and the latest in 2012 after receiving Pan-
demrix in 2011 when residual stocks were used instead of sea-
sonal vaccine.18 Mean time from onset to diagnosis using cases 
with onset in 2009–2011 and diagnosis within 30 mo was 493 
days in four vaccinated cases and 434 in 28 nonvaccinated 
cases (P = 0.69, Kruskal-Wallis test).
Case Coverage Analysis
The primary analysis, which used symptom onset, cases with 
a diagnosis by November 30, 2011 and matching on risk group, 
only included two of the five vaccinated cases but showed an 
elevated odds ratio of 9.06 (1.90–43.17) (Table 2). When in-
cluding all cases ascertained by the date of the centre visit (five 
vaccinated cases) the odds ratio was lower but still significant 
at 4.24 (1.45–12.38). Higher odds ratios (but fewer vaccinated 
cases) were seen when including only cases with onset within 
6 mo of vaccination. When other outcome dates were used 
such as date of first healthcare contact or date of diagnosis, the 
odds ratios reduced and some became nonsignificant (Table 2). 
The sensitivity analyses and age stratification were based on 
Table 1—Demographic features and clinical features of 40 patients with narcolepsy according to ASO3 adjuvanted pandemic A/H1N1 2009 vaccination.
Factor Level Unvaccinated Vaccinated before Onset Total
Age at September 
2009 (years)
18–19 5 1 6
20–24 7 2 9
25–29 5 0 5
30–34 4 0 4
35–39 3 0 3
40–44 7 1 8
45–49 2 0 2
50–54 1 1 2
 ≥ 55 1 0 1
Sex Male 14 1 15
Female 21 4 25
Diagnostic category Narcolepsy with cataplexy 23 5 28
Narcolepsy without cataplexy 8 0 8
Probable narcolepsy 4 0 4
HLA DQB1*06:02 Positive 11 2 13
Negative 3 0 3
Not known 21 3 24
Comorbidity No 32 2 34
Yes 1 3 4
Not known 2 0 2
Seasonal vaccine 
before onset (and 
from 2008/2009)
No 33 2 35
Yes (before symptoms) 1 2 3
Not known 1 1 2
HLA, human leukocyte antigen.
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all cases diagnosed by the center visit date to increase power 
(Table 3). Results were similar when allowing for uncertainty 
in the onset date and remained significant when increasing 
coverage by a relative 20%. Odds ratios were similar for those 
younger than 30 y and older individuals, but the number of 
cases in each age group was small.
Figure 2—Timing of onset for the 40 adult narcolepsy cases by vaccination status and monthly vaccine uptake in the age matched population.
Table 2—Case coverage analysis in patients with narcolepsy showing odds ratios for receipt of ASO3 adjuvanted pandemic A/H1N1 2009 vaccine before 
narcolepsy onset using different index dates, follow-up periods, and risk intervals.
Censoring Date 
for Inclusion by 
Diagnosis
Interval 
before 
Index Date
Number of 
Patients 
Vaccinated 
Total Patients Eligible 
for Vaccination in 
Interval Before Index
Not Matching on Risk Group Matching on Risk Group
Average 
Coverage 
Odds Ratio 
(95% CI)
Average 
Coverage 
Odds Ratio 
(95% CI)
USING FIRST SYMPTOMS
Nov 30, 2011 6 months 2 10 0.026 11.29 (2.05–62.05) 0.016 17.94 (3.34–96.23)Any time 2 10 0.043 5.77 (1.02–28.14) 0.027 9.06 (1.90–43.17)
Center visit 6 months 3 22 0.019 9.64 (2.54–36.57) 0.014 12.74 (3.43–47.26)Any time 5 27 0.047 4.74 (1.77–12.67) 0.063 4.24 (1.45–12.38)
USING FIRST HEALTH CARE CONTACT
Nov 30, 2011 6 months 1 12 0.017 6.10 (0.65–57.10) 0.011 9.72 (1.06–88.79)Any time 2 13 0.044 4.09 (0.89–18.89) 0.028 6.40 (1.40–29.37)
Center visit 6 months 1 17 0.014 5.16 (0.58–45.73) 0.009 8.05 (0.93–69.76)Any time 5 33 0.049 3.54 (1.35–9.27) 0.058 3.37 (1.20–9.48)
USING DATE OF DIAGNOSIS
Nov 30, 2011 6 months 0 14 0.028 0 0.016 0Any time 2 19 0.056 2.03 (0.45–9.14) 0.035 3.32 (0.75–14.66)
Center visit 6 months 0 14 0.028 0 0.016 0Any time 5 40 0.054 2.54 (0.98–6.59) 0.057 2.64 (0.97–7.20)
CI, confidence interval.
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Attributable Risk
The calculation for the vaccine-attributable risk used the odds 
ratio of 4.24 based on symptom onset at any time (Table 2). 
Using the odds ratio to approximate relative risk (RR), the at-
tributable fraction ((RR−1)/RR)) is (3.24/4.24), which applied 
to the five vaccinated patients in the analysis gives an estimate 
of 3.82 attributable cases. HES data indicate that the sleep cen-
ters visited provided a diagnosis for approximately 33% of the 
narcolepsy cases in England in the study period, giving an es-
timated total of 3.82/0.33 = 11.6 attributable cases in England. 
Counting pandemic vaccine doses administered to those aged 
18–59 y gives a total of 1,975,000 based on the final cumula-
tive uptake and the Office for National Statistics population 
data for England in 2009.19 The attributable risk is therefore 
11.6/1,975,000 = 0.59 per 100,000 doses
DISCUSSION
We found a significantly increased risk of narcolepsy in adults 
following AS03 adjuvanted pandemic strain vaccine in Eng-
land. The odds ratio in adults was 9.06 (1.90–43.17) in the 
primary analysis and 4.24 (1.45–12.38) using all cases with 
a diagnosis by the date of the sleep centre visit, with an es-
timated attributable risk 0.59 per 100,000 doses. This risk is 
lower than we found in children where the comparable odds 
ratios were 14.4 (4.3 to 48.5) and 8.3 (3.1 to 22.3) respectively, 
and attributable risk of 1.74 cases per 100,000 doses.8 As in the 
Finnish adult study,12 the risk was highest within 6 mo of vac-
cination with an odds ratio of 12.74 (3.43–47.26).
The mechanism by which narcolepsy with cataplexy is as-
sociated with Pandemrix is not known. HLA DQB1*06:02 
is present in 95% of patients with narcolepsy with cataplexy 
(type 1).20,21 In this study, all five vaccinated narcolepsy patients 
developed narcolepsy with cataplexy. The two tested patients 
were positive for HLA DQB1*06:02. It is possible that Pan-
demrix provides a second hit in those patients with a genetic 
vulnerability to the development of narcolepsy with cataplexy. 
Pandemrix may result in the development or augmentation of 
autoantibodies to hypocretin-producing cells and the destruc-
tion of these cells results in the development of narcolepsy with 
cataplexy. Others have speculated on autoimmunity as a mech-
anism to explain the link between narcolepsy and Pandemrix.21 
As with the pediatric study in England,8 there was no evidence 
that prior swine influenza infection was a risk factor, with only 
one study case reporting influenza-like-illness in the 3 mo prior 
to their narcolepsy symptoms. Recent research, however, sug-
gests that vaccine-induced narcolepsy may be associated with 
the induction of antibodies to the H1N1 nucleoprotein of the 
Pandemrix strain that cross-react with hypocretin receptors.22,23
Our odds ratio for the primary analysis is lower than found 
in the French case control study which reported an odds ratio 
of 16.8 (1.9–149.1) for cases aged 18 years and over using 
symptom onset as the index date.11 In that study 28% of eligible 
cases declined to participate and onset date was based on pa-
tient recall, allowing the potential for participation and recall 
bias which would likely lead to an overestimate of the associa-
tion. In the Swedish record linkage study, which failed to find 
an elevated risk in those aged 20 y and older,13 the narcolepsy 
diagnosis was not verified and the index date was date of di-
agnosis, which would likely underestimate the association. In 
our study, cases were verified by an expert panel according to 
ICSD-2 diagnostic criteria, and onset date was independently 
obtained from referral letters, hospital notes, and GP records. 
Based on this information, we defined the earliest and latest 
possible date of first symptoms; odds ratios generated with 
these extreme dates were similar to the odds ratio using the 
most likely onset date.
To ensure as complete case ascertainment as possible, cases 
were identified by actively searching local electronic patient 
records and databases and cross-checking with cases in the na-
tional hospital database. This approach should avoid selection 
bias arising from differential ascertainment of diagnosed cases 
in vaccinated and unvaccinated individuals, as might occur if 
reliant on clinician recall. In the primary analysis, data were 
censored to only include cases diagnosed by November 30, 
2011 to limit potential bias from accelerated diagnosis in pa-
tients in whom an association with vaccination was suspected 
once the association had generated media interest in December 
2011.8 We found that the odds ratio using cases diagnosed by 
the center visit date was lower than that using cases diagnosed 
by November 30, 2011 rather than higher, which might have 
occurred if there was a tendency for more rapid diagnosis of 
vaccinated cases after the association was publicized.
Our case-coverage approach relies on the representativeness 
of the coverage data used. In this study we used information 
Table 3—Sensitivity analysis and age stratification using vaccination at any time prior to first symptoms and all cases diagnosed by the center visit date.
Analysis
Number of Patients
Vaccinated prior to
First Symptoms
Total Patients Eligible for 
Vaccination prior to
First Symptoms
Average Coverage 
Matching on
Risk Group
Odds Ratio 
(95% CI)
Best estimate of onset date 5 27 0.063 4.24 (1.45–12.38)
Earliest onset date 5 23 0.066 5.25 (1.72–16.02)
Latest onset date 5 28 0.061 4.13 (1.42–12.00)
Coverage reduced by relative 20% 5 27 0.050 5.42 (1.87–15.73)
Coverage increased by relative 20% 5 27 0.075 3.45 (1.18–10.14)
Age 18–29 y on September 1, 2009 3 16 0.059 4.36 (1.11–17.17)
Age 30 y or older on September 1, 2009 2 11 0.067 4.07 (0.73–22.63)
CI, confidence interval.
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from the CPRD, a different GP dataset than we used in the 
pediatric narcolepsy study.8 It was reassuring that age- and 
risk group–specific coverage estimates were similar in both 
GP datasets (data not shown) and were comparable to national 
coverage data.17 The sensitivity analysis showed that even if 
we have underestimated coverage by as much as a relative 20% 
(for example, due to vaccination given outside of general prac-
tice not getting on the record) the association would still be 
significant, odds ratio 3.45 (1.18–10.14) for vaccinated at any 
time before onset.
In conclusion, we found evidence of an increased risk of 
narcolepsy in adults following AS03 adjuvanted pandemic 
strain vaccine in England. We were unable to define how the 
risk varied with age due to the relatively small numbers of 
cases. However, the data do not suggest a threshold age above 
which the risk is zero as vaccine-associated cases were identi-
fied across the age range studied. Further studies in collabora-
tion with other European countries that used Pandemrix may 
help to more accurately define the age-specific risk in adults.
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Table S1—Numbers of potential cases ascertained at each centre, numbers excluded and numbers included in the final analysis. 
 
Centre 
Centre visit 
date 
Number of potential 
cases identified at 
centre visits 
Reasons for initial exclusions at centre visits Expert review 
Final number  
(aged ≥18 years at 
September 2009) 
First 
symptoms 
before 2009 
Diagnosis of  
narcolepsy not 
confirmed by centre 
Notes 
missing/ 
duplicate 
Clear case 
not reviewed 
by experts 
Reviewed 
by expert 
panel 
Not narcolepsy/ 
insufficient evidence 
after panel review 
St Thomas’ London 09/11/2012 220 171 26 0 7 16 7 16 (2) 
UCL, London 15/04/2013 76 58 14 0 3 1 0 4 
Cambridge 21/06/2013 368 197 152 0 8 11 9 10 (2) 
Sheffield 20/11/2013 167 101 61 1 4 0 0 4 
Leicester  12/06/2013 249 108 135 0 3 3 3 3 (1) 
Middlesbrough 04/02/2014 366 291 53 10 5 7 1 11 (3) 
All  1446 926 441 11 30 38 20 40 (8) 
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a b s t  r  a  c  t
The  monovalent  H1N1 (2009) pandemic  influenza vaccine  used  predominantly  in  the UK  in 2009/10  was
a split  virion vaccine  with a  novel oil-in-water  adjuvant  (ASO3).  While  this was  highly immunogenic  it
was  also reactogenic  especially  for fever in  children. There is  a paucity  of  comparative  data on reacto-
genicity of trivalent  influenza vaccine (TIV).  Using the  General  Practice  Research Database  (GPRD)  we
investigated whether there  was  an  increased  risk of convulsions  in children vaccinated with monova-
lent  H1N1  influenza  vaccine  in  the 2009/10  season and  also the  risk  after vaccination with the seasonal
TIVs  using  the self-controlled  case-series  method. A  total  of 2366 children  aged under  10  years with
at  least  one convulsion  recorded  in  the  GPRD and who  had received at least  one  influenza vaccine  at
anytime  (2858 doses  of TIV and 1895  doses of  the monovalent H1N1  influenza  vaccine)  were  identified
between May  2000  and  April 2010. Over  this period these 2366 children  had a  total  of  3846  convulsion
episodes.  There was  no  increase  in  the incidence  rate  ratio  (IRR) in  the week after vaccination  for  either
the  monovalent  H1N1  influenza vaccine  (IRR 0.99,  95%  CI 0.61–1.60)  or  the first dose  of  TIV (IRR  0.89, 95%
CI 0.53–1.52).  A  signal of  an  elevated  risk  in  the first  few  days  after the second dose  of  monovalent  H1N1
influenza  vaccine  was  seen  with an IRR for days 1–3 post vaccination  of  3.48  (95% CI  0.86–14.07).  This
is consistent  with findings  of increased  fever  in  a  clinical  trial. These  results neither  provide  evidence  of
an increased  risk  of convulsions  following  TIV  over a 10-year  surveillance  period  nor following a single
dose of  the ASO3 adjuvanted  monovalent  H1N1  vaccine in  2009/10.
© 2011 Elsevier Ltd. All rights reserved.
1. Introduction
Febrile convulsions occur in young children peaking at the age
of 1 year and are triggered by a sudden rise in body temperature.
The fever can be associated with an infection or  can occur with
some paediatric vaccines. For live vaccines such as  the combined
measles, mumps  and rubella (MMR)  vaccine there is an elevated
risk of  a convulsion 6–11 days later when the viraemia and  asso-
ciated fever occur, the absolute risk being in  the range of  1 in 600
to 1 in 3000 doses [1–3]. For inactivated vaccine such as whole cell
pertussis-containing vaccines, the risk period is within a day or so
of  vaccination [3,4] and has been reduced by the  switch to acellular
pertussis containing vaccines [5–7]. For the inactivated trivalent
influenza vaccine (TIV), its use in children has been limited until
Abbreviations: GPRD, General Practice Research Database; TIV, trivalent
influenza vaccine.
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recently and thus there is  a paucity of data  on any associated risks
of febrile convulsion.
In the UK children aged 6 months and over in a clinical risk  group
(e.g. chronic respiratory, heart, renal, or neurological disease.) are
targeted on  an annual basis to receive one dose of TIV each year or
two doses if  receiving the vaccine for the  first time. The H1N1 (2009)
vaccine used predominantly in the national programme in England
and Wales was a split virion vaccine with an oil-in-water adjuvant
(AS03B-Pandemrix
TM). Compared with the unadjuvanted whole
virion vaccine that was  also purchased for the national programme
(CelvapanTM), the AS03B adjuvanted vaccine was  more immuno-
genic, but also more reactogenic especially for fever at the second
dose which was  reported in 22.4% of children under 5 years of age
vs 8.9% after the first dose [8].  Initially during the H1N1 (2009)
influenza vaccination campaign in the UK only those in risk groups
were offered the vaccine with a  two-dose schedule recommended
for children under 10 years of age  from November to December
2009. From December 2009 due to concerns about the high fever
rate with the second dose,  a single dose of the AS03B adjuvanted
vaccine was recommended in the national programme with a sec-
ond dose only being offered to immunocompromised individuals
0264-410X/$ – see front matter ©  2011 Elsevier Ltd. All rights reserved.
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[9,10]. The whole virion vaccine was recommended for children
who were egg  allergic and was given as a two-dose schedule.
We  investigated whether there was an  increased risk  of con-
vulsions in children following the monovalent AS03B adjuvanted
pandemic strain vaccine and the risk  following vaccination with
the seasonal TIV in the period 1st May 2000 to 30th April 2010
using the self controlled case series method with cases identified
in the General Practice Research Database (GPRD) [4].
2.  Methods
Children were selected from the GPRD if  they had received either
monovalent H1N1 (2009) influenza vaccine or seasonal TIV or both
and had a Read coded convulsion while aged less than 10 years in
the period 1st May  2000 and 30th April 2010. The General Practice
Research Database, which is one of the  world’s largest primary care
databases, holds data on consultations, referrals, prescriptions and
vaccinations for over 3 million active patients in practices through-
out the UK (5.7% of  the population). Diagnostic and medical events
have  very specific Read codes assigned to them, which can be used
to identify such events. It not only holds information on activity
in the primary care setting but secondary care events are  feedback
into the system through hospital discharge letters and  the elec-
tronic reporting of  results. If the patient was first registered with
the GP surgery within the study period the start date for follow-up
was  defined as 3 months after first registration to reduce the  risk  of
retrospective reporting of recent events on registration. The end of
follow-up was defined as  either on the patient’s 10th birthday, the
date transferred out of the practice or the date of last data download
from the practice or 30/4/2010 if any  of these was earlier than the
patient’s 10th birthday patients with an  “acceptable” status were
selected whose practice record had listed an “up-to-standard” date
earlier than the  patient’s first or new consultation for the condi-
tion of interest. The up to-standard date reflects when the practice
complied with specific quality measures based on completeness,
continuity, and plausibility in key  areas. Acceptable status is  given
to a patient when certain data quality conditions have been met,
such as no events recoded before the birth date, age less  than 115
years, and a completed gender field.
The exposure of interest was vaccination with either monova-
lent H1N1 influenza vaccine during the  2009/10 influenza season
or seasonal TIV during the 10 years prior to 2009/10. Code lists
for influenza vaccines were developed using both the product
and medical browsers searching for *flu*, *vaccine*, *celvapan*,
*pandemrix*, *H1N1*. Additional searches were also made using
BNF Code 14040900. The primary outcome of interest was a diag-
nosis of a convulsion; a specific diagnosis of febrile convulsions
was  not  distinguished to allow for coding differences within the
data. The code list for convulsions was developed using the medi-
cal browser searching for ‘convulsi’, ‘seizure’, ‘fit’  to determine an
initial list and then further searches based on similar Read Codes.
The age distribution of vaccinated cases with a convulsion iden-
tified in the GPRD was compared with that of all children under
10 years of age admitted to hospital in England with a convulsion
using Hospital Episode Statistics (HES) [11]. HES data  were obtained
for the year April 2008 to March 2009 for children under 10 years
with a ICD10 code of  R56.0 “Febrile convulsion” or R56.8 “Other
and  unspecified convulsions” in any diagnosis field.
2.1. Statistical methods
To calculate the relative incidence the self-controlled case-
series method was used. This is a case only method so  only cases
of convulsion needed selection from the GPRD. Person time and
events for each individual were stratified by age (1 year age
bands), calendar period (May 2000–April 2005, May 2005–April
2010), season (March–May, June–August, September–November,
December–February) and vaccine risk period (background, 0, 1–3,
4–7 days post vaccination). A pre-vaccination low risk period
of 2 weeks was  taken out of the background risk to allow for
delayed vaccination due to a febrile convulsion. Relative inci-
dence estimates adjusted for age, period and season were obtained
by conditional Poisson regression for seasonal vaccine (combined
across seasons) and pandemic vaccine for 2009/10. The pan-
demic vaccine risk  was  assessed overall and  also split by first
and  second dose. Repeat convulsion episodes within individuals
were regarded as new episodes if  they occurred at least 10 days
apart.
3. Results
A  total of 2366 children received a vaccine in the  follow-up
period and had at least one convulsion episode. The children were
followed up for an average of  5.1 years each (range 0.3–10.0 years)
and had a  total 3846 episodes that were at least 10 days apart. Of
the 2366 children, 1721 (72.7%) had one episode, 324 had  two, 162
had  three and 159 had four  or  more episodes. The children received
a total of 2858 doses of seasonal TIV and 1895 doses of monovalent
H1N1 (2009) vaccine.
The number of children receiving TIV increased each  year over
the study period with the  influenza season 09/10 having the highest
number of children vaccinated. Consistent with how the  vacci-
nation campaign was  implemented, of the children who received
monovalent H1N1 (2009) vaccine only 227 (13.6%) went on to have
a  second dose (Fig. 1). Of these 227 who went on to have a sec-
ond dose 1 had an event on  the day of vaccination, 1 on  day 1
and 1 on day 2. In the study population the peak  of convulsions
occurred at  the age of 1 year. This is similar to the age distribution
seen in hospital admitted children with convulsions for the year
08/09 (Fig. 2). The distribution of cases by season suggested a  rise
in cases in the winter months with 917 in September to November,
1121 in December to February, 1011 in March to  May  and 797 cases
occurring in June to August.
In the 30 days either side of  vaccination with the H1N1 (2009)
vaccine there is a suggestion of an excess of cases on the day of vac-
cination and just afterwards (Fig. 3). However, the self controlled
case series analysis showed no evidence of an  increased relative
incidence in any of the pre-determined risk periods for either the
seasonal TIV or pandemic strain vaccine (Table 1). When H1N1
(2009) was stratified by first and second dose the relative incidence
estimates were higher post second dose, particularly for day 0 and
days 1–3, however, numbers were small and 95% confidence inter-
vals wide (Table 2). A post hoc analysis of the H1N1 (2009) vaccine
cases grouping days 0–2 together, based on  the apparent excess
on days 0–2, was carried out. This relative incidence was 1.69, 95%
confidence interval (CI) 0.93–3.07 overall and, when stratified by
first and second dose,  was 1.35 (95% CI 0.67–2.72) for the first dose
and  5.21 (95% CI 1.66–16.33) for the  second dose.
In  the 2 weeks prior to vaccination there were significantly
fewer convulsion episodes for children who  went on to receive a
first dose of the monovalent H1N1 (2009) vaccine, relative inci-
dence 0.37 (95% CI 0.20–0.68) but this is not evident in the 2 weeks
prior to the receipt of seasonal TIV, or for those receiving a second
dose a the  monovalent H1N1(2009) vaccine (Tables 1 and 2).
4.  Discussion
Seasonal TIV differs from other routinely administered vaccines
as  its composition changes annually in response to the circulating
virus strains and  there may  be adjustment to the manufacturing
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Table 1
Incidence rate ratio (IRR) estimates for the onset of a convulsion episode in relation to the timing of influenza vaccination and type of vaccine administered.
Vaccine Period IRR (95% CI) Events
Trivalent influenza vaccine
Background 1.00  3795
2  Weeks pre-vaccine 1.00 (0.70–1.42) 32
Day  of vaccination 1.23 (0.39–3.83) 3
1–3  Day post vaccine 0.98 (0.47–2.07) 7
4–7  Days post vaccine 0.96 (0.50–1.86) 9
0–7  Days post vaccine 1.00  (0.64–1.59) 19
Monovalent H1N1 vaccine
Background 1.00  3816
2  Weeks pre-vaccine 0.44 (0.25–0.76) 13
Day  of vaccination 1.83 (0.68–4.90) 4
1–3  Day post vaccine 1.08 (0.51–2.28) 7
4–7  Days post vaccine 0.70 (0.31–1.57) 6
0–7  Days post vaccine 0.99 (0.61–1.60) 17
processes without the necessity for  large annual clinical trials. Such
modifications have on occasion changed the safety profile of the
vaccine, as for example with the appearance of a novel adverse
event, ocular respiratory syndrome, in the  2000/2001 influenza
season in Canada associated with one manufacturer’s vaccine [12].
To  ensure the success and  public acceptance of the seasonal TIV pro-
gramme  any vaccine safety concerns need to be robustly assessed
especially if the scope of the seasonal programme were to be
expanded in the future to include the routine immunisation of
otherwise healthy children.
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Fig. 1. Number of children aged under 10 years receiving seasonal trivalent influenza vaccine and monovalent H1N1 vaccine doses by flu season 2000/01 to 2009/10.
Fig. 2. Proportion of episodes of convulsion by age in vaccinated children under 10 years of age recorded in the GPRD between January 2000 and December 2010, and
proportion of all  admissions for  convulsion recorded in the Hospital Episode Statistics (HES) database between April 2008 and March 2009.
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Table  2
Incidence rate ratio (IRR) estimates for the onset of a  convulsion episode in relation to the timing of monovalent H1N1 vaccine.
Dose 1 Dose 2
IRR (95% CI) Events IRR (95% CI) Events
2 Weeks pre-vaccine 0.37 (0.20–0.68) 10 1.24 (0.40–3.88) 3
Day  of vaccination 1.52 (0.49–4.73) 3 5.24 (0.73–37.41) 1
1–3  Day post vaccine 0.85 (0.35–2.04) 5 3.48 (0.86–14.07) 2
4–7  Days post vaccine 0.77 (0.34–1.72) 6 0 (–) 0
0–7  Days post vaccine 0.89 (0.53–1.52) 14 1.96 (0.62–6.14) 3
In response to the H1N1 pandemic in the UK the monovalent
H1N1 (2009) vaccine, PandemrixTM, containing a novel oil-in-water
adjuvant was used for  the first time. The effectiveness of this vac-
cine  given as a single dose to children was high [13] though at
the cost of increased reactogenicity, especially fever [8].  In our
data most children received just one dose of the AS03B adju-
vanted monovalent H1N1 (2009) vaccine, which reflects the one
dose schedule recommended from December 2009 in the UK with
only those who are immunocompromsied recommended to receive
two doses [9,10]. In the UK there was no safety signals concerning
convulsions raised from the passive surveillance in response to the
one dose H1N1 (2009) pandemic vaccine campaign [14] and its
safety profile was considered similar  of  that of TIV, although slightly
more reactogenic [15]. However, given the increased reactogenicity
seen in clinical trials with the AS03B adjuvanted vaccine [8] it  was
considered important to formally assess the risk  and to compare it
with that  after the unadjuvanted TIV vaccine used in previous years.
Our study shows no evidence of an increased risk of a  convulsion
in the  7 days following a first dose of the monovalent H1N1 (2009)
pandemic vaccine when given to young children. These results are
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Fig. 3. Onset of convulsion episode as  recorded in the GPRD in relation to the timing of influenza vaccination.
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reassuring, given that the 2009/10 pandemic was the  first  time that
an influenza vaccine containing this new adjuvant had been used
for mass immunisation of young children. A post hoc assessment
of  the timing of  the events within the 7 days after each dose of
monovalent H1N1 (2009) pandemic vaccine did suggest a possi-
ble increased risk in  the 0–2 day period following the second dose
for which there were 3 events. Although this finding was  not sta-
tistically significant it  is consistent with the increased fever seen
after the second dose of adjuvanted vaccine in a  clinical trial [8]
and supports the Department of Health’s decision to recommend a
single dose for all but  the immunocompromised on  account of the
increase fever after the second dose seen in the clinical trial.
The absence of any evidence of an  increased risk of a convulsion
after seasonal TIV is also reassuring as  some of those recommended
to receive the  vaccine will have underlying chronic conditions
that increase the risk of a febrile convulsion. In  the 2010 sea-
sonal influenza vaccination campaign in Western Australia a large
number of children under 5 years of age experienced fever and
convulsions following TIV. This subsequently led  to the suspen-
sion of the TIV vaccination programme for the under 5-year olds
in Australia [16]. Investigation suggested that  the risk was asso-
ciated with one manufacturer’s vaccine widely used in Australia
and so in July 2010 the vaccine programme resumed using the two
other available brands [17,18]. Febrile convulsions are predomi-
nantly seen in children under 5 years peaking at 1 year. However,
in Australia increased reactogencity was seen up to 9 years of age
and so in response we  assessed the risk of convulsions after TIV in
children up to 10 years of age. The age distribution of vaccinated
children with a  convulsion was similar to that seen in the  gen-
eral population of children admitted to hospital with a convulsion.
There was an  increase in the numbers of  children receiving the TIV
over the study period, corresponding to government initiatives to
improve uptake in all risk  groups.
In  the period 2 weeks before vaccination there are significantly
fewer convulsions in children who subsequently receive a  single
dose of the monovalent H1N1 vaccine. This pre-vaccination low
risk  period is often seen before vaccination as it reflects the patient
waiting to be well after an event such as a convulsion before receiv-
ing the vaccine [19–21].  Unlike other studies, and in this study with
the first dose of pandemic strain vaccine, a pre-vaccination low risk
period was not seen prior to the administration of seasonal TIV or
prior to a second pandemic dose. A possible explanation could be
that seasonal TIV and the two-dose schedule of monovalent H1N1
vaccine was given to children in risk groups who would be routinely
offered TIV vaccine each year, so they may  have had the vaccine pre-
viously and their parents may  feel more confident for their child
to be vaccinated shortly after  a convulsion. The single dose of the
monovalent H1N1 (2009) vaccine was targeted to all children 6
months to 5 years. Parents of such children may  be more hesitant
about their child receiving the vaccine shortly after a convulsion
as  it may  have been the first time their child received an influenza
vaccine.
This study has some limitations, particularly in relation to the
lack of validation of the  clinical diagnoses of a convulsion recorded
in the GPRD. However, we have previously used the GPRD data
for investigating the relationship between convulsions and admin-
istration of pertussis vaccines [5] in which the diagnoses were
validated by reviewing the  “free text” recorded by the GP around
the time of the consultation and by verifying other symptoms relat-
ing to the diagnosis. This showed that the Read codes used for
recording convulsions in the GPRD are reliable and that analyses
based on these codes can detect differences between vaccines. We
have also shown that the age distribution of  the children with
convulsions recorded in the GPRD was similar to that in the HES
database. The ICD codes used in HES have been previously validated
and shown to be specific [4].
Although Pandemrix and Celvapan Read codes were sought
many records were coded with a generic “H1N1” code but since the
national vaccine programme in England and Wales predominantly
used PandemrixTM it is valid to assume the data  primarily reflects
the uptake of Pandemrix TM [25].  A challenge remains in assess-
ing a  risk when more that one vaccine brand is used as databases
such as the GPRD have limited power to identify a product-specific
risk and there is year on year variation between brands. Systematic
recording of  manufacturer and  batch number is needed in routinely
collected data to enable analysis and evaluation.
In conclusion we found no  evidence of an increased risk  of  con-
vulsion in children following a single dose of the monovalent AS03B
adjuvanted pandemic strain vaccine or following vaccination with
the seasonal TIV over a 10-year period using the self controlled
case series method. Although some influenza vaccines may  present
a risk of convulsions in certain circumstances, as  recently docu-
mented in Australia, this should be balanced against the risk  of
influenza virus itself, which can cause fever, convulsions and also
more serious neurological disorders [22,23,24].  Our study provides
evidence that extension of TIV programmes to healthy children,
potentially supplemented by the addition of novel oil in water adju-
vants to influenza vaccine to improve protection [13], is likely to
have an overall beneficial effect on convulsions in this target age
group.
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a b s t r a c t
The suggestion that multi-antigen vaccines might overload the immune system has led to calls for single
antigen vaccines. In 2003 we showed that rather than an increase there appeared to be a reduced risk
of severe bacterial infection in the three months following Measles, Mumps and Rubella vaccine (MMR).
The present analysis of illnesses in a general population is based on an additional 10 years of data for
bacterial infections and also includes admissions with viral infections. Analyses were carried out using
the self-controlled case-series method and separately for bacterial and viral infection cases, using risk
periods of 0–30 days, 31–60 days and 61–90 days post MMR vaccine. An analysis was also carried out for
those cases which were given MMR and Meningococcal serogroup C (MCC) vaccines concomitantly.
A reduced risk was seen in the 0–30-day period for both bacterial infection (relative incidence=0.68,
95%CI 0.54–0.86) and viral infections (relative incidence=0.68, 95%CI 0.49–0.93). Therewas no increased
risk in any period when looking at combined viral or bacterial infections or for individual infections with
the single exception of an increased risk in the 31–60 days post vaccination period for herpes infections
(relative incidence=1.69, 95% CI 1.06–2.70). For the children given Meningococcal group C vaccines con-
comitantly no significantly increased risk was seen in either the bacterial (relative incidence=0.54, 95%
CI 0.26–1.13) or viral cases (relative incidence=0.46, 95% CI 0.11–1.93).
Our studyconfirms that theMMRvaccinedoesnot increase the riskof invasivebacterial orviral infection
in the 90 days after the vaccination and does not support the hypothesis that there is an induced immune
deficiency due to overload from multi-antigen vaccines.
© 2009 Elsevier Ltd. All rights reserved.
1. Background
Addition of a number of new vaccines to the infant vaccina-
tion programme in recent years has raised theoretical concerns
about the possible adverse effects of multiple immunisations on
the developing immune system [1]. One such concern relates to the
potential for increasing susceptibility to other infections as a result
of “immune overload”. When reviewing this issue in 2002, the US
Institute of Medicine concluded that the available epidemiological
evidence favoured rejection of a causal association between multi-
ple immunisations and an increased risk of heterologous infections
[1]. However, most of the studies reviewed related to combined
diphtheria/tetanus/pertussis (DTP) vaccines [2–6].
For combined Measles, Mumps,and Rubella (MMR) vaccine, a
small number of epidemiological studies have also shown no evi-
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Tel.: +20 8327 7485; fax: +20 8327 7404.
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dence of increased risk of heterologous infection [7,2,8] but some
parents remain concerned and uptake of MMR vaccine in the UK
remains sub optimal [9]. This continuing concern has been fuelled
by unsubstantiated allegations about a link between MMR and
autism [10] and claims that administration of three live viral vac-
cines at the same time has adverse immunological effects [11].
We previously tested the hypothesis that the MMR vaccine
induces significant immunosuppression with an increase in hospi-
talisations from bacterial infections in the three months following
the vaccination and found no evidence of such an effect [7]. The
following analysis provides an update for MMR vaccination, using
the same methods and provides an additional 10 years of hospital
admission data to encompass the move to ICD 10 coding, the inclu-
sion of additional codes for viral infections and the concomitant
administration of Meningococcal C conjugate (MCC) vaccine.
2. Methods
Children aged12–23monthswere identified fromcomputerised
hospital admission records from North, East and South London,
Essex, East Anglia, Sussex and Kent, for the period 1st April 1995
0264-410X/$ – see front matter © 2009 Elsevier Ltd. All rights reserved.
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Table 1
Relative incidence (95% confidence intervals) [total cases in period] according to risk
period after MMR vaccination and type of bacterial infection.
Risk period (days) Lobar pneumonia code Invasive bacterial code
−14 to −1 0.24 (0.13–0.46) [9] 0.33 (0.15–0.74) [6]
0 to 30 0.65 (0.48–0.86) [57] 0.75 (0.51–1.12) [30]
31 to 60 0.80 (0.61–1.05) [65] 1.03 (0.70–1.52) [34]
61 to 90 0.90 (0.69–1.18) [69] 0.92 (0.61–1.41) [27]
0 to 90 0.77 (0.64–0.93) [191] 0.89 (0.68–1.16) [91]
to 1st May 2005. Admissions were identified using ICD 9 and 10
codes for bacterial and viral infections (specific codes available on
request). Each episode is coded with an ICD code which can be
found in any of the seven diagnostic fields, with the first field being
the primary diagnosis. Bacterial infections were categorised into
either lobar pneumonia or invasive disease and the viral infections
were categorised into those affecting the central nervous system
(CNS), varicella zoster virus, and other herpes viruses, those caus-
ing viral pneumonia or a miscellaneous group. Varicella zoster
was separated from other herpes viruses because of the known
immunological interference between varicella and MMR vaccines
when administered sequentially within amonth of each other [12].
The analyseswere performed for all bacterial and all viral infections
as well as separately for each category.
The admissions were linked to the dates of independently col-
lected MMR and co-administered MCC vaccination records held on
computerised child health systems by sex, date of birth and full
postcode or where available NHS number as previously described
[7]. Sex, date of birth and full post code is a highly specific link-
ing algorithm when used on these data sets [13]. Only successfully
linked admissions were retained for the analysis as failure to link
did not necessarily mean a child was unvaccinated.
Analysis was carried out using the self-controlled case-series
method which only uses cases and automatically controls for fixed
individual level confounding such as sex and socio-economic status
[14].When using thismethod the relative incidence is calculated by
assigning person time from age 12–23months for each individual
into vaccine and background risk periods and comparing the rate
that outcome events (bacterial, viral infections) occur.
Adjustments for age (in 2-week period) and season (in calen-
dar months) were made in the analysis. The risk periods examined
were 0–30 days, 31–60 days and 61–90 days postMMRvaccine. The
14-day pre vaccination period was excluded from the background
becausevaccinationmightbedelayed if thechildhadastudy illness.
3. Results
A total of 2077 admissions in 2025 children were linked to an
MMR record. An admission within 14 days of an earlier admission
with the same condition was considered part of the same episode.
Of these admissions, 871 were coded as lobar pneumonia and 449
as invasive bacterial infection. Of the children with more than one
bacterial infection, 25 had 2 episodes, 3 had 3 episodes and 1 child
had 8 episodes.
Of the viral infection admissions, 18 were coded as viral
encephalitis/viral meningitis/CNS, 226 as herpes, 61 as pneumonia,
319 as varicella/zoster and 133 viral miscellaneous. Of the children
with multiple episodes 11 had 2 viral episodes and 1 child had 4.
Of these linked cases, 1865 children (92.1%) received a dose
of MMR within the age-range 11–23 months, with the remaining
160 children receiving their first dose later – often about the age
the second dose is usually given. There were 90 admissions occur-
ring in children who received MCC vaccine concomitantly with the
MMR.
3.1. Bacterial infections
The relative incidence estimates in the 30-day period afterMMR
are shown in Table 1. In the first 30 days after vaccination, the rel-
ative incidence estimates were lowest, with a significant reduction
seen for the lobar pneumonia analysis (the confidence interval does
not contain 1.00). In the later periods therewas no evidence of a sig-
nificant reduction. When the whole 90-day period was combined,
the reductionwas only significant for lobar pneumonia. In the anal-
ysis where lobar pneumonia and invasive bacterial infection cases
were combined, the results showed a significant reduction in the
0–30-dayperiod (RI = 0.68, 95%CI0.54–0.86)aswell as in theoverall
0–90-day period (RI = 0.81, 95% CI 0.70–0.95).
Figure 1 shows the number of admissions in 10-day interval
around the time of vaccination. Therewere relatively few cases just
prior to vaccination (because vaccinationwould usually be delayed
if the child was ill). The reduced RI in the 30-day period after vacci-
nation appears to be mainly due to low numbers during the initial
10 days post vaccination period.
Fig. 1. Bacterial infections: Timing of infections relative to date of MMR vaccination in 10-day intervals.
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Table 2
Relative incidence (95% confidence intervals) [total cases in period] according to risk period after MMR vaccination and type of viral infection.
Risk period (days) Encephalitis, Meningitis, CNS Herpes Pneumonia Varicella/zoster Miscellaneous
−14 to −1 0 [0] 0.46 (0.15–1.45) [3] 0.69 (0.15–3.13) [2] 0.16 (0.04–0.56) [2] 0.60 (0.21–1.68) [4]
0 to 30 0.54 (0.06–4.83) [1] 1.00 (0.57–1.74) [16] 0 [0] 0.58 (0.34–0.99) [17] 0.71 (0.37–1.37)[12]
31 to 60 0.74 (0.07–7.47) [1] 1.69 (1.06–2.70) [25] 1.39 (0.49–3.90) [5] 1.23 (0.81–1.87) [32] 0.73 (0.37–1.14) [12]
61 to 90 1.46 (0.23–9.29) [2] 0.89 (0.50–1.59) [14] 1.27 (0.41–3.94) [4] 1.05 (0.66–1.67) [24] 0.61 (0.29–1.28) [9]
0 to 90 0.84 (0.20–3.49) [4] 1.17 (0.56–2.47) [55] 0.72 (0.33–1.62) [9] 0.93 (0.68–1.27) [73] 0.68 (0.43–1.09) [33]
An analysis of cases where MMR and Meningococcal group C
vaccines were given concomitantly was carried out, with 64 bac-
terial cases identified – with 5 events in the 0–90-day risk period
with a RI of 0.54 (95% CI 0.26–1.13).
3.2. Viral infections
The relative incidence estimates in the 30-day period after
MMR are shown in Table 2. Similar to the bacterial infections, the
overall relative incidence in the 0–30 day period after vaccina-
tion was the lowest at 0.68 (95% CI 0.49–0.93). When stratified
by individual diagnostic groups only the RI for the varicella/zoster
group remained significantly low within this period (0.58, 95% CI
0.34–0.99). The distribution of events relative to MMR appeared
lowest during 11–20 days (Figure 2), unlike the bacterial infections,
which appeared lowest in the first 10 days after vaccination. With
the single exception of the herpes group which showed a signifi-
cantly increased risk in 31–60 days after the MMR vaccine (RI 1.69,
95% CI 1.06–2.70) no other diagnostic group showed a significant
increase within the 90 days risk period. There were 26 viral infec-
tions identified following the MMR and Meningococcal group C
vaccines given concomitantly; of these three occurred in the 0–90
days risk period giving a RI of 0.46 (95% CI 0.11–1.93)
4. Discussion
Our results show that MMR vaccine administered in the sec-
ond year of life, either alone or with concomitant MCC vaccine,
does not increase the risk of severe infection, bacterial or viral, in
various periods up to three months after vaccination. It therefore
adds weight to the existing epidemiological evidence that multiple
immunisations do not “overload” the immune system and increase
susceptibility to heterologous infection [1]. Moreover, there is no
scientific rationale for the hypothesis; young infants have an enor-
mous capacity to respond to multiple vaccines, as well as to the
many other antigenic challenges present in the environment, with-
out demonstrated ill-effects. It has been estimated that an infant
has the theoretical capacity to respond to some 10,000 immuno-
gens and with advances in antigen vaccine production, particularly
the change from whole cell to purified acellular pertussis vaccine,
infants now receive fewer vaccine antigens than in the past, despite
an increase in the number of vaccines given [15]. For measles con-
taining vaccines, specific concerns have been raised because wild
measles virus can have profound immunosuppressive effects but
this has not been shown for attenuated vaccine virus [16].
Our results for bacterial infections, showed that both overall and
in the lobar pneumonia group, there was a significant reduced risk
in the 0–90 day period post-MMR vaccine. This was mainly due to
the reduced risk in the 10 days after MMR vaccine and could sug-
gest a healthy-vaccinee effect where individuals who are unwell
but not (yet) hospitalised, have vaccination postponed. In our pre-
vious study [7] there was some evidence of a reduction in risk for
lobar pneumonia in the 61–90 days postMMRwith a RI 0.52 (95%CI
0.30–0.90). In this updated study we did not find such a reduction,
although the present estimateweobserved of 0.90 is still consistent
with our previous estimate and its confidence interval.
In the viral infections analysis, the overall reduction in risk was
significant in the 0–30 day period, but unlike the bacterial infec-
tion analysis the reduction appeared to be in the 11–20 day period
not the 1–10 day period (Figures 1 and 2). When stratified by cate-
gory (Table 2) only the varicella/zoster group showed a significantly
reduced risk in the 0–30 day period. Misdiagnosis of hospitalised
cases of chicken pox or zoster seems unlikely as does a healthy
vaccinee-effect occurring this late after vaccination. Bias resulting
from a reduced propensity to admit children to a hospital because
they were vaccinated some weeks previously also seems unlikely
while bias due to individual level confounders is also automatically
controlled for in the self-controlled case-series method [14].
The reduced risk in late post-vaccination periods in our current
and earlier study [7] may be chance findings, but others have also
Fig. 2. Viral infections: Timing of infections relative to date of MMR vaccination in 10-day intervals.
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reported reduced risks after DTP and MMR vaccination [8,2,5,6].
For example, Black et al. [2] using the case control approach found
an odds ratio of 0.29 (95% CI 0.09 to 0.95) for an invasive bacterial
infection 8–30days after any dose ofDTP,MMRor oral polio vaccine
after controlling for confounders such as day care attendance and
well carevisits.While someof theseapparentprotectiveeffectsmay
be due to residual confounding, it is also possible that vaccination
does provide a short-termprotective effect by a non-specific stimu-
lation of the immune system, for example by interleukin 2 induced
enhancement of immunological activity or interferon production
[5,17].
The only significantly increased relative incidence was in the
herpes group where the RI was 1.69 (95% CI 1.06–2.70) 31–60 days
post vaccination. There was no increased RI of herpes infections in
the other risk periods and it is therefore most plausible that this is
a chance finding due to the number of risk periods and categories
being analysed.
Our study confirms that the MMR vaccine, with or without con-
comitantly administeredMCC vaccine, does not increase the risk of
bacterial infections, or severe viral infections in the 90 days after
vaccination and does not support the hypothesis that there is an
immune overload due tomulti-antigen vaccines. It provides further
evidence of a possible short-term protective effect of MMR vaccine
against heterologous infection.
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In 1976, the national swine influenza vaccination program in the United States was suspended because of an
increased risk of Guillain-Barre´ syndrome. Subsequent studies of seasonal influenza vaccine have given conflict-
ing results. The authors used the self-controlled case series method to investigate the relation of Guillain-Barre´
syndrome with influenza vaccine and influenzalike illness using cases recorded in the General Practice Research
Database from 1990 to 2005 in the United Kingdom. The relative incidence of Guillain-Barre´ syndrome within 90
days of vaccination was 0.76 (95% confidence interval: 0.41, 1.40). In contrast, the relative incidence of Guillain-
Barre´ syndrome within 90 days of an influenzalike illness was 7.35 (95% confidence interval: 4.36, 12.38), with the
greatest relative incidence (16.64, 95% confidence interval: 9.37, 29.54) within 30 days. The relative incidence was
similar (0.89, 95% confidence interval: 0.42, 1.89) when the analysis was restricted to a subset of validated cases.
The authors found no evidence of an increased risk of Guillain-Barre´ syndrome after seasonal influenza vaccine.
The finding of a greatly increased risk after influenzalike illness is consistent with anecdotal reports of a preceding
respiratory illness in Guillain-Barre´ syndrome and has important implications for the risk/benefit assessment that
would be carried out should pandemic vaccines be deployed in the future.
association; Great Britain; Guillain-Barre´ syndrome; influenza, human; influenza vaccines; safety
Abbreviations: GPRD, General Practice Research Database; HES, Hospital Episode Statistics; VAERS, Vaccine Adverse Event
Reporting System.
Guillain-Barre´ syndrome is an autoimmune disease often
preceded by a respiratory or gastrointestinal illness. It is the
commonest cause of acute neuromuscular paralysis in the
United Kingdom, with an estimated annual incidence of 1.5/
100,000 (95% confidence interval: 1.3, 1.8) (1). Clinical
features include motor, sensory, and autonomic dysfunction
such as limb weakness, severe pain, and sinus arrhythmia.
Cases can present in any age group, but incidence increases
with age, with an excess in males (2).
In 1976, the national influenza immunization program in
the United States was suspended following an increased
number of reports of Guillain-Barre´ syndrome after admin-
istration of swine influenza vaccine. A subsequent epidemi-
ologic study showed relative risks of 4.0 and 7.6 for the
6- and 8-week postvaccination periods, respectively, with
an attributable risk of just less than 1 case per 100,000
vaccinations (3). Studies with seasonal influenza vaccines
over the period 1978–1988 showed no evidence of an in-
creased risk of Guillain-Barre´ syndrome in the postvaccine
period (4–6). However, following an increase in reports of
vaccine-associated Guillain-Barre´ syndrome to the US na-
tional Vaccine Adverse Event Reporting System (VAERS),
from 37 in 1992–1993 to 74 in 1993–1994, a further study
was conducted (7). This study found no difference in risk
between the 2 seasons, although there was an increased rel-
ative risk of 1.7 (P ¼ 0.04) for the 2 seasons combined.
Furthermore, a recent analysis of VAERS data (8) identified
2 features of influenza-vaccine-associated Guillain-Barre´
syndrome reports that suggested a possible causal associa-
tion. First, the proportion of VAERS-reported cases with
Correspondence to Julia Stowe, Immunisation Department, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9
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a preceding illness was lower than usually reported for
non-vaccine-associated cases; second, there was an excess
of VAERS cases with onset in the second week after
vaccination.
These findings require further research to investigate the
temporal association between influenza vaccine and
Guillain-Barre´ syndrome. Cohort and case-control studies
have traditionally been used for investigating putative
vaccine-associated risks but pose problems when dealing
with influenza vaccines. First, influenza vaccine is frequently
given to individuals with specific clinical indications, thus
raising the possibility of confounding by indication. Second,
when the cohort approach is used, comprehensive population-
based data are not usually available and person-time denom-
inators inside and outside the risk period have been estimated
from vaccination data obtained from small population sam-
ples (4, 5, 7). The self-controlled case series method (9)
does not have these limitations. Based on a novel cases-only
approach, this method automatically controls for individual-
level confounders and requires only data on cases with their
linked vaccination records.
We used the self-controlled case series method to inves-
tigate the temporal relation between influenza vaccine and
Guillain-Barre´ syndrome. We also used this methodology to
assess the risk of Guillain-Barre´ syndrome after influenza-
like illness.
MATERIALS AND METHODS
We identified consultations for Guillain-Barre´ syndrome
from the General Practice Research Database (GPRD), one
of the world’s largest primary care databases. It holds data
on consultations, referrals, prescriptions, and vaccinations
for more than 3 million active patients in practices through-
out the United Kingdom (5.7% of the population). We
selected any patient in the GPRD whose practice record
had an ‘‘acceptable’’ status and listed an ‘‘up-to-standard’’
date earlier than the patient’s first or new consultation for
Guillain-Barre´ syndrome in the period 1990–2005. The up-
to-standard date reflects when the practice complied with
specific quality measures based on completeness, continu-
ity, and plausibility in key areas. Acceptable status is given
to a patient when certain data quality conditions have been
met, such as no events recoded before the birth date, age less
than 115 years, and a completed gender field. Consultations
for Guillain-Barre´ syndrome were identified by using one
of the following codes: READ F370000 (Guillian-Barre´
Syndrome), READ F370.00 (Acute Infective Polyneuritis),
OXMIS 354 GB (Syndrome Guillian-Barre´), or OXMIS 354
P (Polyneuritis). Influenza and influenzalike illness were
identified by using any READ or OXMIS codes that in-
cluded the terms ‘‘influenza*’’ or ‘‘flu’’ (a full list is avail-
able from the authors).
Two-stage validation of Guillain-Barre´ syndrome coding
was carried out for just those individuals who received at
least one dose of vaccine, since they contributed most of the
power for looking at vaccine effects. First, the patient profile
was reviewed to identify confirmatory clinical symptoms
such as limb weakness at the time of diagnosis and to iden-
tify any cases with an earlier date of onset than the first
coded diagnosis of Guillain-Barre´ syndrome. The patient
profile is a summary of the whole patient record that in-
cludes dates and information on consultations, prescrip-
tions, test results, referrals, and immunizations. Second,
anonymized free-text comments were reviewed for 1 week
before to 23 weeks after the date of the Guillain-Barre´
syndrome consultation to verify date of diagnosis and to
identify supporting clinical information.
Analysis was carried out on all Guillain-Barre´ syndrome
episodes, and, after review of the patient profile, just those
episodes with supporting symptoms, and finally just those
with supporting evidence and a confirmed earliest date of
symptoms. The date that influenza vaccine was given was
identified along with the date of any pneumococcal vaccine,
which is recommended for the same age and clinical risk
groups as influenza vaccine and, when given, is often ad-
ministered at the same time as influenza vaccine.
The self-controlled case series method (6) was used to
test the hypothesis of an increased risk of Guillain-Barre´
syndrome in the 3 risk periods of 0–30 days, 31–60 days,
and 61–90 days after vaccination or influenzalike illness.
Age was controlled for by using the 12 age periods of less
than 8 years, 8–15 years, 16–23 years, 24–31 years, 32–39
years, 40–47 years, 48–55 years, 56–63 years, 64–71 years,
72–79 years, 80–87 years, and 88 years or older. Season was
also controlled for in the analysis by using calendar month
because influenza vaccine is given mainly between October
and December. In this paper, relative incidence estimates
are reported with 95% confidence intervals. A prevaccina-
tion low-risk period of 2 weeks was taken out of the back-
ground risk to allow for delayed vaccination because of
Guillain-Barre´ syndrome. Repeat episodes with an interval
of at least 6 months were counted as a separate episode.
To validate the recording of Guillain-Barre´ syndrome in
a primary care setting, the GPRD consultation rate was
compared with the admission rate from the Hospital Episode
Statistics (HES) data set over the same period. HES holds
details of discharge diagnoses for all National Health
Service hospital admissions in England and, since April
1996, has used the International Statistical Classification
of Diseases and Related Health Problems, Tenth Revision,
diagnosis codes. Annual HES admissions for the period
1997–2004 were extracted by using code G610 (Guillain-
Barre´ syndrome) in the primary diagnosis field, with an
additional admission within 6 months being classified as
the same episode. Repeat episodes in the same patient were
identified by using the unique identifier HES ID. The overall
annual and average age-specific incidence over the period
was calculated by using the Office of National Statistics
population statistic for England as the denominator. The
overall annual and age-specific incidence of GPRD recorded
cases was estimated by using episodes recorded between
1997 and 2004 using the GPRD population statistic for each
year.
RESULTS
A total of 989 episodes of Guillain-Barre´ syndrome
within the study period were identified in the GPRD.
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Seventeen episodes were excluded because the Guillain-
Barre´ syndrome date was unknown, and one individual
with 19 episodes of influenzalike illness was also excluded
because no other individual experienced more than 3 epi-
sodes. Of the remainder, 196 episodes were excluded
because they recurred within 6 months of a previous epi-
sode, which left 775 episodes for analysis. These 775
episodes occurred in 690 individuals; 372 were male and
318 female. The majority of individuals (n ¼ 625, 91%)
had only one episode recorded, 52 had 2 episodes, 9 had
3, 2 had 4, one had 5, and one had 6. Of these 775 GBS
episodes in the analysis, 692 (89 percent) were coded as
GBS and 83 (11 percent) as polyneuritis.
Of the 690 individuals, 169 had at least one influenza
vaccine, 69 at least one pneumococcal vaccine, and 99 at
least one influenzalike illness recorded. Although no mini-
mum interval between influenzalike illness was prespeci-
fied, no repeat episodes within 4 months were identified.
Table 1 shows the number of individuals and Guillain-Barre´
syndrome episodes according to the number of vaccine
doses and influenzalike illness episodes. The ages of the
individuals when the 775 separate episodes of Guillain-
Barre´ syndrome occurred peaked in the group 56–63 years,
whereas the ages in the subset of 199 with a linked influenza
or pneumococcal vaccine record peaked in the group 64–71
years (Figure 1). The seasonal distribution of cases of
Guillain-Barre´ syndrome showed an increase in January
compared with the other months (chi-squared test P < 0.001)
(Figure 2).
Vaccinations
We found no evidence of an increased risk of Guillain-
Barre´ syndrome after pneumococcal vaccine or influenza
vaccine, with relative incidence estimates for the 0–90-day
period of 0.61 and 0.76, respectively (Table 2). An addi-
tional analysis was performed restricted to only those indi-
viduals who received at least one vaccination in case those
without a recorded vaccination were missing vaccination
Table 1. Number of Individuals and Guillain-Barre´ Syndrome
Episodes According to Number of Doses of Influenza and
Pneumococcal Vaccines Received and Influenzalike Illness
Episodes Recorded, United Kingdom, 1990–2005
Risk Factor
No. of Individuals
(n 5 690)
No. of Episodes
(n 5 775)
Influenza vaccination,
no. of doses
0 521 589
1 47 49
2 26 27
3 22 27
4 18 22
5 9 10
6 13 15
7 12 12
8–18 22 24
Pneumococcal vaccination,
no. of doses
0 621 698
1 67 75
2 2 2
Influenzalike illness,
no. of episodes
0 591 662
1 83 97
2 13 13
3 2 2
4 1 1
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Figure 1. Age groups of individuals at onset of Guillain-Barre´
syndrome considering all episodes in the analysis (n ¼ 775) and
the subset with linked influenza or pneumococcal vaccination records
(n ¼ 199), United Kingdom, 1990–2005.
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recorded in the General Practice Research Database (GPRD) and
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information. In this analysis, the relative incidence in the 90
days after influenza vaccination was 0.81, with a 95% con-
fidence interval of 0.44, 1.48. To further investigate the low
relative incidence in the 90-day period and hence a possible
protective effect, the postvaccination period was extended to
180 days. Doing so resulted in a relative incidence of 0.80
and a 95% confidence interval of 0.51, 1.27.
Influenzalike illness
An increased risk was seen following a consultation for
influenzalike illness, with 19 events in the 0–90-day period
and a relative incidence of 7.35 (95% confidence interval:
4.36, 12.38) (Table 2, Figure 3). Fifteen of the 19 episodes
occurred in the 0–30-day period, with a relative incidence of
16.64 (95% confidence interval: 9.37, 29.54), with no epi-
sodes in the 61–90-day period. The number of Guillain-
Barre´ syndrome events attributable to influenzalike illness
was calculated to be 17.2, with an attributable fraction of
2.2%, assuming all influenzalike illness events were cap-
tured. An alternative calculation of the excess due to influ-
enzalike illness is to compare the number of cases in
January and February with the average from the other
10 months and attribute the excess to influenzalike illness.
This comparison gives an estimated excess of 58.2, which is
an attributable fraction of 7.5% of all cases.
Validation
After reviewing the patient profiles, 107 of the 199 epi-
sodes in individuals with a linked influenza vaccine record
had information supporting the diagnosis of Guillain-Barre´
syndrome, such as leg weakness, a feeling of ‘‘pins and
needles,’’ leg pain, or referral to the hospital. Of these
107, 47 had a date of first symptoms, for which 39 episodes
had the symptom recorded prior to the Guillain-Barre´ syn-
drome date (23 within 30 days, 9 within 31–60 days, and 7
within more than 60 days). The relative incidence in the 90-
day period when the analysis was restricted to the 107 cases
with supporting evidence was 0.77 (95% confidence inter-
val: 0.35, 1.69). When the analysis was restricted further to
the 47 cases with a first recorded symptom, the relative in-
cidence was 0.89 (95% confidence interval: 0.42, 1.89). This
estimate is similar to the overall relative incidence of 0.76
(95% confidence interval: 0.41, 1.40) based on all episodes
of Guillain-Barre´ syndrome.
Comparison with HES
A total of 6,340 admissions were found in the HES data
set, which gave an overall incidence of 1.61/100,000 pop-
ulation, with a peak in admissions in January similar to that
seen in the GPRD data set (Figure 2). There were 481 GPRD
consultations over the same period, giving an overall inci-
dence rate of 2.05/100,000 population. Age-specific inci-
dence in HES and GPRD followed a similar pattern, with
a peak in the age group 64–71 years (Figure 4).
DISCUSSION
This study found no evidence of an association between
influenza vaccination and Guillain-Barre´ syndrome, with an
upper end of the 95% confidence intervals excluding a rela-
tive incidence of 1.5. An increased risk of Guillain-Barre´
syndrome was seen in the period shortly after influenzalike
illness, consistent with observations that Guillain-Barre´ syn-
drome is often preceded by a respiratory illness. A recent
case-control study using the GPRD and restricted to cases of
Guillain-Barre´ syndrome occurring between 1990 and 2001
also found evidence of an increased risk in the 2 months
after an influenzalike illness (odds ratio ¼ 18.64, 95% con-
fidence interval: 7.49, 46.37) (10). The association with
Table 2. Relative Incidence, 95%Confidence Interval, and Number
of Episodes of Guillain-Barre´ Syndrome in Specified Intervals After
Influenza and Pneumococcal Vaccines and a Consultation for
Influenzalike Illness, United Kingdom, 1990–2005
Factor and Risk
Period (Days)
RIa 95% CI
No. of
Events
Influenza vaccination
0–30 0.58 0.18, 1.86 3
31–60 0.39 0.10, 1.60 2
61–90 1.25 0.57, 2.73 7
0–90 0.76 0.41, 1.40 12
Pneumococcal vaccination
0–90 0.61 0.08, 4.42 1
Influenzalike illness
0–30 16.64 9.37, 29.54 15
31–60 4.70 1.70, 13.0 4
61–90 0 0
0–90 7.35 4.36, 12.38 19
Abbreviations: CI, confidence interval; RI, relative incidence.
a Adjusted for age and calendar month.
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influenzalike illness may explain the seasonal pattern of
Guillain-Barre´ syndrome, with an increase in cases during
the influenza season that was evident in both the GPRD and
HES data sets. Whether this association is specific to
influenza virus infection or more generically with other re-
spiratory pathogens that can present as influenzalike illness
is difficult to discern since other respiratory infections also
peak in the winter.
A time-series analysis investigating the short-term corre-
lations between weekly laboratory-confirmed reports of
putative triggering pathogens found a positive association
between number of influenza reports in any week and hos-
pital admissions for Guillain-Barre´ syndrome in the same
week (11). The authors of this analysis suggested that
absence of a lag period was consistent with a causal asso-
ciation with influenza vaccine rather than influenza infec-
tion, since the vaccine is usually administered some weeks
before the influenza season begins. However, the correlation
with other respiratory pathogens such as respiratory syncy-
tial virus was not investigated. Since the winter peak of
respiratory syncytial virus often precedes that of influenza
(12), a causal relation between respiratory syncytial virus
and Guillain-Barre´ syndrome is a plausible alternative ex-
planation. Further work to explore the temporal relation
between Guillain-Barre´ syndrome and the viruses known
to contribute to the syndrome of influenzalike illness is in
progress. The use of a clinical case definition of influenza-
like illness as an indicator that influenza incidence has been
studied extensively, and corresponding increases in viral
positivity rates and general practice consultation rates, have
been illustrated (13).
The increased risk of Guillain-Barre´ syndrome after in-
fluenzalike illness, if specific to infection with influenza
virus, together with the absence of a causal association with
influenza vaccine suggests that influenza vaccine should
protect against Guillain-Barre´ syndrome. While the relative
incidence in the 180 days after vaccination was 0.80, the
95% confidence interval spanned 1, so a significant protec-
tive effect was not demonstrated. However, a reduction of
20% is plausible given that the efficacy of seasonal influenza
vaccine against influenzalike illness is approximately
15%–30% depending on the match between the vaccine
and circulating strain (14). Tam et al. (10), using the case-
control approach, reported an odds ratio of 0.16 for the risk
of Guillain-Barre´ syndrome within 2 months of influenza
vaccine. However, this reduction was not significant and
the analysis was based on a total of 18 cases, only one of
which occurred in the risk period. Furthermore, a protective
effect of this magnitude against the nonspecific disease end-
point of influenzalike illness is not plausible.
The relation among Guillain-Barre´ syndrome, influenza
vaccine, and influenza infection is relevant to the debate
about the safety of pandemic influenza vaccines, for which
Guillain-Barre´ syndrome has been identified as a potential
adverse effect that requires enhanced surveillance. If such
vaccines are protective against the pandemic strain, then,
even if they are associated with a small risk of Guillain-
Barre´ syndrome, the overall risk-benefit analysis for this
outcome may be favorable. Clearly, in addition to establish-
ing rapid systems for evaluating the risk of vaccine-
associated adverse events such as Guillain-Barre´ syndrome,
it will be equally important to evaluate the risk of such
events from pandemic influenza and the degree of protection
afforded by the vaccine in order to make an overall risk-
benefit assessment.
Our finding of an increased risk of Guillain-Barre´ syn-
drome after influenzalike illness is also relevant to evaluat-
ing the robustness of the prior studies suggesting an
increased risk after swine influenza or seasonal influenza
vaccines. Any risk from influenzalike illness (or Campylo-
bacter) would be a potential confounder in ecologic
approaches as carried out with US Army data, where no
increase in Guillain-Barre´ syndrome was seen after vacci-
nation (6). A marginally significant increased relative risk of
1.7 (95% confidence interval: 1.0, 2.8) was reported with the
seasonal vaccine by Lasky et al. (7) based on cases occur-
ring in the 1992/1993 and 1993/1994 influenza seasons
combined. These periods were chosen because passive
reports to VAERS had shown a substantial rise in 1993/
1994 compared with 1992/1993. However, when data were
analyzed by individual season, the relative risk was not
significantly different from 1 in the 1993/1994 season, with
only the 1992/1993 season giving a signal (relative risk¼ 1.5,
95% confidence interval: 1.0, 4.3). This study used a cohort
design in which person-time denominators were estimated
from a population sample and did not take account of the
effect of influenzalike illness.
Passive reporting systems such as VAERS also have ma-
jor limitations when trying to assess causal associations.
Evidence cited by Haber et al. (8) in support of a possible
causal association with seasonal influenza vaccines was the
lower-than-expected proportion of Guillain-Barre´ syndrome
cases reported to VAERS who had a preceding illness. How-
ever, suspicion that a case of Guillain-Barre´ syndrome may
be vaccine attributable is likely to be greater for those with
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
≥19 20–39 40–59 60–79 ≥80
A
n
n
u
a
l 
In
c
id
e
n
c
e
 p
e
r 
1
0
0
,0
0
0
 P
o
p
u
la
ti
o
n
Age, years
HES Data
GPRD
Figure 4. Average age-specific incidence of episodes of Guillain-
Barre´ syndrome over the period 1997–2004 recorded in Hospital Epi-
sodes Statistics (HES) and the General Practice Research Database
(GPRD), United Kingdom.
Investigation of Guillain-Barre´ Syndrome and Influenza Vaccine 5
no other suspected cause, so this reasoning is not convinc-
ing. Neither is the apparent excess of VAERS reported cases
with onset within the second week after vaccination, since it
may also be affected by reporters’ judgments regarding the
likely interval for a causal association.
The advantage of the self-controlled case series method
for assessing causal associations is that it should be free of
the individual-level confounding that may affect cohort and
case-control studies (9). An earlier study by Juurlink et al.
(15) also used the self-controlled case series method to in-
vestigate the relation between seasonal influenza vaccine
and Guillain-Barre´ syndrome, and it found a marginally in-
creased relative incidence of 1.45 (95% confidence interval:
1.05, 1.99; P ¼ 0.02) in the period 2–7 weeks after admin-
istration of influenza vaccine. However, information on the
type of vaccine given was not available, and the analysis was
restricted to adults who received a vaccine in October or
November on the assumption that the majority of vaccines
given in these months would be for influenza. Apart from
the inherent uncertainty in this assumption, it did not in-
corporate seasonality, nor did it include influenzalike illness
as a potential confounder. The results of this analysis should
therefore be treated with caution.
Although our self-controlled case series analysis was not
subject to these limitations, there may still be limitations in
the GPRD data set that we used for this analysis. The date on
which the first Guillain-Barre´ syndrome consultation is re-
corded may not be accurate and may reflect the date on
which the patient was admitted or discharged from the hos-
pital with the diagnosis. Thus, there may be a time lag
between the onset of symptoms and recorded diagnosis. In
addition, the coding of Guillain-Barre´ syndrome in the
GPRD may not be accurate. Both these factors would lead
to a reduced relative risk estimate. To assess this possibility,
an analysis was performed on a vaccinated subset with ad-
ditional supporting information on the date of onset and
accuracy of diagnosis. Although only a relatively low pro-
portion were validated, no significant difference in relative
incidence was seen in this subset compared with that found
by using all Guillain-Barre´ syndrome episodes. This finding
suggests that a vaccine-attributable effect has not been
missed. The finding of a 17-fold increased risk of Guillain-
Barre´ syndrome in the month after an influenzalike illness
provides further evidence that the GPRD data are suitable
for detecting a vaccine-attributable effect. Further reassur-
ance was provided by the similarity between the GPRD and
HES data with respect to the age-specific and monthly
incidence.
A further potential criticism of the GPRD data set is that
not all influenza vaccine is given by general practitioners;
a proportion is administered by occupational health practi-
tioners, for example, to health care workers. However, loss
of these data should not affect our results because the self-
controlled case series method was also run confined to just
those individuals with an influenza vaccine recorded, with
similar results.
In conclusion, our study provides robust evidence that
seasonal influenza vaccination does not cause Guillain-
Barre´ syndrome. It also shows that patients presenting with
influenzalike illness in general practice have a greatly
increased risk of developing Guillain-Barre´ syndrome in
the subsequent month. Our findings have implications for
the risk assessment process that will need to be put in place
to evaluate the utility of pandemic influenza vaccines. They
also call into question the robustness of earlier studies that
suggest a causal association of swine influenza and seasonal
influenza vaccines with Guillain-Barre´ syndrome. Our
study provides further evidence of the power of the self-
controlled case series method for evaluating putative causal
associations.
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was stopped now have their symptoms
managed by combinations of paracetamol
and mefenamic acid.
In our practice Depo-Provera is not
currently used in these adolescents because
of the concern over decreased acquisition of
bone mineral density in conjunction with
the use of anticonvulsants. Norethisterone is
sometimes used to postpone menstruation if
requested by the families or carers.
Most of the carers and families did not
have specific concerns relating to menstrual
management documented in the medical
notes, however it is well recognised that
many families and particularly mothers
worry how their daughters with severe
learning difficulties will manage menstrua-
tion. With appropriate support and advice,
concerns appear to dissipate through time.
The centre is devising an advice leaflet for
families entitled ‘‘Practical management of
periods’’. Two of the families had considered
more definitive surgical management
options in the past but are not currently
pursuing this line of treatment.
We agree there is little evidence to guide
clinicians’ practice in this area and welcome
your review in the first instance to stimulate
debate and encourage further studies.
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Idiopathic thrombocytopenic
purpura and the second dose of
MMR
An increase in idiopathic thrombocytopenic
purpura (ITP) cases in the 6 weeks following
the first dose of the measles, mumps and
rubella (MMR) vaccine has been established,
with absolute risks estimated as 1 in 22 3001
and 1 in 21 000 vaccine doses,2 with two in
every three cases attributable to the vaccine.
However, the risk after a second dose of
MMR vaccine has not been investigated.
Hospital admissions for children aged from
3 to,6 yearswith a discharge diagnosis of ITP
(ICD-code D693 in any diagnosis field) were
identified from computerised hospital episode
data from North, East and South London,
Essex, East Anglia, Sussex and Kent for the
period from 1 April 1997 to 31 December 2005.
These admissions were then linked to second
MMR dose records held on population-
based child-health database systems. Only
successfully linked admissions were used for
the analysis.
A re-admission for ITP within 10 days was
classed as a continuation of the previous
episode Validation of the coding was not
undertaken because comprehensive valida-
tion in an earlier study using the same
hospital discharge data set confirmed the
diagnosis coding to be accurate.1 Analysis
was carried out using the self-controlled
cases series method, which only uses cases
and automatically controls for fixed indivi-
dual level confounding.3 The method enables
us to estimate the relative incidence, which
is the ratio of the rate of events in the
6 weeks after vaccination to the rate of
events in the absence of this exposure, with
adjustment for age.
A total of 106 ITP admissions in 78
individuals who had received a second dose
of MMR vaccine were identified; 14 admis-
sions were excluded because they occurred
closer than 10 days to an earlier admission,
leaving a total of 92 admissions satisfying
the study criteria. Of these 92 admissions,
four took place within the period of interest
(fig 1). The relative incidence of an ITP
episode during the 6-week post-vaccination
period compared to the control period was
estimated as 1.04 (95% CI 0.37 to 2.92). To
identify the size of the risk excluded by this
study the upper end of the 95% CI for the
attributable risk was calculated as follows:
the expected number of cases in the risk
period is 4/1.04 = 3.85; the expected
number attributable to MMR if the relative
incidence is 2.92 is 3.85*(2.9221) = 7.4; the
attributable fraction of all cases is 7.4/92 =
8%; the annual incidence of ITP in 3–6 year
olds in England is 14 per 100 000 (Hospital
Episode data for the period April 1997 to
March 2005); the upper 95% CI for the risk
is therefore 0.08*14 = 1 per 100,000.
This study found no evidence of an
increased risk of ITP within 6 weeks of the
second dose of MMR and excludes risks of
more than about 1 per 100 000. There have
been isolated reports of ITP after both a first
dose and second dose of a measles-contain-
ing vaccine 4 5 but we were unable to
identify a cohort of children with ITP within
6 weeks of the first dose who then went on
to receive the second dose. Indeed there may
be few such children because it is recom-
mended6 that children who develop ITP
within 6 weeks of the first dose are tested
for antibodies and only receive the second
dose if susceptible to one or more of the
viruses. Of the 33 children who were
admitted for ITP after the age of 3 years
and before their second dose of MMR, none
had a recurrence within 6 weeks of the
second MMR.
In conclusion, our study provides reassur-
ance that among children receiving a second
dose of MMR vaccine there is no evidence of
an increased risk of ITP.
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Trial of naloxone imperative in
children with unexplained
reduced consciousness level
The recent Royal College of Paediatrics and
Child Health (RCPCH) guideline on decreased
conscious level in children1 overlooks a trea-
table cause of coma. Opiates or benzodiaze-
pines can cause coma following deliberate or
accidental ingestion. The guideline advises
considering drug ingestion and urine toxicol-
ogy but fails to explicitly recommend nalox-
one or flumazenil as immediate therapy.
These are harmless drugs and response is
dramatic if intoxication is present.
History of drug ingestion might be with-
held. Clinical signs such as pinpoint pupils
are unreliable as pupils can dilate when
oxygen saturations are low. Toxicology
screens can take days to come back. In
addition, opiates can cause hyperglycaemia,
leading to diagnostic confusion.
High-profile cases have hit the news
recently of child deaths following metha-
done overdose.
According to the 2006 British Crime Survey,
0.2% of adults use opiates,2 and 4% of 15 year
olds have used class A drugs.3 In Scotland
21 000 people are on prescribed methadone.
7000 have children under 16 living with them.
Studies suggest only half of patients store
methadone safely.4 A survey in Dublin found
that a quarter of methadone users used babies’
bottles for storage.
Thirteen cases of methadone overdose in
children were reported in London in 1998. In
the Whittington Hospital, North London,
during a 9-month period, two patients were
admitted following methadone overdoses.
In the absence of a cause for coma, a dose
of naloxone (10 mcg/kg then 100 mcg/kg
bolus followed by infusion at 5–20 mcg/kg/h)
and flumazenil (10 mcg/kg) are essential. In
obese patients prolonged naloxone infusion
might be required because opiates are stored in
fatty tissue.
Naloxone can be administered by para-
medics without prescription. It is not
enough simply to consider drug intoxication
— opiate and benzodiazepine poisoning
needs to be reliably excluded as a cause for
unexplained reduced conscious level if
further deaths are to be prevented.
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Asthma guidelines: are they
implemented on discharge?
Asthma affects approximately 1 in 10
children in the UK.1 The British Thoracic
Soceity/Scottish Intercollegiate Guidelines
Network algorithms2 are widely used; how-
ever, personal experience suggested that
their recommendations for patient educa-
tion were not being used. We undertook a
postal questionnaire to determine whether
the guidelines were being implemented as
recommended.
The questionnaire was sent to 150 ran-
domly selected NHS hospitals in England,
Scotland and Wales. Of 54 replies, six were
excluded because the hospitals did not have in-
patient paediatric facilities, leaving 48
responses (38 district general hospitals, seven
teaching hospitals and three childrens hospi-
tals). Forty-six hospitals have written asthma
guidelines, of which 18 use the BTS guidelines
and 28 use local guidelines. Of the 46, 39
hospitals guidelines (85%) specified that writ-
ten advice should be provided on discharge. Of
these, 29 hospitals use some form of asthma
action plan to give the advice.
The BTS/SIGN guidelines suggest written
information should be provided on the
management of an acute attack including
oral steroid use if indicated, use of preventa-
tive measures identification of triggers and
check on inhaler technique.2
Of the 39 hospitals whose protocols
included giving written advice on discharge,
only 14 complied fully with the BTS guide-
lines. Thirteen of the remaining 25 had
indicated that they use the BTS guideline as
their protocol, despite 12 omitting informa-
tion on triggers, seven omitting inhaler-
technique check, five omitting information
on acute attacks, five omitting use of oral
steroids and two omitting the use of
preventative measures. Evidently, using the
BTS guideline does not guarantee its recom-
mendations are followed.
Of units that responded, 27% failed to
give written information on early recogni-
tion and management of an acute attack.
Written advice on the use of preventers was
not provided by 25%, and 27% fail to
provide written advice on use of oral
steroids. Omission of the need to check
and document inhaler technique on dis-
charge in 44% of responses is a concern. As
triggers are often unavoidable in attacks in
children, the absence of written avoidance
advice in 65% is more understandable.
This failure to follow BTS recommenda-
tions is mirrored in a recent study looking at
GP prescribing for children with asthma.3
Over 120 000 prescriptions for bronchodila-
tor syrups were issued in 2006, despite BTS
guidelines advising against their use. It
would be unthinkable to discharge a child
with insulin-dependent diabetes mellitus
without education, review and a support
network. We still seem to be failing our
asthmatic children.
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Oral rehydration therapy: a lesson
from the developing world
Oral rehydration therapy (ORT) is the best
treatment for rehydrating patients with
acute infectious diarrhoea and its use has
reduced childhood mortality worldwide.1
Despite this, and despite better resources,
success with oral rehydration is lower in
developed countries, which have a higher
frequency of intravenous fluid administra-
tion.2 This may be either due to different
aetiology or because we are worse at using
oral rehydration effectively. The aim of our
study was to assess current professional
conventions and attitudes surrounding oral
rehydration in England and identify any
incorrect but easily remedied practices.
We conducted a telephone questionnaire
study. A total of 109 units in England with
acute admitting paediatric inpatient facil-
ities were contacted and the most senior
paediatric nurse available completed the
questionnaire. The questions were based
on the clinical scenario of a child below
2 years of age presenting with acute diar-
rhoea and moderate dehydration.
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Research Paper
Bell's Palsy and Parenteral Inactivated Influenza Vaccine
ABSTRACT
Concern about a possible increased risk of Bell’s palsy after parenteral inactivated
influenza vaccine was raised following the publication in 2004 of a Swiss study in which
there was an increased risk following the nasal inactivated formulation of the vaccine.
When data from passive reporting systems in the United States and the United Kingdom
were examined there was some evidence of increased reporting following the parenteral
vaccine. A large population based study using the General Practice Research Database
(GPRD) was therefore performed to test the hypothesis that there was an increased risk of
Bell’s palsy in the three months following parenteral inactivated influenza vaccine. The
risk was also assessed for the same period following pneumococcal vaccine and was
stratified into three age groups (<45, 45–64 and 65+ years). Relative incidence (RI)
estimates were calculated using the self-controlled case-series method and showed no
evidence of an increased risk in the three months following parenteral inactivated influenza
vaccine RI 0.92 (95% confidence interval 0.78–1.08). There was also no evidence of an
increased risk in any age group or following pneumococcal vaccine. A significant
increase was seen on the day of vaccination (day 0) probably due to opportunistic
recording of cases.
INTRODUCTION
Bell’s palsy is an acute facial paralysis affecting the 7th facial nerve with no detectable
cause. It has a reported incidence of about 25 cases per 100 000 population annually1 and
accounts for half of all paralyses affecting the face. Within 3 months 80% of cases recover
but some people are affected permanently, 5–9% have a recurrence, with the average time
span between episodes being 10 years.
Cases usually present in the community and it is thought that most people report to
their GP. Incidence is similar in men and women and no seasonal variation is seen. An
increase in incidence is seen with increased age.2 Treatment is limited but steroids can be
given within the first 24 hours of onset or acyclovir used in combination with steroids,
although recent Cochrane reviews have shown limited evidence of effectiveness.1
An inactive nasal formulation of the influenza vaccine was introduced to the immu-
nization campaign in Switzerland in October 2000. After this introduction an increased
number of Bell’s palsy cases were reported after vaccination. Mutsch et al carried out a case
control study and an association between intranasal inactivated influenza vaccine and Bell’s
palsy was found, OR 84.0 (95% confidence interval (CI) 20.1–351.9). Self-controlled
case-series analysis was also carried out within the risk periods of 1 to 30 days, 31 to 60
days and 61 to 91 days after vaccination. The highest risk was seen in the 31 to 60 day
period, relative incidence 35.6 (95% CI 14.1–89.8).3
In the same study in Switzerland, Mutsch et al.3 also looked at the risk with parenteral
inactivated influenza vaccine but no causal association was found OR1.1 (95% CI 0.6–2.0).
Although this study showed no association very few patients had received the parenteral
vaccine and the study design had a number of limitations and biases that may have led to
missing a true association.
Following the findings in the Swiss study, Zhou et al.4 conducted an analysis of cases
of suspected Bell’s palsy following parenteral inactivated influenza vaccine using the
Vaccine Adverse Event Reporting System (VAERS) in the US for the period 1991 to 2001,
and found a 2 to 4 fold increased proportional reporting ratio in the 1–3 day and 1–30
day post vaccination periods. An increase of cases reported through the UK’s Yellow Card
Scheme has also been found and seems to support the US findings. Although the findings
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from the passive reporting systems must be treated with caution they
constitute a potential signal. It is therefore necessary to carry out a
hypothesis testing study using population-based data.
It was proposed that the General Practice Research Database
(GPRD) be used to investigate the signal indicated by the passive
reporting systems and to test the hypothesis that there is an increased
risk of Bell’s palsy in the three risk periods 1 to 30 days, 31 to 60
days and 61 to 91 days post parenteral inactivated influenza vaccine.
METHODS
The General Practice Research Database is one of the largest
primary care databases in the world. It holds data on consultations,
referrals, prescriptions and vaccinations for over 3 million active
patients in practices throughout the UK (5.7% of the population).
Patients were included in the study if they had a READ or
OXMIS coded consultation for Bell’s palsy between July 1st 1992
and June 30th 2005 and also received influenza vaccine in at least
one of the 13 July–June influenza seasons. Data had to achieve
GPRD up-to-standard status. All patients who had more than one
dose of influenza vaccine recorded in the same flu season were
dropped due to likely data entry errors, although it is possible that
children under thirteen could have been given two doses in the first
year they received the vaccine. Also for patients with more than one
consultation of Bell’s palsy any second consultation within 6 months
of a previous one was regarded as part of the same episode. For each
patient follow-up time was from July 1st 1992, or first registration in
the practice if later, to the earliest of 30th June 2005, death, date
patient left the practice and the date data were last obtained from the
practice. In addition to follow-up dates, data obtained on each
patient were year of birth, sex, date at each Bell’s palsy episode, date
of each influenza vaccine and date of each pneumoccoccal vaccine.
Validation of the diagnosis coding using the GPRD patient
profile was carried out on a randomly selected sample of individual
diagnoses. A diagnosis was confirmed if the patient was prescribed
steroids, acyclovir or eye drops/ointments within a month of diag-
nosis and no other reason for the prescription was identified. In
addition to this, free text comments were reviewed for episodes
where the diagnosis could not be confirmed using the patient profile
and for Bell’s palsy events on the day of vaccination.
Analysis was carried out using the self-controlled case-series
method (SCCS), which automatically controls for fixed individual
level confounding.5 The analysis was restricted to cases of Bell’s palsy
with one or more valid influenza vaccine dates. Age was adjusted for
in 5-year age bands, and season and year were adjusted for by year
and quarter.
In the 14 days prior to vaccination a reduced number of Bell’s
palsy episodes were expected due to delayed vaccination following an
episode. Inclusion of this ‘low risk’ period in the background risk
period can introduce bias so it was removed from the background by
treating it as a separate risk period in the analysis. Opportunistic
recording of episodes on the day of vaccination (day 0) was also
anticipated so this day was also regarded as a separate risk period.
Relative incidence estimates were obtained for the entire
3-month (91 day) post vaccination period as well as in the 1–30,
31–60 and 61-91 day periods. Relative incidence was also calculated
separately for three age groups (<45, 45–64 and 65+).
In a separate model the 3 month post vaccination relative incidence
was estimated for both influenza and pneumoccocal vaccines—this
allows for any potential confounding of one vaccine on the other.
Finally the 3-month risk was calculated with day 0 included in the
risk period. Relative incidence estimates are reported with 95%
confidence intervals. The available sample size from GPRD of at
least 2000 vaccinated individuals each with approximately 4 vaccine
doses was estimated to have 90% power for detecting a relative
incidence of 1.3 or greater at a 5% significance level.
RESULTS
A total of 2313 Bell’s palsy episodes were identified in the study
period with an interval of at least 6 months from any previous
episode. READ code F310.00 Bell’s (facial) palsy held the majority
of the data (96%).
Fourty-six individuals (50 episodes), including one child aged
under thirteen, were excluded because they were recorded as having
had two flu vaccines in the same flu year. This left 2263 episodes that
occurred in 1156 females and 972 males. 118 individuals had two
episodes, 13 had three episodes, 2 had four and 2 had five. The age
range was from 2 years to 95 years although most of the episodes
were in those aged over 50 years (1905/2263, 84%). This is likely to
be because this is the age most flu vaccine is given and we only
included individuals with flu vaccine. Only 77 episodes were in indi-
viduals aged under 30 years, so this was taken as the youngest age
group for analysis with age then increasing in five years steps to 85
years+. The total number of episodes in each month showed little
variability (range 174 to 202). The number of episodes was also fairly
constant over time by flu year (range 161 to 209) with the exception
2004/05 when the number of episodes was only 71. This is due to
the fact that not all practices had reported data to the end of June
2005. The 2128 individuals were followed up for an average of 9.6
years and received a total of 8376 flu doses (average 3.9) and 724
pneumococcal vaccine doses (average 0.34). Over 50% (385/724) of
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Table 1 Age specific relative incidence (and 95% confidence intervals) of a general practice consultation for 
Bell’s palsy within 91 days of influenza vaccine
Risk Period All ages [N=2263] Age 0 to 44 [N=264 ] Age 45 to 64 [N=766 ] Age 65 + [N=1233 ]
-14 to -1 0.72 (0.48-1.07) [25] 1.25 (0.39-4.00) [3] 0.68 (0.32-1.43) [7] 0.70 (0.42-1.17) [15]
Day 0 4.38 (2.47-7.79) [11] 17.3 (5.4-55.5) [3] 2.76 (0.76-10.03) [2] 3.90 (1.80-8.45) [6]
1 to 91 0.92 (0.78-1.08) [212] 0.83 (0.47-1.48) [14] 0.84 (0.62-1.13) [56] 0.99 (0.80-1.21) [142]
1 to 30 0.99 (0.77-1.27) [75] 1.74 (0.85-3.57) [9] 0.58 (0.33-1.03) [13] 1.13 (0.83-1.54) [53]
31 to 60 0.91 (0.71-1.17) [69] 0.37 (0.09-1.50) [2] 1.08 (0.70-1.67) [24] 0.92 (0.66-1.27) [43]
61 to 91 0.86 (0.67-1.10) [68] 0.50 (0.16-1.57) [3] 0.84 (0.52-1.35) [19] 0.93 (0.68-1.27) [46]
Number of cases in each time interval in square brackets.
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the pneumococcal vaccine doses were given at the same time as a Flu
dose.
In the analysis looking at influenza vaccine alone in the whole
1 to 91 day period there was no evidence of a significantly increased
relative incidence of Bell’s palsy following flu vaccine within any of
the age groups or overall (all ages) (Table 1).
When the risk period was divided into three 30-day periods and
the relative incidence estimated in each of these, no significant
increase in risk was seen in these periods either overall or in any of
the three age groups (Table 1).
On day 0 a significant increase was seen in all ages overall and in
each age group except the 45 to 64 year olds group. When overall
analysis was carried out to include the day 0 episodes (i.e., day 0 to
day 91) the relative incidence increased as expected but remained
below one, RI 0.95 (95% CI 0.81–1.11).
When a model was fitted with a 1–91 day risk period following
both influenza vaccine and pneumococcal vaccine neither showed a
significant association with RI 0.97 (95% CI 0.84–1.13) for
influenza vaccine and 0.67 (95% CI 0.38–1.17) for pneumococcal
vaccine.
A total of 100 Bell’s palsy episodes were randomly selected for
validation. Diagnosis was confirmed using the patient profile for 69
episodes. A confirmation was defined as a prescription record for
steroids, antiviral or eye drops/ointment within a month of the episode
when no other reason for the prescription was identified.
For the remaining 31 episodes free text was sought for the 2 week
period either side of the Bell’s palsy episode. Free text was identified
for 22 episodes; of these 8 episodes mentioned Bell’s palsy, facial
weakness or which side of the face was affected within the free text.
Free text was also sought for the 11 episodes that were recorded
on the same day as the vaccine, 1 of which was included in the orig-
inal 100 selected for validation. Of these 11 episodes 8 had free text
available but none mentioned sudden onset of Bell’s palsy on the day
of vaccination. In two instances, the free text indicated that Bell’s
palsy was already present prior to vaccination but the diagnosis made
at the earlier consultation had not been coded and in one instance
the diagnosis of mild facial weakness of which the patient was
unaware was made at the time of vaccination.
DISCUSSION
This study found no evidence of an increased risk of Bell’s palsy
in the three months following parenteral inactivated influenza
vaccine using a self-controlled case-series analysis of cases with their
vaccination history ascertained using GPRD. The observed increase
in risk on the day of vaccination is unlikely to represent a causal asso-
ciation on grounds of biological plausibility and can be explained by
opportunistic recording of cases at time of vaccination. For example,
patients may have had their Bell’s palsy diagnosed when presenting
for the influenza vaccination or the vaccine was given opportunisti-
cally when the consultation was for Bell’s palsy, as confirmed by the
text comments for some patients. This opportunistic recording of
events on the day of vaccination has been reported elsewhere6 where
no causal link between vaccine and diagnosis was recognized.
This validation exercise also demonstrated that many cases of
Bell’s palsy are not treated with medication and symptoms such as
dry eyes are treated with eye drops and ointment only. Damage to
the 7th nerve can often disrupt the closing of the eyelid and moisture
conservation is important to protect the eye. As it is thought that less
than 20% of cases of Bell’s palsy are referred for specialist care2 the
strength of using the GPRD is that it allows for the identification of
these non-hospitalized patients. As the analysis used only cases with
an influenza vaccine history and this is mainly given to older
patients, the sex ratio of 1156 females (54.3%) and 973 males
(45.7%) was not unexpected.
Although there was no evidence of seasonality for Bell’s palsy the
analysis had to adjust for season due to the highly seasonal timing of
influenza vaccination.
Our results concur with Mutsch et al.3 who found no causal asso-
ciation in a small number of patients. This study suggests that the
association seen with the inactivated intranasal influenza vaccine3
may be specific to the administration of the intranasal vaccine and
the association observed cannot be extrapolated to the parenteral
inactivated vaccine. The importance of testing hypotheses raised by
signals generated by passive adverse event reports is emphasized.
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9. Table: 
Table 2: Health data systems and coding 
Level of 
care Area of NHS Name System Population covered Type of coded data name of coding system  
computer system 
name: 
Primary 
General Practice  
The Health 
Improvement 
Network (THIN) 6% of UK population 
clinical, procedures, 
prescriptions, 
vaccinations, referrals READ/CTV2/3 SNOWMED VISION 
Primary 
General Practice  
Clinical Practice 
Research Database 
(formally GPRD) 
9% of UK population 
clinical, procedures, 
prescriptions, 
vaccinations, referrals- 
linked to secondary 
care for a subset READ/CTV2/SNOWMED VISION/EMIS 
Primary 
General Practice  
Royal College of 
General Practioners 
(RCGP) 
1.5% of English 
population  - 107 
practices 
clinical, procedures, 
prescriptions, 
vaccinations, referrals READ/CTV2/3 SNOWMED 
Covers a number of 
systems 
Primary 
General Practice  Qresearch 
1000  practices in UK 
clinical, procedures, 
prescriptions, 
vaccinations, referrals- 
links to secondary care  READ/CTV2/3 SNOWMED EMIS 
Primary Child Health Information Systems TPP 
46% of Local 
Authorities 
immunisation, 
screening,  
non-standard- specific  to 
database   
Primary Child Health Information Systems 
Health Solution 
Wales 
18% of Local 
Authorities 
immunisation, 
screening,  
non-standard- specific  to 
database   
Primary Child Health Information Systems 
CarePlus 
(McKesson) 
16% of Local 
Authorities 
immunisation, 
screening,  
nonstandard- specific  to 
database   
Primary Child Health Information Systems RIO 
12% of Local 
Authorities 
immunisation, 
screening,  
non-standard- specific  to 
database   
Secondary Hospital Inpatient 
Hospital Episode 
Statistics 
All NHS  hospital in 
England clinical & procedures ICD10/OPCS-4 
Patient administration 
systems 
Secondary Hospital Outpatient 
Hospital Episode 
Statistics 
All NHS  hospital in 
England none   
Patient administration 
systems 
Secondary 
Hospital Accident and 
Emergency  
Hospital Episode 
Statistics 
All NHS  hospital in 
England none   
Patient administration 
systems 
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